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ABSTRACT 
 Herein are described the first total syntheses of several members of the 
transtaganolide and basiliolide natural product family.  A general strategy, hinging upon 
the use of a biomimetic Ireland–Claisen rearrangement/Diels–Alder cycloaddition 
cascade, was developed. It allowed for the rapid assembly of the most structurally 
complex, and biologically active members of the family. 
 A brief introduction that surveys the use of the pyrone Diels–Alder cycloaddition 
in total synthesis precedes details of our synthetic efforts.  The diversity of structural 
motifs accessible through this reaction manifold is described through literature examples. 
 The account of our experimental work begins with details of extensive model 
studies.  First, a simple system was prepared which probed the ability to construct 
basiliolide B via an intramolecular pyrone Diels–Alder reaction.  It was demonstrated 
that the sterically congested core could be constructed in a highly diastereoselective 
fashion using this technology.   Second, a simple prenylated pyrone was constructed, and 
shown to undergo a facile Ireland–Claisen rearrangement under a variety of conditions. 
 Subsequently, the utilization of these two methods within a cascade allowed for 
the rapid construction of racemic transtaganolide C, transtaganolide D, basiliolide B, and 
epi-8-basiliolide B.  Furthermore, a novel Pd-catalyzed [5+2] annulation technology is 
utilized to construct the venerable, carboxy-ketene-acetal containing C-ring present in 
most of the metabolites.  
Integration of asymmetry into our general strategy is also described.  Utilization 
of a chiral silane directing group allowed for the successful and rare application of an 
enantioselective Ireland–Claisen rearrangement, culminating in the total syntheses of (+)-
transtaganolide C, (–)-transtaganolide D, (+)-transtaganolide B, and (–)-transtaganolide 
A.   Furthermore, the impact of this work on existing biosynthetic hypotheses is 
discussed. 
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  xxiii 
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eq   equation 
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CHAPTER 1 
Highlights of The Pyrone Diels–Alder Reaction in Total Synthesis 
 
1.1  Introduction 
Among the organic reactions known to generate stereochemical complexity, the Diels–
Alder reaction is perhaps the most well studied and frequently applied.  Since initial 
literature accounts,1 the [4+2] cycloaddition between a diene and a dienophile has been 
applied to the syntheses of countless natural products,2 polymers,3 materials,3a and has 
been invoked as a fundamentally important enzymatic process in nature.4  Many variants 
of the Diels–Alder reaction have been disclosed, including hetero Diels–Alder reactions5 
and intramolecular Diels–Alder reactions.6  Furthermore, several methods to impart 
stereoselectivity have been disclosed.7 
Shortly after their initial report of the Diels–Alder reaction,1 Diels and Alder 
disclosed that methyl coumalic acid (1) undergoes [4+2] cycloaddition with maleic 
anhydride (2) to yield mixtures of oxabicyclo[2.2.2]octene 3 and bicyclo[2.2.2]octene 5 
(Scheme 1.1).8  Oxabicyclo[2.2.2]octene 3 derives from direct cycloaddition of coumarin 
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1 and anhydride 2, while bicyclo[2.2.2]octene 5 arises from the retro [4+2] extrusion of 
CO2 from intermediate 3, followed by a second [4+2] cycloaddition of an additional 
equivalent of maleic anhydride (2) to the resulting diene (4).  The demonstrated ability to 
prepare substituted and structurally complex cyclohexenes in this early example 
foreshadows the utility of the Pyrone Diels–Alder (PDA) reaction manifold.  
 
Scheme 1.1.  Diels’ and Alder’s 1931 PDA 
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Indeed, in the 79 years since this seminal report, methods have been developed 
that allow for complete exploitation of the PDA reaction (Scheme 1.2).9  Functionalized 
oxabicyclo[2.2.2]octenes (7), functionalized cyclohexenes (8), functionalized 
cyclohexadienes (9) and substituted aromatics (10), have all been prepared by PDA 
reactions.9  Furthermore, methods for control of absolute and relative stereochemistry 
have been demonstrated.10 
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Scheme 1.2.  The pyrone Diels–Alder (PDA) reaction manifold 
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α-Pyrones (or 2-pyrones) (6) undergo [4+2] cycloadditions less readily than other 
cyclic dienes due to their partial aromatic character (Scheme 1.3).  This review highlights 
the many approaches necessary to overcome this inherent reactivity.9b  Such techniques 
include: high temperature, high pressure, catalysis, template direction, and electronic 
perturbations through substrate design.  The products obtained from the PDA reaction 
manifold are largely determined by the conditions employed.  As shown in Scheme 1.2, 
the PDA reaction of α-pyrone 6 can yield oxabicyclo[2.2.2]octene 7, highly oxygenated 
cyclohexene 8, diene 9, or aromatic ring 10 as dictated by the conditions employed. 
 
Scheme 1.3.  Partial aromaticity of 6 due to resonance contribution from 6a 
                                             
O
O
6
O+
O-
6a
aromatic resonance contribution  
 
While multiple reviews have addressed the PDA from the perspective of methods 
development and mechanism,9 it is the goal of this document to highlight its application 
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within the realm of total synthesis.  In particular, we will survey the types of structural 
motifs accessible from this reaction manifold by a discussion of reactions and substrates 
utilized in complex molecule synthesis.  This chapter is not meant to be comprehensive, 
but rather a brief survey that highlights an underutilized transformation in organic 
synthesis.  
1.2  Synthesis of Aromatic Systems 
Due to the aromatic character of α-pyrones (Scheme 1.3), the use of high 
temperatures to facilitate cycloaddition is often necessary.  Under such conditions, 
extrusion of CO2 via retro [4+2] is facile, which in turn leads to diene formation (Scheme 
1.4).  When the dienophile is either an alkyne or alkene, where X is a leaving group (11), 
aromatic products will be formed.  In the case of alkynyl dienophiles, the intermediate 
bicyclo[2.2.2]octadiene 12 is highly strained, and readily decomposes by CO2 extrusion 
to the corresponding aromatic ring.11  When alkenyl dienophiles are substituted with a 
leaving group (11), HX elimination from the intermediate diene 13 is required to form 
aromatic systems. The necessary elimination can occur with or without the addition of 
exogenous base.  Additionally, in situ oxidation of the intermediate diene 13 to the 
aromatic ring system has been demonstrated in polyaromatic systems.9b 
 
Scheme 1.4.  Formation of aromatic rings by PDA reactions 
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1.2.1  Boger’s Synthesis of Azafluoranthene Alkaloids 
 In an early utilization of the PDA reaction, Boger and co-workers synthesized 
biologically active azafluoranthene alkaloids  rufescine (17) and imeluteine (18) (Scheme 
1.5).12  Both 1,1-dimethoxyethylene and 1,1,2-trimethoxyethylene underwent smooth 
cycloaddition with electron-deficient coumarin 14 to yield the cores of rufescine (15) and 
imeluteine (16).  It is notable that, while CO2 extrusion was facile under the reaction 
conditions, treatment of the diene PDA product 16 with DBU was needed to facilitate the 
elimination of methanol to form the aromatic system of 18.  Conversely, aromatic 
product 15 was formed in situ, as the needed elimination of MeOH was accomplished 
without additional base.  Intermediates 15 and 16 were advanced to the natural product 
targets after saponification and Cu-catalyzed decarboxylation. 
 
Scheme 1.5.  Boger’s total synthesis of and rufescine (17) and imeluteine (18)  
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1.2.2  Utilization of Triple Bonds in the PDA Cycloaddition 
α-Pyrones readily undergo [4+2] cycloaddition reactions with arynes.  In Guitan’s 
formal synthesis of nitidine (23),13 cycloaddition of pyrone diene 19 with an aryne 
derived from catechol efficiently constructs the core of the target (Scheme 1.6).  Notably, 
Dyke and co-workers had previously tried to utilize diene 20 in the synthesis of nitidine 
(23), but they only obtained trace yields of the desired product 21a.14  Subsequent to the 
key PDA reaction, saponification and decarboxylation yield tetracycle 22, which had 
previously been advanced to the cationic natural product.15  It is noteworthy that the α-
pyrone ring reacts with the aryne dienophile, while the pyridone ring remains untouched; 
establishing the chemoselectivity between two analogous ring systems known to undergo 
[4+2] cycloaddition.9b 
 
Scheme 1.6.  Guitan’s synthesis of nitidine (23) 
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Perhaps the most daring utilization of an aromatic forming PDA cycloaddition 
comes from Baran and Burns.  In particular, the unusual bent aromatic ring (highlighted 
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in red) was forged by microwave irradiation of alkyne-pyrone 24 to the yield the natural 
product (±)-haouamine A (26) (Scheme 1.7).16 As noted by Baran, the formation of such 
a ring suggested to him “that a non-aromatic conformational mimic of the bent aromatic 
ring might serve as a viable precursor if it were able to undergo subsequent 
aromatization.”16  The PDA, with bicyclo[2.2.2]octene intermediate 25, is particularly 
suited to this task.  Further confounding his bold late-stage application of the PDA was 
the atropoisomerism of the bent aromatic ring and the daunting task of forming an 11-
membered ring via intramolecular PDA.  Remarkably, the reaction proceeded in greater 
than 10:1 atroposelectivity, and the natural product target was isolated in 21% yield.  
 
Scheme 1.7.  Baran’s total synthesis of (±)-haouamine A (26)        
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1.2.3  The Biosynthetic PDA 
Attempts to characterize a putative Diels–Alderase, frequently evoked in 
biosynthetic pathways, have been extensive.4  Perhaps the most well known of the 
candidates for this role is macrophomate synthase, an enzyme found in the 
phytopathogenic fungus Macrophoma commelinae.17  It has been shown to catalyze the 
formation of benzoates such as macrophomate (30) from the corresponding oxaloacetate 
(28) and substituted α-pyrone 27 (Scheme 1.8). Macrophomate synthase has been 
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demonstrated to be imperative in decarboxylative enolate formation, C–C bond forming 
events, and CO2 extrusion.17  While the debate has raged in the literature as to whether 
this transformation is truly a concerted [4+2] cycloaddition18 or a Michael–Aldol 
stepwise sequence, recent computational19 and experimental evidence20 that favor the 
latter mechanism has been reported.  Nonetheless, this transformation represents the most 
debated PDA in the literature.21 
 
Scheme 1.8.  Macrophomate synthase catalyzed PDA from nature  
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1.3. Synthesis of Dienes 
In systems where an olefin dienophile is not substituted with a latent leaving 
group, or when no base or external oxidant is supplied, PDA reactions will often yield 
dienes by CO2 extrusion from oxabicyclo[2.2.2]octene intermediate (Scheme 1.2).  As 
early as 1972, E. J. Corey and co-workers recognized this, and exploited the PDA 
cycloaddition to prepare dienes in the key step of the syntheses of the copaenes and 
ylangenes (Scheme 1.9, 35–38).22  Heating of pyrone 31 with β,γ-unsaturated ketone 32 
led to the formation of 34 with “remarkable selectivity”.22  Corey rationalized that the 
reaction proceeded through the enol tautomer (32a), which is consistent with the 
observed regioselectivity.  Notably, dienophiles 39, 40, and 41 failed to react with pyrone 
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31 under similar conditions, a testament to the careful electronic matching required to 
carry out the PDA reaction (Scheme 1.10).  
 
Scheme 1.9.  Corey’s total syntheses of the copaenes (35 and 37) and ylangenes (36 and 38) 
O
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Scheme 1.10.  Evidence for reactivity through enol tautomer 
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1.4  Synthesis of Substituted Cyclohexenes: PDA without CO2 Extrusion 
The application of the PDA to the synthesis of dienes and aromatics is a very 
powerful method, as discussed in sections 1.2 and 1.3.  However, the examples in which 
CO2 extrusion is not observed are perhaps the most powerful.  In these cases up to four 
contiguous stereocenters are generated in the initial bicyclo[2.2.2]octene (43) and can be 
elaborated into a number of highly oxygenated cyclic systems (e.g., 44, Scheme 1.11). 
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Scheme 1.11.  PDA without CO2 extrusion 
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As discussed, the aromatic character of α-pyrones often necessitates harsh 
reaction conditions for efficient [4+2] cycloaddition.  Unfortunately isolation of the 
stereochemically rich bicyclo[2.2.2]octene (43) or its derivatives is unlikely under such 
conditions, as intermediates such as 43 have been shown to extrude CO2 at temperatures 
as low as 50 ºC.9b Therefore, careful choice of reactive partners and/or reaction 
conditions are required to allow for low temperature cycloadditions that do not favor CO2 
extrusion. Several approaches to address this challenge have been developed, including 
substituents that enhance electronic matching, catalysis, and use of intramolecular 
reactions.9b  While it is more desirable to lower the HOMO-LUMO gap via catalysis, 
covalent substituents on the pyrone diene or olefinic dienophile have been used 
extensively.  
1.4.1  Nicolaou’s Total Synthesis of Taxol: Use of Templating in the PDA Reaction 
The first total synthesis of Taxol (50),23 which stands as one of the major 
chemical achievements of the 20th century, is an exemplary use of the PDA to rapidly 
install stereochemical complexity (Scheme 1.12 and 1.13).  The cyclohexenyl C-ring, 
which contains four contiguous stereocenters, posed a significant challenge to standard 
Diels–Alder technology.  As noted by the authors, “[the] ring C of Taxol (50), with its 
numerous stereocenters and high degree of oxygenation, presented a more serious 
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challenge [than the A-ring] to the Diels–Alder approach.”23b  Their initial efforts focused 
on the use of carboxymethyl pyrone 31 and dienophile 45 (Scheme 1.12).  Much to the 
author’s disappointment, heating of these reactants to 155 °C led to the formation of 
undesired intermediate 46, instead of 47, the former of which undergoes facile 
decarboxylation to yield unexpected diene 48. 
 
Scheme 1.12.  First attempts at taxol C-Ring     
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Despite this unfortunate result, Nicolaou and co-workers continued to work 
within the PDA reaction manifold, eventually finding the use of a temporary tether to 
force the desired stereochemical outcome (Scheme 1.13).  Based on earlier work by 
Narasaka,24 treatment of dienophile 51 and hydroxypyrone 52, with phenylboronic acid 
under dehydrating conditions yielded bicycle 55 after cleavage of the temporary boronic 
ester linkage.  It is worthy to note that, under reduced temperatures, the 
oxabicyclo[2.2.2]octene 54 did not undergo thermal decarboxylation and was isolable as 
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the initial product.  Subsequent to decomplexation, intramolecular transacetalization 
yields the desired C-ring fragment (55) that was subsequently advanced to taxol (50). 
 
Scheme 1.13.  Synthesis of taxol C-Ring 
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1.4.2. Posner’s Covalent Modification Approach 
Posner and co-workers have demonstrated that strongly electron withdrawing 
pyrone substituents, such as sulfinyls25 and sulfonyls,26 allow for low temperature 
inverse-demand cycloadditions.  For example, 1,1–dimethoxyethylene (56) undergoes 
cycloaddition with 3-sulfinyl-2-pyrone 57 at a modest 25 ºC (Scheme 1.14).  
Bicyclo[2.2.2]octene 58 was resistant to CO2 extrusion and easily isolated at this 
temperature. 
 
Scheme 1.14.  Substituent-assisted inverse-demand PDA 
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2-Pyridones (e.g., 60, Scheme 1.15), which are normally more resistant to 
cycloaddition than their oxygen analogs, were also demonstrated to have enhanced 
reactivity due to sulfonyl substitution.27  1,3-Disulfonyl-2-pyridone 60 underwent smooth 
cycloaddition with butyl vinyl ether 59 at low temperatures and near ambient pressures.  
Bicycle 61 was isolated, and the resulting olefin was reduced.  Notably, further reduction 
with NaBH4 allowed isolation of oxygenated aminocyclohexane 62. 
 
Scheme 1.15.  Substituent-assisted normal-demand pyridone Diels–Alder 
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A further example of the application of the PDA to complex molecule synthesis is 
Posner’s synthesis of (–)-methyl triacetyl-4-epishikimate28 (68, Scheme 1.16).  This 
compound had been previously prepared by resolution of a racemate29 or from the chiral 
pool.30  Of note to Posner’s synthesis is the use of the sulfone-modified pyrone 64, which 
allows for a low temperature cycloaddition and isolation of bicycle 65.   Furthermore, in 
a rare example of a diastereoselective PDA, excellent facial selectivity was imparted 
from the non-racemic, chiral ether 63, despite free rotation about the oxygen atom.  The 
bridging ester (65) was hydrolyzed at low temperature by treatment with NaOMe.  
Importantly, cyclohexene 66 was desulfonylated by treatment with mercury-aluminum 
amalgam and oxidized to epoxide 67, which was advanced to the target compound (68). 
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Scheme 1.16.  Synthesis of (–)-methyl triacetyl-4-epishikimate (68) 
            
O
O
O
O
64 65 66
SO2Tol
SO2Tol
OMe
OOPh
H
63
TolO2S NaOMe
OH
O
1) Al-Hg
2) p-NO2C6H4CO3H
OMeO
OAC
68
OAcAcO
25 °C
(84% yield)
O
Ph
H
H
Ph
H
OMeO
OH
O
OPh
H
67  
 
 Modification of the α-pyrone skeleton with strong electron withdrawing groups is 
an effective method for lowering the activation barrier and allowing for isolation of the 
initial oxabicyclo[2.2.2]octene adduct, as exemplified by the previous examples. 
However, this modification is limited to inverse-demand PDAs with electron rich 
dienophiles.  Furthermore, the conditions required to remove the activating group are 
harsh and suffer from low functional group compatibility. 
 Posner and co-workers have demonstrated that halogenation at the 3- and/or 5- 
positions of α-pyrones improves reactivity in both inverse- and normal-demand PDA 
cycloadditions.31,9b  In early work toward calcitrol derivatives (74a and 74b, Scheme 
1.17), they demonstrated the propensity of brominated pyrones to undergo normal-
demand PDAs.32   Heating of 3-bromo-2-pyrone (69) with acrolien (70) yielded isolable 
oxabicyclo[2.2.2]octene 71 in good yield.  Following functional group manipulations, the 
bridgehead bromine of bicycle 72 was reduced selectively and with high efficiency by 
treatment with tributyltin hydride and AIBN.  This highly functionalized bicycle (73) was 
further manipulated to the C-ring of calcitrol derivatives 74a and 74b. 
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Scheme 1.17.  Posner’s use of bromopyrone for calcitrol synthesis 
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Perhaps there are no natural products better suited for synthesis via a PDA 
reaction than the transtaganolides (75) and basiliolides (76) (Scheme 1.18).  These 
metabolites, recently isolated from plants belonging to the genus thapsia, possess a 
common oxabicyclo[2.2.2]octene core, which has been proposed to arise from a 
biosynthetic PDA cycloaddition.33 
 
Scheme 1.18.  The transtaganolides and basiliolides 
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 Recognizing this structural motif, shortly after their isolation Nelson and Stoltz 
set out to prepare the transtaganolides (75) and basiliolides (76) utilizing the  PDA 
reaction.34  In their initial efforts, pyrone 77 was heated to 120 °C for three days, leading 
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to undesired CO2 extrusion and formation of diene 79 (Scheme 1.19).  Introduction of a 
bromine at the 3-position (80), however, allowed for a lower-temperature cycloaddition, 
and oxabicyclo[2.2.2]octene 81 was isolated (Scheme 1.20).  Following this report, 
several other groups reported transtaganolide model systems based on the PDA 
reaction.35, 33c 
 
Scheme 1.19.  Initial PDA reactions 
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Scheme 1.20.  Successful isolation of oxabicyclooctene intermediate 
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 Nelson and Stoltz went on to prepare transtaganolides A–D (75, 85) and 
basiliolide B (76) utilizing the PDA as part of a cascade reaction (Scheme 1.21).36  
Pyrone ester 82, when exposed to N,O-bis(trimethylsilyl)acetamide (BSA), NEt3, and 
heat, underwent an Ireland–Claisen rearrangement to produce intermediate 83.  
Subsequent heating effected the desired PDA cycloaddition and formation of the 
oxabicyclo[2.2.2]octene-containing cores (84) of the natural product targets.  It is notable 
that allylic strain dictated the reactive conformations of intermediate 83, selectively 
Chapter 1 — Highlights of The Pyrone Diels–Alder Reaction in Total Synthesis 
 
 17 
forming the desired stereoisomers.  Intermediates 84 were rapidly advanced to the natural 
product targets (75, 76, and 85). 
 
Scheme 1.21.  Utilization of the PDA in the total syntheses of the transtaganolides (75 and 85) and 
basiliolides (76) 
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1.5 Conclusions and Outlook 
 Since its first report by Diels and Alder, the [4+2] cycloaddition, in which the 
diene component is an α-pyrone, has proven itself as an effective method for the 
construction of complex molecules.  The ability to obtain aromatic, cyclohexadienyl, or 
cyclohexyl products based on reaction conditions and substitution patterns is a unique 
feature absent from all other common [4+2] cycloadditions.  Furthermore, through the 
synthesis of natural products, α-pyrone has filled a niche as a dienophile capable of 
achieving stereoselectivity and reactivity not possible with an “average” acyclic or cyclic 
diene. Despite these facts, the pyrone Diels–Alder reaction remains underutilized. 
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 It is the authors’ opinion that this lack of use in medicinal chemistry and total 
synthesis is due to the dearth of catalytic asymmetric PDA methods available.  While 
there are examples of diastereoselectivity utilizing chiral auxiliaries and diastereomeric 
reactions of chiral substrates, the number of catalytic asymmetric PDA reactions is 
exceedingly small.10d Development of chiral reagents that catalyze the [4+2] reaction of 
α-pyrones with both electron-rich and electron-poor dienophiles will surely increase the 
usage of the PDA reaction in complex molecule synthesis. 
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CHAPTER 2 
Model Studies Aimed at The Total Syntheses of The Transtaganolide 
Natural Products 
 
2.1 Introduction  
2.1.1 Biological Activity 
Thapsia garganica L., an herb native to Mediterranean countries, has a long history as a 
medicinal plant, with therapeutic attributes first reported by Hippocrates in 400 BC.1 Its 
roots have traditionally been used for the treatment of pulmonary diseases, catarrh, and 
rheumatoid arthritis.1  Thapsigargin (TG)(86, Scheme 2.1), the principal chemical 
component of T. garganica L., is a powerful histamine liberator and a non-TPA type 
tumor promoter.2,3  However, TG (86) is best known as a selective and potent microsomal 
SERCA-ATPase inhibitor, and is widely used as a chemical tool for cell physiological 
studies.4  Its utility as a biological tool is evident from its frequent appearance in the 
literature: since 1985, when TG (86) was first shown to selectively inhibit SERCA-
ATPase, published reports involving TG (86) have averaged more than one a day.5 
Because of its high cost6 and variable concentration in T. garganica L., several 
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groups have attempted to isolate TG (86) analogues from T. garganica L., as well as from 
other members of the Thapsia genus.  Recent efforts have led to the isolation of several 
new compounds, the transtaganolides and basiliolides (75, 76, 85 and 87–91, Scheme 
2.2).7  
 
Scheme 2.1. Thapsigargin and thapsigargin bound SERCA-ATPase 
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Scheme 2.2. The meroterpenoids of Thapsia transtagana 
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 Interestingly, despite obvious structural differences between TG and the 
transtaganolides (86 vs. 75 and 76), compounds 75 and 76 have also been shown to 
induce an increase in cytosolic [Ca2+].  This biological activity is the primary action of 
SERCA-ATPase inhibitors such as TG (86).8 While it was initially suggested that 
compounds 75 and 76 were also SERCA-ATPase inhibitors, there is evidence that these 
compounds may act through a different mechanism.7b,8  In particular, TG (86) is known 
to irreversibly inhibit SERCA-ATPase, causing an increase in cytosolic [Ca2+] which 
leads to endoplasmic reticulum (ER) stress and eventual apoptosis.9  However, it has 
been demonstrated that unlike TG, the cytosolic [Ca2+] increase induced by compounds 
75 and 76 is reversible.8 Furthermore, in vivo studies show that the cytosolic [Ca2+] 
concentration increase is limited and does not cause cell lysis.8  
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In addition to its potential application as a [Ca2+] homeostasis probe, several 
structural comparisons have been made between the transtaganolides and the privileged 
anti-parasitic agent artemisinin.10 While speculative at best, small molecule libraries 
inspired by the core ring system of the transtaganolides have been shown to be effective 
against African Sleeping Sickness, with potencies rivaling that of artemisinin.11  
Beyond their biological activity, we were also drawn to the densely 
functionalized, structurally novel frameworks present in these natural products.  In 
particular, the metabolites isolated from T. garganica L. and T. transtagana (75 and 76) 
contain an interesting tetracyclic core featuring a bicyclic lactone (Scheme 2.2, 75 and 
76, AB rings).  Furthermore, the 7-methoxy-4,5-dihydro-3H-oxepin-2-one ring (C-ring) 
common to all of the transtaganolides is an unprecedented structural motif. 
2.1.2 Biosynthetic Proposals 
 Since isolation, the transtaganolides (Scheme 2.2) have been the subject of 
multiple biosynthetic proposals. In 2005, Appendino and co-workers proposed a 
biosynthesis based on a polyolefin rearrangement of farnesyl pyrophosphate (92) with 
several subsequent CO2 abstractions (Scheme 2.3).7b While polyolefin/cation cascades 
are well precedented in terpenoid biosynthesis,12 carbon dioxide abstraction is not. 
Furthermore, with no robust method for olefin carboxylation, and no clear path of 
inducing stereochemical selectivity, we chose not to explore this biosynthetic hypothesis 
in a laboratory setting. 
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Scheme 2.3. Appendino’s biosynthetic hypothesis 
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In 2007 Rubal and co-workers proposed a biosynthesis in which co-isolated 
coumarin 103 serves as the biosynthetic precursor of the transtaganolides.13  Under this 
scenario, myriad biosynthetic pathways are possible. As shown in Scheme 2.4, a 
sequence of intramolecular pyrone diels–alder (IMPDA)/ claisen rearrangement (CR) 
/electrocyclic ring opening (ERO) reactions are responsible for the formation of the 
natural products (Scheme 2.4).  At the time of this proposal, no particular order of 
transformations was proposed. 
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Scheme 2.4. Rubal’s biosynthetic proposal 
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In 2008, Larsson and co-workers proposed a more specific version of Rubal’s 
hypothesis (Scheme 2.5).14  They posited that co-isolated, prenylated pyrone 89 is the 
direct biosynthetic precursor of transtaganolides C (74a) and D (74b).  Under this 
scenario, they state that an unprecedented enzymatic enolate-Claisen rearrangement leads 
to the formation of intermediate 109, which subsequently undergoes a spontaneous 
pyrone Diels–Alder (PDA) cycloaddition to yield the cores of the natural products (91, 
Scheme 2.5).  It is noteworthy that the C8 diastereomers obtained by this biosynthetic 
pathway would likely share the same absolute stereochemistry at C8 and be of opposite 
enantiomeric series at all other stereocenters (91a and 91b, Scheme 2.5). 
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Scheme 2.5. Larsson’s biosynthetic proposal 
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2.2 Synthetic Strategy 
Inspired by these biosynthetic proposals, we envisioned that the cores of the 
transtaganolide natural products (111) could be prepared in the laboratory via an Ireland–
Claisen rearrangement (ICR)/intramolecular pyrone Diels–Alder (IMPDA) sequence 
(Scheme 2.6).  We proposed that the oxepinone ring (ring C) would need to be formed 
subsequent to the IMPDA, as formation of the oxepinone prior to the cycloaddition could 
potentially lead to the incorrect relative stereochemistry (116 to 117, Scheme 2.7). 
Furthermore, we envisioned that the reactivity of the C-ring could interfere with core-
forming chemical transformations.  Intermediate 111 would arise from pyrone 112 via 
an IMPDA. The IMPDA substrate 112 would be prepared from the ICR of pyrone ester 
113. The ICR substrate (113) could be synthesized by coupling of geraniol derivatives 
(114) to pyrone acid 115.  
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Scheme 2.6. Retrosynthetic analysis  
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Scheme 2.7. Reasoning for late-stage oxepinone formation 
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2.3 Model Studies 
At the outset of the project, we sought to validate our retrosynthetic analysis via 
model studies. Of particular importance was the key IMPDA reaction, as this 
transformation constructs four of the six stereocenters in the natural product and two of 
its four rings in a single step.  Furthermore, the well-documented propensity for thermal 
pyrone Diels–Alder cycloaddition products to undergo cycloreversion with extrusion of 
CO2 threatened our approach.15  Additionally confounding our synthetic proposal was the 
lack of precedence for ICRs with a pendant electron-withdrawing group, such as 
molecule 113.  Similar systems, such as those employed in the Carroll rearrangement, are 
also known to undergo thermal decarboxylation.16    
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2.3.1 Intramolecular Pyrone Diels–Alder Model System 
We envisioned that a compound such as 117 might serve as an adequate model to  
probe the capacity of geraniol derivative 112 to undergo IMPDA under thermal or Lewis 
acidic conditions.  We proposed that preparation of the IMPDA model system 112 could 
be achieved via alkylation of a malonate (120) with a pyrone electrophile such as 118 
followed by an electrophilic dienophile fragment such as 119 (Scheme 2.8).  
 
Scheme 2.8. Retrosynthetic analysis of IMPDA model system 
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The preparation of 119 began with the partial reduction of γ-butyrolactone (121) 
to the corresponding lactol, which was immediately treated  with stabilized ylide 12217 to 
afford hydroxyenoate 123 (Scheme 2.9).  Alcohol 123 was converted to iodide 119a by 
treatment with iodine, imidazole, and PPh3.  
 
Scheme 2.9. Synthesis of dienophile fragment 
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In parallel, pyrone 124 was assembled by substitution reaction of chloride 118a 
with the anion of dimethyl malonate (120a, Scheme 2.10).  Coupling of pyrone 124 to 
alkyl iodide 119a furnished the IMPDA substrate 117a in 83% yield.   
Unfortunately, upon exposure of pyrone 117a to thermal or Lewis acid catalyzed 
Chapter 2 — Model Studies Aimed at The Total Syntheses of The Transtaganolide Natural Products 
 
 32 
reaction conditions, we were unable to obtain the desired IMPDA product 116a.18  In 
accord with literature precedent,19 we found that higher temperatures were required to 
obtain noticeable production of a Diels-Alder adduct.  Furthermore, at these temperatures 
(≥120 °C) the decarboxylated product (125) was formed as the predominant product in 
62% yield. 
 
Scheme 2.10. Initial IMPDA attempts 
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Given the lack of desired reactivity in our model compound 117a, we turned our 
attention toward brominated derivative 117b (Scheme 2.11).  Posner and others have 
demonstrated that halogen substitution at the 3- and/or 5-position of pyrone rings 
activates them toward electron-poor and electron-rich dienophiles, allowing for lower- 
temperature non-decarboxylative cycloadditions.20   Although direct mono-bromination 
of 117a proved challenging due to competing bromination of the enoate moiety, we were 
delighted to find that treatment of pyrone 124 with bromine yielded bromopyrone 126 
and dibrominated pyrone 127 in 48% and 32% yield, respectively (Scheme 2.11).  
Additionally, dibromide 127 could be smoothly monodehalogenated  by exposure to Zn 
dust and acetic acid, providing bromopyrone 126 in an overall 74% yield from pyrone 
124.  The alkylative coupling of 126 with 119a was achieved using a carbonate base to 
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provide IMPDA substrate 117b in 58% yield.  Importantly, upon heating bromide 117b 
in a sealed tube at 90 °C, smooth cycloaddition occurred to produce tricycle 116b as a 
single diastereomer in 76% yield.21  The structure and relative stereochemistry of endo 
Diels–Alder adduct 116b was unambiguously established by single crystal X-ray 
diffraction (Scheme 2.12).22  Treatment of the IMPDA product 116b with tributyltin 
hydride and AIBN allowed for removal of the bridgehead bromine to provide 116a in 
50% yield.20b  
 
Scheme 2.11. Implementation of the Posner modification 
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Scheme 2.12. X-ray crystal structure of 116b 
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Following our initial report, several other groups reported IMPDA approaches to 
the transtaganolide/basiliolide natural products. Dudley and co-workers demonstrated 
that 5-iodopyrone 128 undergoes facile IMPDA to yield tricycle 129 when heated to 100 
°C for 3 days (Scheme 2.13).23  Notably, his 5-iodo substitution of the pyrone allows for 
possible elaboration to the C-ring of basiliolide B.  
 
Scheme 2.13. Dudley’s approach to the core of basiliolide B  
                                        
I
I
O
EtO2C
O
H
Toluene
100 °C, 72 h
(39% yield)
O
O
CO2Et128 129  
 Lee and co-workers reported an elegant approach to the core that relied on the use 
of base catalysis.24 Oxidation of dihydropyrone 130 with Jones’ reagent formed an 
intermediate 5-hydroxypyrone that under basic conditions underwent facile normal- 
demand IMPDA to yield ketone 131.  Notably, Lee’s system is also appropriately 
substituted for elaboration of the C-ring and advancement to the natural product targets. 
 
Scheme 2.14. Lee’s approach to the core of basiliolide B  
                                                    
O
OH
O
CO2Me
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O
H
1) Jones oxidation
2) Hex2NMe (cat.)
    t-BuOH 10 d
      (50% yield)
O
CO2Me
O
CO2Et130 131  
2.4 Conclusion 
 In conclusion, we have proposed a highly modular route to the transtaganolides.  This 
route is strongly supported by extensive model study work. An intramolecular pyrone 
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Diels–Alder (IMPDA) model system was constructed and used to forge the tricyclic core 
of the natural product targets. 
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2.5 Experimental Section 
2.5.1 Comments on IMPDA 
As stated in the text, heating of 117a  to  reflux in benzene results in  low conversion to 
116a. Shown below is a 1H NMR spectra taken after 86 hours. For comparison, the spectra 
of pure 116a  (prepared by radical dehalogenation of 116b), and the spectra of 117a are 
shown. 
 
Figure 2.1. IMPDA reaction 
 
117a
116a
117a116a
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2.5.2 Materials and Methods 
Unless otherwise stated, reactions were performed in flame-dried glassware under an argon 
or nitrogen atmosphere using dry deoxygenated solvents. Solvents were dried by passage 
through an activated alumina column under argon. 6-Chloro-2H-pyran-2-one was 
purchased from Sigma-Aldrich Chemical Company and used as received. 1-
Methoxycarbonylethylidenetriphenylphosphorane was prepared using known methods1. 
Thin-layer chromatography ( TLC ), both preparatory and analytical, were performed using 
E. Merck silica gel 60 F254 pre-coated plates ( 0.25 mm ) and visualized by UV 
fluorescence quenching, p-anisaldehyde, I2,  or KMnO4 staining. ICN Silica gel (particle 
size 0.032–0.063 mm) was used for flash chromatography. 1H NMR, and 13C NMR spectra 
were recorded on a Varian Mercury 300 (at 300 MHz) or on a Varian Unity Inova 500 (at 
500 MHz). 1H NMR spectra are reported relative to CDCl3 ( 7.26 ppm ). Data for 1H NMR 
spectra are reported as follows: chemical shift, multiplicity, coupling constant ( Hz ), 
integration. Multiplicities are reported as follows: s = singlet, d = doublet, t = triplet, q = 
quartet, sept. = septet, m= multiplet, comp. m = complex multiplet, app. = apparent, bs = 
broad singlet. 13C NMR were reported relative to CDCl3 ( 77.0 ppm ).  FTIR spectra were  
recorded on a Perkin Elmer SpectrumBX spectrometer and are reported in frequency of 
absorption (cm-1). High resolution mass spectra were obtained from the Caltech Mass 
Spectral Facility. Crystallographic data were obtained from the Caltech X-ray Diffraction 
Facility. 
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2.5.3 Experimental Procedures 
 
O
CO2Me
CO2Me
O  
 
Dimethyl 2-(2-oxo-2H-pyran-6-yl)propanedioate (124). To a suspension of Sodium 
hydride (60% in mineral oil) ( 399 mg, 16.6 mmol, 1.9 equiv )  in tetrahydrofuran ( 75 ml 
) at 0 °C was added dimethyl malonate ( 2 ml, 17.5 mmol, 2 equiv ) over 5 minutes. The 
mixture was warmed to ambient temperature and stirred for 20 minutes. The solution was 
then cooled to 0 °C, and a solution of 6-chloro-2H-pyran-2-one ( 1.1 g, 8.8 mmol, 1 equiv 
) in tetrahydrofuran ( 5 ml ) was added dropwise over 5 minutes. The reaction was 
allowed to come to ambient temperature, then stirred for an additional hour.   The 
reaction mixture was acidified to pH 5 by the addition of 3N HCl(aq).  Water was then 
added ( 50 mL ), and the reaction mixture was extracted with CH2Cl2 ( 3 x 200 ml ). The 
combined organic extracts were dried over Na2SO4(anhydrous) and concentrated by 
rotary evaporation. The resulting residue was chromatographed ( 50%⇒100% diethyl 
ether in petroleum ether on SiO2  ) to yield  1.7 g of 124 as a yellow oil ( 84.5%). 1H 
NMR (300 MHz, CDCl3 ) δ 7.31 (dd, J = 9.5, 6.8 Hz, 1H), 6.34 (d, J = 6.6 Hz, 1H),  6.26 
(d, J = 9.3 Hz, 1H), 4.52 (s, 1H), 3.78 (s, 6H); 13C NMR (75 MHz, CDCl3 )  δ 165.5, 
161.4, 155.6, 143.3, 116.0, 105.9, 56.2, 53.8; FTIR (Neat Film NaCl)   1740, 1640, 1559, 
1437, 1277, 1241, 1201, 1155, 1099, 1027, 808 cm-1 ; HRMS  (EI) m/z calc’d for 
C10H10O6  [M+]: 226.0477, found 226.0479. 
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O
CO2Me
CO2Me
O
Br
 
 
Dimethyl 2-(3-bromo-2-oxo-2H-pyran-6-yl)propanedioate (126). To a solution of  124 
( 283.0 mg, 1.2 mmol, 1.0 equiv ) in CCl4 ( 10 mL ) was added bromine ( 312 mg, 100 
µL , 1.9 mmol, 1.6 equiv ). The reaction mixture was stirred at ambient temperatures for 
72 hours then quenched by the addition of 20 mL of 20% Na2SO4(aq). The solution was 
extracted with CH2Cl2 ( 3 x 40 mL) and the combined organic layers were collected and 
dried over Na2SO4(anhydrous). After concentration by rotary evaporation, the crude 
residue was chromatographed ( 50% diethyl ether in petroleum ether on SiO2 ) to yield 
126 as a white powder ( 181 mg, 48%)  and 127 as a yellow powder ( 152 mg, 32%). 
To a flame-dried flask charged with 127 ( 28.0 mg, 0.07 mmol, 1 equiv ), Zn dust ( 10 
mg, 0.15, 2 equiv), and tetrahydrofuran ( 0.50 mL ) was added glacial acetic acid ( 0.25 
mL ). The reaction was stirred at ambient temperatures for 30 minutes, filtered through 
Celite, and then  extracted with CH2Cl2 ( 2 x 1 mL ). The combined organic layers were 
washed with brine. After drying over Na2SO4(anhydrous) and concentration by rotary 
evaporation, the crude residue was chromatographed ( 50% diethyl ether in petroleum 
ether on SiO2 ) to yield 126 (18 mg, 81%) as a white powder.  
126: 1H NMR (300 MHz, CDCl3 ) δ 7.68 (d, J = 7.2, 1H), 6.30 (d, J = 7.2 Hz, 1H),  4.55 
(s,  1H), 3.79 (s, 6H); 13C NMR (75 MHz, CDCl3 ) δ 164.1, 157.9, 154.9, 144.4, 112.1, 
106.6, 55.8, 53.9 ; FTIR (Neat Film NaCl)   1743, 1642, 1542, 1436, 1313, 1240, 1201, 
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1153, 1100, 1027, 978, 750 cm-1 ; HRMS  (EI) m/z calc’d for C10H9BrO6  [M+]:300 
.9582, found 303.9587. 
 
O
MeO2C CO2Me
O
Br
Br
 
 
Dimethyl 2-bromo-2-(3-bromo-2-oxo-2H-pyran-6-yl)propanedioate (127). See 
preparation of 126 for experimental details. 1H NMR (300 MHz, CDCl3 ) δ 7.69 (d, J = 
7.2, 1H), 6.70 (d, J = 7.2 Hz, 1H), 3.90 (s, 6H); 13C NMR (75 MHz, CDCl3 ) δ 164.1, 
156.8, 155.4, 143.8, 113.4, 106.4, 57.1, 55.2; FTIR (Neat Film NaCl)   1748, 1634, 1541, 
1436, 1336, 1265, 1228, 1102, 1052, 1020, 979, 772, 748 cm-1 ; HRMS  (EI) m/z calc’d 
for C10H9BrO6  [M+]: 383.8667, found 383.8657.   
 
HO CO2Me
 
 
(E)-Methyl 6-hydroxy-2-methylhex-2-enoate (123).   To a flame-dried flask charged 
with CH2Cl2 ( 60 mL ) was added γ-butyrolactone (121) ( 1.1 g, 13.0 mmol, 1 equiv).  
The reaction was cooled to -78° C, and a solution of DIBAL-H ( 2.0 g, 14.3 mmol, 1.1 
equiv ) in dry hexanes ( 11.5 ml ) was added over 15 minutes. The reaction was stirred 
for two hours then diluted with ethyl acetate ( 50 mL ), and a saturated solution of 
sodium/potassium tartrate ( 50 mL ) was then added.  After separation, the aqueous layer 
was  further extracted with ethyl acetate ( 2 x 50 mL ). The combined organics were 
combined, dried over MgSO4(anhydrous), and concentrated by rotary evaporation.  The 
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crude oil was dissolved in benzene ( 50 mL ) and added to a flask charged with stabilized 
ylide 122 ( 4.3 g, 12.3 mmol, 1.2 equiv ) and the reaction was heated to reflux and stirred 
for 12 hours. The reaction was cooled to ambient temperatures then diluted with diethyl 
ether ( 50 ml ) and saturated brine solution ( 50 mL). After separation the aqueous layers 
were further extracted with ether, and the combined organics were dried over 
MgSO4(anhydrous) and concentrated by rotary evaporation. The crude oil was 
chromatographed ( 0⇒100% ether in petroleum ether on SiO2 ) to yield 1.4 g ( 68% ) of 
123 as a clear colorless oil.  1H NMR ( 300 MHz, CDCl3 ) δ 6.70 ( t,  J = 7.5, 1H ), 3.66 ( 
s,  3H ),  3.58 ( t, J = 6.3  Hz, 3H ), 2.64 ( br s, 1H ), 2.20 ( m, 2H ), 1.78( s, 3H ), 1.64 ( 
m, 2H ); 13C NMR (75 MHz, CDCl3 ) δ 169.0, 142.2, 128.1, 62.1, 51.9, 31.6, 25.2, 12.5; 
FTIR (Neat Film NaCl)   3404, 1714, 1649, 1438, 1268.81196, 1129, 1059, 747 cm-1 ; 
HRMS  (EI) m/z calc’d for C8H14O3  [M+]: 158.0943, found 158.0943. 
 
I CO2Me
 
 
(E)-Methyl 6-iodo-2-methylhex-2-enoate (119a).  To a flame-dried flask was added 
(E)-Methyl 6-hydroxy-2-methylhex-2-enoate (123) ( 700 mg, 4.4 mmol, 1 equiv ), iodine 
chips ( 2.0 g, 7.9 mmol, 1.8 equiv ), imidazole ( 897 mg, 13.2 mmol, 3 equiv ),  
triphenylphosphine ( 1.9 g, 7.0 mmol, 1.6 equiv ), and toluene ( 45 mL ).  The reaction 
was stirred at room temperature for 2 hours then diluted with saturated NaHCO3 (aq) (  
20 mL ) and saturated Na2S2O3(aq)( 5 mL ). It was then extracted with Ethyl Acetate ( 3 
x 20 mL ). The combined organic extracts were washed with brine, dried over anhydrous 
MgSO4, and concentrated by rotary evaporation. The crude oil was chromatographed ( 
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hexanes in ethyl acetate 10:1 ⇒ 3:1 on SiO2 ) to give iodide 119a as a yellow oil ( 873 
mg, 74% ).1H NMR ( 300 MHz, CDCl3  ) δ 6.65 ( t,  J = 7.5, 1H ), 3.70 ( s,  3H ),  3.16 ( 
t, J = 6.7  Hz, 2H ), 2.26 ( m, 2H ), 1.92 ( m, 2H ), 1.84 ( s, 3H ); 13C NMR (75 MHz, 
CDCl3 ) δ 168.5, 140.1, 129.2, 52.0, 32.4, 29.5, 12.8, 6.2; FTIR ( Neat Film NaCl ) 1715, 
1651, 1435, 1282, 1260, 1219, 1167, 1107 cm-1 ; HRMS  ( EI ) m/z calc’d for C8H13O2I 
[M+]: 267.9961, found 267.9967. 
 
O
O
CO2Me
CO2MeMeO2C
  
(E)-Trimethyl 1-(2-oxo-2H-pyran-6-yl)hex-4-ene-1,1,5-tricarboxylate (117a). To an 
ice cold mixture of  acetonitrile ( 1 mL ) and Cs2CO3 ( 132.0 mg, 0.4 mmol, 1.1 equiv ) 
was added a solution of 124 ( 100.0 mg, 0.442 mmol, 1.2 equiv ) in acetonitrile (0.5 mL). 
The reaction was brought to ambient  temperature and stirred for 10 minutes, then cooled 
to 0° C.   A solution of 119a ( 99.0 mg, .4 mmol, 1 equiv ) in acetonitrile ( 0.5 mL ) was  
then added over 5 minutes. The reaction was allowed to warm to ambient temperature, 
then brought to reflux and stirred for 15 hours.   The reaction was then cooled to room 
temperature and  diluted with saturated NH4Cl(aq) ( 2 mL ) and extracted with ethyl 
acetate ( 3 x 2 mL). The combined organics were dried over Na2SO4 (anhydrous) and 
concentrated by rotary evaporation. The crude oil was chromatographed ( ethyl acetate in 
hexanes gradient 0⇒100% on SiO2 ) to yield 111 mg ( 83% ) of yellow oil. 1H NMR ( 
300 MHz, CDCl3  ) δ 7.32  ( dd,  J = 6.3, 6.9 Hz , 1H ), 6.66 ( t, J=7.4 Hz,  1H ),  6.58 ( d, 
J = 6.6  Hz, 1H ), 6.25 ( d, J = 6.3  Hz, 1H ) , 3.78 ( s, 6H ), 3.72 ( s, 3H ), 2.22 ( m, 4H ), 
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1.80 ( s, 3H ), 1.43 ( m, 3H ); 13C NMR (75 MHz, CDCl3 ) δ 168.7, 168.0, 161.3, 159.3, 
143.3, 141.2, 128.6, 115.5, 105.5, 62.6, 53.6, 52.0, 34.0, 28.7, 24.1, 12.7; FTIR ( Neat 
Film NaCl ) 1741, 1636, 1556, 1436, 1240, 1093, 807 cm-1 ; HRMS  ( EI)  m/z calc’d for 
C8H13O2I [M+]: 366.1314, found 366.1330.  
 
O
O
CO2Me
CO2MeMeO2C
Br
 
 
(E)-Trimethyl 1-(3-bromo-2-oxo-2H-pyran-6-yl)hex-4-ene-1,1,5-tricarboxylate 
(117b). To a mixture of dimethylformamide ( 3 mL ) and K2CO3 ( 64.7 mg, 0.5 mmol, 
1.1 equiv )  at 0° C was added a solution of 126 ( 130.2 mg, 0.4 mmol, 1.0 equiv )  in 
dimethylformamide ( 0.5 mL ) and 119a  ( 342.10 mg, 1.28 mmol, 3.0 equiv ) in 
dimethylformamide ( 0.5 mL ). The reaction mix was brought to room temperature and 
stirred for 10 minutes, then heated to 50° C for 5 hours.  The reaction was then cooled to 
room temperature and diluted with saturated aqueous NH4Cl ( 20 mL ) and extracted with 
ethyl acetate ( 3 x 10 mL ). The combined organic extracts were washed with brine ( 6 x  
10 mL ), dried over Na2SO4(anhydrous) and concentrated by rotary evaporation. The 
crude oil was chromatographed ( diethyl ether in petroleum ether gradient 50⇒100% on 
SiO2 ) to yield 110 mg ( 58% ) of 117b as a yellow powder. Furthermore, 170 mg of 
119a was recovered as a clear oil. 1H NMR ( 300 MHz, CDCl3 ) δ 7.66  ( d,  J = 6.6 Hz, 
1H ), 6.66 ( t, J=7.4 Hz,  1H ),  6.54 ( d, J = 6.6  Hz, 1H ),  3.79 ( s, 6H ), 3.72 ( s, 3H ), 
2.22 ( m, 4H ), 1.81 ( s, 3H ), 1.4 ( m, 2H ); 13C NMR (75 MHz, CDCl3 ) δ 168.5, 167.6, 
158.7, 157.6, 144.4, 141.0, 128.7, 111.2, 106.0, 62.3, 53.8, 52.0, 33.9, 28.6, 24.0, 12.7; 
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FTIR ( Neat Film NaCl ) 1742, 1714, 1634, 1542, 1436, 1242, 1073, 974, 749 cm-1 ; 
HRMS  ( EI ) m/z calc’d for C18H21O881Br [M+H]: 447.0477, found 447.0461. 
 
MeO2C
CO2Me
CO2MeO
O
Br
H  
 
Tricycle 116b  
A solution of 117b ( 63.0 mg, 0.15 mmol, 1.0 equiv ) in benzene ( 10 mL ), was sealed in 
a scintillation vial and heated to reflux for 72 hours. The reaction mixture was cooled to 
room temperature, the solvent removed by rotary evaporation, and the crude residue 
chromatographed (chloroform/diethyl ether/n-heptane, 1:1:1 on SiO2 ) to yield 117b as 
48 mg ( 76% ) of white powder. 1H NMR (500 MHz), CDCl3 δ 6.61  (d,  J = 8.1 Hz, 1H), 
6.59 (d, J=8.1 Hz,  1H), 3.77 (s, 1H) , 3.74 (s, 3H), 3.73 (s, 3H), 2.85 ( dd, J= 15.0 Hz, 
5.5 Hz, 1H), 2.23 (m, 2H), 1.8 (m, 2H), 1.4 (m, 1H), 1.38 (s, 3H), 1.2 (m, 1H); 13C NMR 
(75 MHz, CDCl3 ) δ 172.6, 169.3, 168.3, 166.7, 134.8, 133.3, 82.9, 66.0, 59.5, 53.1, 53.0, 
52.8, 52.6, 46.1, 27.9, 24.8, 20.3, 19.1; FTIR (Neat Film NaCl) 1773, 1734, 1435, 1304, 
1255, 1208, 1173, 1158, 1124, 1022, 945 cm-1 ; HRMS  (EI) m/z calc’d for C18H21O8Br 
[M+]: 444.0420, found 444.0411. Crystals were grown from dichloromethane/Hexanes. 
MP: 156–170° C (at these temperatures decarboxylation is thought to occur, as the crystal 
and the resulting liquid were vigorously bubbling, thus  it is unclear whether thermal 
decomposition precluded state change). 
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MeO2C
CO2Me
CO2MeO
O
H
H  
 
Tricycle 116a 
116b ( 18 mg, 0.04 mmol, 1.0 equiv ), Bu3SnH ( 18 mg, 0.06 mmol, 1.5 equiv ), AIBN ( 
1.5 mg, 0.009 mmol, 0.2 equiv ) and benzene ( 0.40 mL) were combined in a 1 dm vial, 
and stirred at reflux for 3 hours. The reaction was cooled to ambient temperature, 
concentrated by rotary evaporation, diluted with wet diethyl ether ( 1 mL ),  and 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) ( 10.5 mg, .07 mmol, 1.7 equiv ) was added. The 
resulting white suspension was stirred for 15 minutes, then filtered through Celite. The 
solvent was removed under vacuum, and the crude residue was purified by preparatory 
thin-layer chromatography   (chloroform/diethyl ether/n-heptane, 1:1:1 ) to yield 7.5 mg 
(50%) of 116a as a white residue. 1H NMR ( 500 MHz  CDCl3)   δ 6.75  ( d,  J = 8.0 Hz, 
1H ), 6.36 ( dd, J= 8.0, 6.0 Hz,  1H ), 3.77 ( s, 1H ) , 3.73 ( s, 3H ), 3.70 ( s, 3H ), 3.56 ( d, 
J= 6.0 Hz, 1H ), 3.01 ( dd, J=13 HZ, 6 HZ, 1H ), 2.3 ( m, 2H ), 1.8 ( m, 2H ), 1.36 ( m, 
2H ), 1.27 ( s, 3H ); 13C NMR (75 MHz, CDCl3 ) δ 175.4, 171.5, 169.5, 168.8, 136.2, 
128.304, 83.5, 59.4, 53.0, 52.9, 52.7, 49.3, 48.0, 42.2, 28.1, 24.0, 21.4, 20.6; FTIR (Neat 
Film NaCl) 1761, 1734, 1626, 1542, 1434, 1255, 1203, 1160, 1108, 1019, 689 cm-1 ; 
HRMS  (EI) m/z calc’d for C18H22O8 [M+H]+: 367.1393, found 367.1392. 
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MeO2C
CO2MeMeO2C
H  
 
Diene 125 
A solution of 117a ( 63.0 mg, 0.15 mmol, 1.0 equiv ) in toluene ( 10 mL ) was sealed in a 
scintillation vial and heated to reflux for 72 hours.  The reaction mixture was cooled to 
room temperature, the solvent removed by rotary evaporation, and the crude residue was 
purified by preparatory thin-layer chromatography  (30% ethyl acetate in hexanes) to 
yield 125 as 6.8 mg (62%) of white residue. 1H NMR (500 MHz), CDCl3 δ 5.91  (dd,  J = 
9.0, 5.5 Hz, 1H), 5.67 (d, J= 5.5 Hz,  1H), 5.61 (d, J = 9.0 Hz, 1H) , 3.78 (s, 3H), 3.76 (s, 
3H), 3.71 ( s, 3H),  3.00 ( dd, J= 6.0 Hz, 1H), 3.01 (dd, J = 13, 4.5 Hz, 1H), 2.44 ( d, J = 
13.5 Hz 1H), 1.82 (m, 1H), 1.62 (m, 1H), 1.38 (m, 2H), 1.26 (s, 1H), 1.19, (s, 2H); 13C 
NMR (75 MHz, CDCl3 ) δ 177.2, 171.2, 170.9, 136.6, 129.7, 122.5, 119.5, 62.3, 52.8, 
52.7, 52.4, 46.7, 41.1, 33.3, 29.7, 25.3, 21.6, 18.5; FTIR (Neat Film NaCl) 1731, 1435, 
1255,  1139, 801 cm-1 ; HRMS  (EI) m/z calc’d for C17H22O7 [M+H]+: 323.1495, found 
323.1485. 
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Figure A1.1.3  13C NMR (125 MHz, CDCl3) of compound 124 
Figure A1.1.2  Infrared spectrum (thin film/NaCl) of compound 124 
Appendix 1 — Spectra relevant to Chapter 2 
 
 53 
O
CO
2M
e
CO
2M
e
O
Br
 
Fi
gu
re
 A
1.
2.
1 
1 H
 N
M
R
 (5
00
 M
H
z,
 C
D
C
l 3)
 o
f c
om
po
un
d 
12
6 
 
Appendix 1 — Spectra relevant to Chapter 2 
 
 54 
 
Figure A1.2.3  13C NMR (125 MHz, CDCl3) of compound 126 
 
Figure A1.2.2  Infrared spectrum (thin film/NaCl) of compound 126 
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Figure A1.3.3  13C NMR (125 MHz, CDCl3) of compound 127 
 
Figure A1.3.2  Infrared spectrum (thin film/NaCl) of compound 127 
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Figure A1.4.3  13C NMR (125 MHz, CDCl3) of compound 123 
 
Figure A1.4.2  Infrared spectrum (thin film/NaCl) of compound 123 
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Figure A1.5.3  13C NMR (125 MHz, CDCl3) of compound 119a 
 
Figure A1.5.2  Infrared spectrum (thin film/NaCl) of compound 119a 
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Figure A1.6.3  13C NMR (125 MHz, CDCl3) of compound 117a 
 
Figure A1.6.2  Infrared spectrum (thin film/NaCl) of compound 117a 
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Figure A1.7.3  13C NMR (125 MHz, CDCl3) of compound 117b 
 
Figure A1.7.2  Infrared spectrum (thin film/NaCl) of compound 117b 
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Figure A1.8.3  13C NMR (125 MHz, CDCl3) of compound 116b 
 
Figure A1.8.2  Infrared spectrum (thin film/NaCl) of compound 116b 
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Figure A1.9.3  13C NMR (125 MHz, CDCl3) of compound 116a 
 
Figure A1.9.2  Infrared spectrum (thin film/NaCl) of compound 116a 
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 Figure A1.10.3  13C NMR (125 MHz, CDCl3) of compound 125 
 
Figure A1.10.2  Infrared spectrum (thin film/NaCl) of compound 125 
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Figure A2.1. ORTEP diagram of 116a. Shown at 50% probabilities The 
crystallographic data have been deposited in the Cambridge 
Database (CCDC) and has been placed on hold pending further 
instructions from me.  The deposition number is 656115.  Ideally the 
CCDC would like the publication to contain a footnote of the type: 
"Crystallographic data have been deposited at the CCDC, 12 Union 
Road, Cambridge CB2 1EZ, UK and copies can be obtained on 
request, free of charge, by quoting the publication citation and the 
deposition number 656115." 
 
116a 
 
 
Table A2.1.  Crystal data and structure refinement for HMN01 (CCDC 656115). 
Empirical formula  C18H21O8Br 
Formula weight  445.26 
Crystallization Solvent  Dichloromethane/hexanes 
Crystal Habit  Fragment 
Crystal size 0.30 x 0.15 x 0.05 mm3 
Crystal color  Colorless  
 Data Collection  
Type of diffractometer  Bruker SMART 1000 
Wavelength  0.71073 Å MoKα  
Data Collection Temperature  100(2) K 
θ range for 4422 reflections used 
in lattice determination  2.50 to 30.90° 
Unit cell dimensions a = 6.6117(3) Å 
 b = 19.4403(16) Å β= 101.003(3)° 
 c = 14.6195(13) Å 
Volume 1844.6(2) Å3 
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Z 4 
Crystal system  Monoclinic 
Space group  P21/c 
Density (calculated) 1.603 Mg/m3 
F(000) 912 
Data collection program Bruker SMART v5.630 
θ range for data collection 1.76 to 33.90° 
Completeness to θ = 33.90° 89.1 %  
Index ranges -10 ≤ h ≤ 9, 0 ≤ k ≤ 29, 0 ≤ l ≤ 22 
Data collection scan type  ω scans at 5 φ settings 
Data reduction program  Bruker SAINT v6.45A 
Reflections collected 11273 
Independent reflections 11273 [Rint= 0.0000] 
Absorption coefficient 2.273 mm-1 
Absorption correction TWINABS 
Max. and min. transmission 0.7466 and 0.5283 
 
 Structure Solution and Refinement  
Structure solution program  SHELXS-97 (Sheldrick, 1990) 
Primary solution method  Direct methods 
Secondary solution method  Difference Fourier map 
Hydrogen placement  Geometric positions 
Structure refinement program  SHELXL-97 (Sheldrick, 1997) 
Refinement method Full matrix least-squares on F2 
Data / restraints / parameters 11273 / 0 / 249 
Treatment of hydrogen atoms  Riding 
Goodness-of-fit on F2 1.437 
Final R indices [I>2σ(I),  7706 reflections] R1 = 0.0691, wR2 = 0.1161 
R indices (all data) R1 = 0.1128, wR2 = 0.1245 
Type of weighting scheme used Sigma 
Weighting scheme used w=1/σ2(Fo2) 
Max shift/error  0.001 
Average shift/error  0.000 
Largest diff. peak and hole 1.261 and -0.700 e.Å-3 
 Special Refinement Details  
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The crystal is twinned.  CELL_NOW was used to establish the following 
relationship between domains. Domain 2 is rotated from first domain by 180.0 degrees 
about reciprocal axis -0.001  0.000  1.000  and real axis  0.425 -0.001  1.000.  Of 999 
reflections, 869 reflections within 0.250 of an integer index are assigned to domain 1 
(130 reflections not yet assigned to a domain), 646 reflections within 0.250 of an integer 
index are assigned to domain 2, 121 of them exclusively. 
The data were integrated with SAINT to give the following; (Rint all scans = 
0.1057) 
     8959 data (   2726 unique ) involve domain  1 only,  mean I/sigma   4.1 
     8923 data (   2744 unique ) involve domain  2 only,  mean I/sigma   2.7 
    19687 data (   6016 unique ) involve   2 domains,  mean I/sigma   4.2 
Refinement of F2 against ALL reflections.  The weighted R-factor (wR) and 
goodness of fit (S) are based on F2, conventional R-factors (R) are based on F, with F set 
to zero for negative F2. The threshold expression of F2 > 2σ( F2) is used only for 
calculating R-factors(gt) etc. and is not relevant to the choice of reflections for 
refinement.  R-factors based on F2 are statistically about twice as large as those based on 
F, and R-factors based on ALL data will be even larger. 
All esds (except the esd in the dihedral angle between two l.s. planes) are 
estimated using the full covariance matrix.  The cell esds are taken into account 
individually in the estimation of esds in distances, angles and torsion angles; correlations 
between esds in cell parameters are only used when they are defined by crystal 
symmetry.  An approximate (isotropic) treatment of cell esds is used for estimating esds 
involving l.s. planes. 
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Table A2.2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement 
parameters (Å2x 103) for 116a (CCDC 656115).  U(eq) is defined as the trace of 
the orthogonalized Uij tensor.  
________________________________________________________________________
________  
 x y z Ueq 
________________________________________________________________________
________   
Br 2249(1) 6847(1) 71(1) 23(1) 
O(1) 184(3) 6893(1) 1925(1) 25(1) 
O(2) 2607(3) 6719(1) 3196(1) 20(1) 
O(3) 5675(3) 7904(1) 152(1) 20(1) 
O(4) 5019(3) 8586(1) 1275(1) 13(1) 
O(5) 5955(3) 10171(1) 1567(2) 28(1) 
O(6) 2525(3) 10033(1) 1213(2) 20(1) 
O(7) 1630(3) 9172(1) 3348(1) 17(1) 
O(8) 3101(3) 10212(1) 3340(2) 23(1) 
C(1) 2879(4) 7589(1) 969(2) 15(1) 
C(2) 1050(4) 8065(1) 944(2) 14(1) 
C(3) 1473(4) 8608(1) 1471(2) 13(1) 
C(4) 3680(4) 8651(1) 1978(2) 13(1) 
C(5) 4156(4) 8012(1) 2618(2) 12(1) 
C(6) 3644(4) 7343(1) 1997(2) 13(1) 
C(7) 5477(4) 6843(2) 2057(2) 19(1) 
C(8) 1915(4) 6963(1) 2347(2) 15(1) 
C(9) 1088(4) 6368(2) 3626(2) 22(1) 
C(10) 4658(4) 8021(1) 728(2) 14(1) 
C(11) 4347(4) 9350(1) 2453(2) 13(1) 
C(12) 6527(4) 9303(2) 3073(2) 20(1) 
C(13) 6723(4) 8703(1) 3736(2) 19(1) 
C(14) 6345(4) 8030(1) 3211(2) 16(1) 
C(15) 4393(5) 9904(1) 1703(2) 18(1) 
C(16) 2494(5) 10525(2) 463(2) 29(1) 
C(17) 2832(4) 9553(1) 3078(2) 16(1) 
C(18) 1813(5) 10453(2) 3980(2) 27(1) 
________________________________________________________________________
________ 
Appendix 2 — X-Ray Data Relevant to Chapter 2 
 78 
Table A2.3.   Bond lengths [Å] and angles [°] for  116a (CCDC 656115) 
________________________________________________________________________
Br-C(1)  1.940(3) 
O(1)-C(8)  1.200(3) 
O(2)-C(8)  1.325(3) 
O(2)-C(9)  1.453(3) 
O(3)-C(10)  1.196(3) 
O(4)-C(10)  1.352(3) 
O(4)-C(4)  1.484(3) 
O(5)-C(15)  1.206(3) 
O(6)-C(15)  1.328(3) 
O(6)-C(16)  1.451(3) 
O(7)-C(17)  1.206(3) 
O(8)-C(17)  1.339(3) 
O(8)-C(18)  1.457(3) 
C(1)-C(2)  1.517(4) 
C(1)-C(10)  1.541(4) 
C(1)-C(6)  1.565(4) 
C(2)-C(3)  1.307(4) 
C(3)-C(4)  1.508(4) 
C(4)-C(5)  1.551(4) 
C(4)-C(11)  1.551(4) 
C(5)-C(14)  1.539(4) 
C(5)-C(6)  1.584(4) 
(6)-C(8)  1.529(4) 
C(6)-C(7)  1.543(4) 
C(11)-C(17)  1.531(4) 
C(11)-C(15)  1.542(4) 
C(11)-C(12)  1.553(4) 
C(12)-C(13)  1.506(4) 
C(13)-C(14)  1.514(4) 
 
C(8)-O(2)-C(9) 115.5(2) 
C(10)-O(4)-C(4) 114.65(19) 
C(15)-O(6)-C(16) 114.2(2) 
C(17)-O(8)-C(18) 115.4(2) 
C(2)-C(1)-C(10) 107.5(2) 
C(2)-C(1)-C(6) 108.6(2) 
C(10)-C(1)-C(6) 105.4(2) 
C(2)-C(1)-Br 111.65(18) 
C(10)-C(1)-Br 108.98(18) 
C(6)-C(1)-Br 114.29(17) 
C(3)-C(2)-C(1) 113.5(2) 
C(2)-C(3)-C(4) 114.3(2) 
O(4)-C(4)-C(3) 107.7(2) 
O(4)-C(4)-C(5) 105.71(19) 
C(3)-C(4)-C(5) 108.6(2) 
O(4)-C(4)-C(11) 103.18(19) 
C(3)-C(4)-C(11) 115.7(2) 
C(5)-C(4)-C(11) 115.1(2) 
C(14)-C(5)-C(4) 112.5(2) 
C(14)-C(5)-C(6) 114.6(2) 
C(4)-C(5)-C(6) 108.3(2) 
C(8)-C(6)-C(7) 107.8(2) 
C(8)-C(6)-C(1) 110.1(2) 
C(7)-C(6)-C(1) 110.7(2) 
C(8)-C(6)-C(5) 107.2(2) 
C(7)-C(6)-C(5) 113.9(2) 
C(1)-C(6)-C(5) 107.2(2) 
O(1)-C(8)-O(2) 124.4(2) 
O(1)-C(8)-C(6) 125.7(3) 
O(2)-C(8)-C(6) 109.9(2) 
O(3)-C(10)-O(4) 120.8(2) 
O(3)-C(10)-C(1) 127.9(2) 
O(4)-C(10)-C(1) 111.3(2) 
C(17)-C(11)-C(15) 110.3(2) 
C(17)-C(11)-C(12) 107.9(2) 
C(15)-C(11)-C(12) 108.3(2) 
C(17)-C(11)-C(4) 109.3(2) 
C(15)-C(11)-C(4) 109.7(2) 
C(12)-C(11)-C(4) 111.3(2) 
C(13)-C(12)-C(11) 112.2(2) 
C(12)-C(13)-C(14) 111.0(2) 
C(13)-C(14)-C(5) 110.6(2) 
O(5)-C(15)-O(6) 124.6(3) 
O(5)-C(15)-C(11) 123.5(3) 
O(6)-C(15)-C(11) 111.9(2) 
O(7)-C(17)-O(8) 123.6(3) 
O(7)-C(17)-C(11) 125.7(2) 
O(8)-C(17)-C(11) 110.6(2)
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Table A2.4.   Anisotropic displacement parameters  (Å2x 104 ) for 116a (CCDC 656115).  
The anisotropic displacement factor exponent takes the form: -2π2 [ h2 a*2U 11  + ... + 
2 h k a* b* U12 ]. 
________________________________________________________________________
______  
 U11 U22  U33 U23 U13 U12 
________________________________________________________________________
______  
Br 227(2)  246(1) 214(2)  -91(1) 69(1)  -62(1) 
O(1) 142(10)  318(12) 278(12)  49(10) 22(9)  -55(10) 
O(2) 184(11)  222(11) 209(12)  53(8) 57(9)  -57(8) 
O(3) 211(11)  248(11) 174(11)  -37(8) 99(9)  -33(8) 
O(4) 111(10)  171(9) 116(10)  -7(8) 47(8)  -12(7) 
O(5) 227(13)  270(11) 388(14)  65(10) 169(10)  -56(9) 
O(6) 258(12)  163(10) 205(12)  73(8) 79(10)  34(8) 
O(7) 153(10)  159(10) 229(12)  3(8) 86(9)  -23(8) 
O(8) 309(13)  156(10) 277(13)  -61(9) 155(10)  -50(9) 
C(1) 131(15)  166(13) 164(15)  -44(11) 50(12)  -27(11) 
C(2) 98(13)  209(14) 112(14)  30(11) 11(11)  -4(11) 
C(3) 106(13)  164(13) 134(15)  32(11) 25(11)  20(11) 
C(4) 129(14)  139(12) 123(14)  3(10) 52(12)  -9(11) 
C(5) 116(14)  133(13) 114(14)  18(10) 18(11)  4(10) 
C(6) 105(13)  133(12) 152(15)  3(10) 61(12)  3(10) 
C(7) 161(14)  153(12) 270(16)  -18(13) 57(12)  18(12) 
C(8) 147(15)  116(14) 208(16)  -11(11) 86(12)  4(11) 
C(9) 236(17)  225(15) 245(18)  57(13) 142(14)  -24(13) 
C(10) 133(13)  166(14) 98(14)  -6(10) -22(11)  3(11) 
C(11) 110(13)  148(13) 143(15)  -20(11) 31(12)  -40(11) 
C(12) 180(16)  219(14) 200(16)  -51(12) 37(13)  -52(12) 
C(13) 129(14)  255(15) 170(16)  -21(12) -10(13)  -29(12) 
C(14) 116(13)  208(15) 160(15)  27(11) 9(12)  10(11) 
C(15) 226(16)  162(14) 189(17)  -12(12) 106(14)  -1(12) 
C(16) 470(20)  234(16) 214(17)  93(13) 207(16)  111(14) 
C(17) 195(15)  140(13) 142(16)  3(11) -10(12)  16(11) 
C(18) 384(19)  211(15) 260(18)  -82(13) 205(16)  -32(14) 
________________________________________________________________________
______  
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A3.1 Ireland–Claisen Model Studies 
Having successfully established proof of concept for the key intramolecular pyrone 
Diels–Alder cycloaddition, we sought to model the proposed Ireland–Claisen 
rearrangement (ICR).  Our initial plan was to prepare prenylated pyrone 132 by coupling 
of pyrone acid 133 with geraniol. Pyrone acid 133 would in turn be prepared from 
saponification and decarboxylation of malonates 124 or 125 (Scheme A3.1).  
 
Scheme A3.1.  Retrosynthetic analysis of ICR model system       
     
O
O
O
OH
O O
O
O
O
O
O
O
OMe
MeO
132 133
X = H, 124
X = Br, 126
X
XX
geraniol decarboxylation
 
However, in practice, treatment of malonates 124 or 126 with acidic or basic aqueous 
conditions led to complex mixtures of decomposition products. Furthermore, under a 
variety of Krapcho’s decarboxylation conditions, non-productive decomposition of the 
pyrone was also observed (Scheme A3.2). 
 
Scheme A3.2.  Initial attempts of saponification/decarboxylation 
                                 
Krapcho's conditions
acid or baseO
O
O
O
OMe
MeO
X = H, 124
X = Br, 126
X
O
O
O
OH
133
X
.       
  
We hypothesized that hydrolysis of the pyrone moiety was the cause of 
decomposition.1 In light of this hypothesis, our attention turned to a milder, nonaqueous, 
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decarboxylative method (Scheme A3.3).  We envisioned that substrate 113a could be 
derived from the Pd-catalyzed decarboxylative protonation of allyl ester 134.  
 
Scheme A3.3.  Revised retrosynthetic analysis of ICR model system       
                 
O O
O
O
O
O
O
O
O
OPd-catalyzeddecarboxylative 
protonation
113a 134  
The construction of desired pyrone ester 113a is shown in Scheme A3.4. Heating 
of Meldrum’s acid (135) with a stoichiometric amount of geraniol provided smooth 
conversion to half-acid 136.  Treatment of 136 with allyl bromide and K2CO3 gave the 
mixed malonate 137 in excellent yield. Exposure of mixed malonate 137 to 6-choloro-2-
pyrone and NaH yielded pyrone malonate 134.  Gratifyingly, treatment of 134 with 
Pd(PPh3)4, NEt3, and formic acid yielded the desired ester 113a. Although the Pd-
catalyzed, decarboxylative protonation gave variable yields (0–82%) of the desired ester, 
sufficient material for our Ireland–Claisen model studies were prepared.  No attempts 
were made to optimize this reaction, but in the best case the desired protonation product 
(113a) was made exclusively.  In the lower yielding cases, allylation was identified as the 
competing process.  
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Scheme A3.4. Construction of the ICR model compound 
O
O
O
O
 geraniol,
toluene,12h,
 reflux
     
(78% yield)
O
O O
OH
allyl bromide,
K2CO3, DMF
(83% yield)
geranyl-O
O O
O-allyl
6-chloro-2-pyrone,
 NaH, THF
(73% yield)
 HCO2H,
Pd(PPh3)4,NEt3,
THF
(0-82%)
O O
O
O
O
O
O
O
O
O
134
135 136 137
113a
 
Importantly, treatment of ester 113a with LDA and TMSCl at low temperatures 
allowed for smooth [3,3] sigmatropic rearrangement to desired ICR product 112a.  While 
initial efforts used THF as solvent, it was found that the use of HMPA as a co-solvent 
increased the reaction rate and improved the diastereoselectivity from 1.5:1 to 5:1 
(Scheme A3.5).  Much to our disappointment, attempts to directly cyclize ICR product 
111a via IMPDA were unsuccessful.  
The relative stereochemistry of the Ireland–Claisen rearrangement product has not yet 
been established.  However, control over E/Z selectivity in enolate formation, as well as 
the use of geraniol and its olefin isomer nerol are envisioned to allow for sufficient 
stereochemical modularity to prepare most of the transtaganolides, many of which are 
epimers at C8 (Scheme 2.2).   
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Scheme A3.5. Completion of ICR model study 
                     
O O
O
O
LDA, TMSCl
-78 °C, THF
1.5:1  dr
(ca. 20% yield)
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THF/HMPA
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113a
O
O
OHO
O
O
OHO
112a 111a
 
A3.2 Conclusion 
In conclusion, we have proposed a highly modular route to the transtaganolides.  This 
route is strongly supported by extensive model study work. An intramolecular pyrone 
Diels–Alder (IMPDA) model system was constructed and used to forge the tricyclic core 
of the natural product targets. Furthermore, an Ireland–Claisen model system was 
prepared and utilized in the construction of the C8 quaternary stereocenter.  
 
 
                                                
1) Eicher, T.; Hauptmann, S.; 6.3 2H-Pyran-2-one. The Chemistry of Heterocycles, 
2nd edition. Wiley-VCH: New York, 2003; pp 233–256. 
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Chapter 3 
The Total Syntheses of (±)-Transtaganolide C, (±)-Transtaganolide D, 
(±)-Basiliolide B, and (±)-epi-8-Basiliolide B 
 
3.1       Introduction 
Owing to their interesting biological activity and striking architectures, the 
transtaganolides (75 and 85) and basiliolides (76) have inspired significant interest from 
the synthetic community (Scheme 2.2).  Initial synthetic efforts from our own group,1 as 
well as those of Dudley2 and Lee,3 have utilized an intramolecular pyrone Diels–Alder 
(IMPDA) cycloaddition to construct the oxabicyclo[2.2.2]octene moiety constituting the 
ABD ring system of 75, 76 and 85.  However, these studies failed to install the C8 
quaternary center present in all of the transtaganolides and basiliolides (Scheme 2.2).  
Unpublished model studies from our group demonstrated the propensity of 
prenylated pyrones such as 113a to undergo facile Ireland–Claisen rearrangements (ICR) 
(Scheme 2.16). However, initial efforts to coax that ICR product 113a to cyclize via 
IMPDA were unsuccessful. As evidenced by our own IMPDA work, and extensive 
literature precedent, activation of the pyrone moiety by halogenation was needed to allow 
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IMPDA to proceed.4  Furthermore, we posited that halogenation of the 5–position would 
have the additional benefit of allowing for elaboration of the core to the natural product 
targets.   
3.2 Retrosynthetic Analysis 
Retrosynthetically, we envisioned that transtaganolide C (75a), transtaganolide D 
(75b) basiliolide B (76a), and epi-8-basiliolide B (76b) could be prepared in the 
laboratory via an Ireland–Claisen rearrangement (ICR)/intramolecular pyrone Diels–
Alder (IMPDA) sequence (Scheme 3.1).   We proposed that intermediate 138 could arise 
from pyrone 139 via an IMPDA.  Furthermore, we reasoned that IMPDA substrate 139 
could be derived from the Ireland–Claisen rearrangement of pyrone ester 140.  The ICR 
substrate (140) was to arise from the coupling of a geraniol derivative (141) to pyrone 
acid 142, which possesses the requisite halogenation.  
 
Scheme 3.1. Retrosynthetic analysis 
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3.3  Synthesis of Halogenated Substrate 
The synthesis began with the palladium catalyzed coupling of known (Z)-methyl 
iodoacrylate 1435 with commercially available 3-butyn-1-ol to provide methylester 144 in 
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good yield (Scheme 3.2).  Heating of ester 144 with CuBr2 in the presence of a catalytic 
amount of dicyclohexylamine hydrobromide led to the formation of bromopyrone 145.9  
Jones oxidation of the resulting primary alcohol 145 yielded the desired pyrone acid 142a 
in moderate yield.  Direct DCC coupling of the pyrone acid 142a to geraniol cleanly 
provided Ireland–Claisen substrate 140a.  We were delighted to find that a slow addition 
of a NaHMDS solution to a cold mixture of pyrone ester 140a and TMSCl promoted a 
high yielding Ireland–Claisen rearrangement.  After removal of volatiles from the crude 
ICR reaction,6 prolonged heating in a sealed tube charged with benzene and argon 
smoothly afforded the IMPDA product 138d in 87% yield from 140a as a mixture of C(8) 
diastereomers (~2:1 dr). 
 
Scheme 3.2. Synthesis  of the functionalized core 
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3.4  Larsson’s ICR Conditions and Our Development of an ICR/IMPDA Cascade 
Shortly after our preparation of brominated tricycle 138d, Larsson and co-workers 
reported a nearly identical strategy for the synthesis of the cores of the transtaganolides 
(Scheme 3.3).6  Notable in their strategy was the catalytic use of a mild base to induce the 
ICR. Furthermore, they demonstrated that tricycle 147 was a competent cross-coupling 
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partner, as 148 could be prepared by treatment with TMS-acetylene employing 
Sonagashira’s conditions. 
 
Scheme 3.3. Larsson’s partial synthesis 
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While the authors specifically stated that the IMPDA did not proceed under their 
ICR conditions due to substrate decomposition, we knew from our work that if the 
intermediate TMS-ester was not hydrolyzed, the ICR product could be used directly in 
the IMPDA reaction. Capitalizing on Larsson’s successful choice of reaction conditions, 
and experimental insight gained by our group, we were able to develop conditions for a 
one-pot ICR/IMPDA cascade reaction, preparing 138b from 140b in a single operation 
(Scheme 3.4). 
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Scheme 3.4. Development of the ICR/IMPDA cascade reaction 
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3.5  The Total Syntheses of Transtaganolides C and D 
The challenge in advancing intermediates akin to tricycle 138b (Scheme 3.4) to 
the natural products lies in the formation of the unusual 7-methoxy-4,5-dihydrooxepin-
2(3H)-one ring (ring C, Scheme 3.5).7  Embedded within this ring is an acyl ketene acetal 
that is potentially labile to both acid and base, as evidenced by the co-isolation of seco 
acid derivatives (90 and 91, Scheme 2.2) from Thapsia sp.8   Retrosynthetically, we 
envisioned that the C-ring could be prepared by a formal [5+2] annulation process of 
advanced tricycle 138b and methoxyacetylene, or a suitable derivative, leading directly to 
the natural products (Scheme 3.5).  Tricycle 138 would be prepared from the tandem 
Claisen/Diels-Alder sequence of ester 140.  Importantly, with an available late stage 
construction of ring C, variants of this ester (e.g., 140b and 140c) prepared from geraniol 
derivatives could provide rapid access to a number of basiliolide and transtaganolide 
natural products. 
 
Scheme 3.5. Retrosynthetic analysis of end-game strategy 
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At the outset of our studies to build the C-ring, we attempted a variety of inter- 
and intramolecular annulation strategies but were unable to affect formation of the 
daunting C-ring.  Having few remaining options, we turned our attention to approaches 
involving palladium-mediated cross-coupling reactions.9   In addition to the possible 
steric hindrance of vinyl halide 138, no successful cross-coupling reactions of 
methoxyacetylene or derivatives thereof have been reported to any vinyl or aryl halide.  
Nonetheless, limited reports of tin and zinc derivatives of commercial ethoxyacetylene in 
palladium-catalyzed cross-couplings have been published and provided some precedent 
for the coupling.10,11  Hence, efforts turned to the preparation of stannane 151 (Scheme 
3.6). We were pleased to find, that when exposed to LiNEt2, 1,1-dimethoxy-2-chloro-
acetaldehyde (149) was transformed into lithium acetylide 150,12 which could be 
quenched with tributyltin chloride to safely13 afford stannane 151 in 78% yield in a single 
operation. 
 
 Scheme 3.6. Synthesis of methoxyacetylene reagent 
                                    
Cl
H
OMeMeO OMe
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OMe
Bu3Sn
LiNEt2 
(3 equiv)
THF
0 °C, 2 h
Bu3SnCl
0!23 °C, 4 h 
(78% yield)149 150 151  
 
Attempts to directly couple stannane 151 to iodoacid 138b (prepared from 140b) 
were unsuccessful under standard cross-coupling conditions.  We attributed the lack of 
desired reactivity to acid-mediated decomposition of stannane 151.14  Therefore, 
extensive efforts were undertaken to devise a suitable protecting group strategy for the 
carboxylic acid moiety.  Ultimately, acid 138b was transformed into tert-butyl 
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dimethylsilyl ester 15215 by treatment with TBSCl and imidazole.16  Exposure of silyl 
ester 152 and stannane 151 to Pd(PPh3)4 or Fu’s Pd(Pt-Bu3)217 led to transient formation 
of enyne 153.  While observable by mass spectrometry and 1H NMR analysis, direct 
isolation of methoxyenyne 153 proved difficult.  After optimization of the reaction 
conditions, we found that aqueous work-up effected an situ desilylation and cyclization to 
afford a separable mixture of transtaganolide C (75a) and transtaganolide D (75b) in 21% 
and 10% yield, respectively (19% and 10% with Fu’s catalyst).  The relative 
stereochemistry of synthetic transtaganolide C (75a) was unambiguously confirmed by 
X-ray crystallography,18 and synthetic transtaganolides C and D were spectroscopically 
indistinguishable from the naturally occurring isolates.19  
 
Scheme 3.7. Total synthesis of transtaganolides C and D and X-ray crystal structure 
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3.6  The Total Syntheses of Basiliolide B and Epi-8-Basiliolide B 
With the syntheses of transtaganolide C (75a) and transtaganolide D (75b) 
serving as a proof of concept, we sought to extend our approach to the rapid total 
synthesis of more complex members of this family.  Our efforts to prepare basiliolide B 
(76a) were undertaken by preparation of known geraniol derivative 141a (available in 3 
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steps)20 and coupling to iodopyrone acid 142b producing ester 140c in excellent yield 
(Scheme 3.8). 
We were pleased to find that treatment of ester 140c with N,O-
bis(trimethylsilyl)acetamide (BSA) and triethylamine resulted in a Claisen/Diels-Alder 
cascade to yield the resulting acid 138c in a single operation and in 67% yield as a 2:1 
mixture of diastereomers (Scheme 3.8).  This represents a significant improvement over 
previous, two-step procedures that required isolation and/or manipulation of the Claisen 
products (see Schemes 3.2–3.4), and is the first example in this area that utilizes a more 
functionalized dienophile.  Following silylation of the free acid (138c→154),21 the 
resulting silyl ester 154 was exposed to our methoxyalkynylation conditions comprised of 
stannane 151 and Pd(Pt-Bu3)2.  Gratifyingly, cross-coupling and treatment of the crude 
product mixture with H2O resulted in the production and isolation of basiliolide B (76a)22 
and previously unreported epi-8-basiliolide B (76b) in 5% and 14% yields, respectively 
(6% and 12% with Pd(PPh3)4).  
 
Scheme 3.8. Synthesis of basiliolide B and epi-8-basiliolide B  
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3.7  Conclusion 
A rapid, modular, and convergent strategy for the synthesis of the basiliolides and 
transtaganolides has been described. Basiliolide B (76a), epi-8-basiliolide B (76b), 
transtaganolide C (75a) and transtaganolide D (75b) were each prepared in only seven 
steps (longest linear sequence) from commercially available materials.  Critical to the 
success of this effort was the development of an effective preparation of, and cross-
coupling protocol for, methoxyacetylide 151.  Remarkably, the disclosed end-game 
procedure transforms simple, monocyclic, achiral precursors to the stereochemically rich, 
tetracyclic natural products in three steps (e.g., 140c→76a).  
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3.8  Experimental Section 
3.8.1  Materials and Methods  
Unless otherwise stated, reactions were performed in flame-dried glassware under an argon 
or nitrogen atmosphere using dry deoxygenated solvents.  Solvents were dried by passage 
through an activated alumina column under argon. Pd(t-Bu3P)2, N,N'-
dicyclohexylcarbodiimide, 1,1-dimethoxy-2-chloro-acetaldehyde, N,O-
bis(trimethylsilyl)acetamide, N-methyl-N-(tert-butyldimethylsilyl)trifluoroacetamide, and 
imidazole were purchased from Sigma-Aldrich Chemical Company and used as received. 
Pd(PPh3)4 was prepared using known methods. Thin-layer chromatography (TLC), both 
preparatory and analytical, were performed using E. Merck silica gel 60 F254 precoated 
plates (0.25 mm) and visualized by UV fluorescence quenching, p-anisaldehyde, I2, or 
KMnO4 staining.  ICN Silica gel (particle size 0.032–0.063 mm) was used for flash 
chromatography.  1H NMR, and 13C NMR spectra were recorded on a Varian Mercury 300 
(at 300 MHz) or on a Varian Unity Inova 500 (at 500 MHz).  1H NMR spectra are reported 
relative to CDCl3 (7.26 ppm).  Data for 1H NMR spectra are reported as follows: chemical 
shift, multiplicity, coupling constant (Hz), integration.  Multiplicities are reported as follows: 
s = singlet, d = doublet, t = triplet, q = quartet, sept. = septet, m = multiplet, comp. m = 
complex multiplet, app. = apparent, bs = broad singlet.  13C NMR spectra are reported 
relative to CDCl3 (77.0 ppm).   FTIR spectra were recorded on a Perkin Elmer SpectrumBX 
spectrometer and are reported in frequency of absorption (cm-1).  HRMS were acquired 
using an Agilent 6200 Series TOF with an Agilent G1978A Multimode source in 
electrospray ionization (ESI), atmospheric pressure chemical ionization (APCI) or 
multimode-ESI/APCI.  Crystallographic data were obtained from the Caltech X-ray 
Diffraction Facility. 
 
Chapter 3 — The Total Syntheses of (±)-Transtaganolide C, (±)-Transtaganolide D, (±)-Basiliolide B, and 
(±)-epi-8-Basiliolide B 
 
 95 
3.8.2  Experimental Procedures 
 
O OH
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Iodoacid 138b.  To a solution of 140b (6.2 g, 15 mmol, 1.0 equiv) in toluene (75 mL) at 
25 ˚C in a sealed tube was added N,O-bis(trimethylsilyl)acetamide (7.2 mL, 30 mmol 2.0 
equiv).  To the reaction mixture was then added triethylamine (0.41 mL, 3.0 mmol, 0.20 
equiv).  The reaction mixture was heated to 110 ˚C and stirred for 20 minutes.  The 
mixture was cooled to 25 ˚C and diluted with toluene (750 mL).  The reaction mixture 
was then re-heated to 100 ˚C and stirred for 4 days. The mixture was cooled to 25 ˚C and 
extracted with saturated aqueous NaHCO3 (7 x 100 mL). To the combined aqueous 
extracts was added 1 M aqueous HCl until pH = 3.  The aqueous layer was then extracted 
with ethyl acetate (3 x 100 mL).  The combined organics were dried over Na2SO4, and 
concentrated by rotary evaporation to yield 3.2 g (51%) of 138a as a tan foam.  
Major: 1H NMR (500 MHz, CDCl3) δ 6.93 (d, J = 6.5 Hz, 1H), 6.01 (dd, J = 10.5, 17.5 
Hz, 1H), 5.05–5.02 (m, 2H), 3.00–2.94 (m, 2H), 1.68–1.42 (m, 5H), 1.29 (s, 3H), 1.08 (s, 
3H), 1.00 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 172.7, 170.5, 148.0, 140.0, 111.5, 97.9, 
84.7, 59.4, 56.5, 47.9, 39.8, 38.2, 36.8, 29.8, 24.5, 20.5, 18.4. 
Minor: 1H NMR (500 MHz, CDCl3) δ 6.93 (d, J = 6.5 Hz, 1H), 6.35 (dd, J = 11.0, 17.5 
Hz, 1H), 5.09 (d, J = 11.0 Hz, 1H), 5.05–5.02 (m, 1H), 3.00–2.94 (m, 2H), 1.92–1.90 (m, 
1H), 1.68–1.42 (m, 4H), 1.26 (s, 3H), 1.08 (s, 3H), 1.00 (s, 3H); 13C NMR (125 MHz, 
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CDCl3) δ 172.7, 170.4, 140.4, 140.3, 113.7, 97.4, 84.8, 61.0, 56.6, 48.0, 39.3, 38.7, 37.0, 
29.8, 29.5, 24.5, 20.6. 
FTIR (Neat Film NaCl) 3082, 2967, 2931, 1754, 1741, 1738, 1732, 1708, 1414, 1396, 
1219, 1175, 964, 916, 874, 797, 736 cm-1; HRMS (Multimode-ESI/APCI) m/z calc’d for 
C17H21O4I [M+H]+: 417.0557, found 417.0553. 
 
 
O OTBS
O
O
H
I
 
 
tert-Butyldimethylsilyl ester 152.  To a solution of 138a (46 mg, 0.11 mmol, 1.0 equiv) 
in dimethylformamide (0.30 mL) were added tert-butyldimethylsilylchloride (84 mg, 
0.56 mmol, 5.0 equiv) and imidazole (76 mg, 1.1 mmol, 10 equiv).  The reaction was 
warmed to 40 ˚C and then stirred for 12 hours.  The reaction mixture was then diluted 
with saturated aqueous NaCl (1 mL) and extracted with diethyl ether/hexane  (1:1) (3 x 2 
mL).  The combined organic extracts were washed with saturated aqueous KHSO4  (1 
mL) and then with saturated aqueous NaCl (3 x 1 mL). The combined organics were 
dried over Na2SO4, and concentrated by rotary evaporation.  The crude oil was 
chromatographed (ethyl acetate in hexane 10⇒50% on SiO2) to yield 39 mg (66%) of 6b 
as a white powder.   
Procedure 2.  To a solution of 138a (180 mg, 0.43 mmol, 1.0 equiv) in acetonitrile (0.43 
mL) was added N-methyl-N-(tert-butyldimethylsilyl)trifluoroacetamide (1.0 g, 4.3 mmol, 
10 equiv) at 25 ºC and stirred for 15 minutes. The reaction mixture was diluted with 
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saturated aqueous NaCl (1 mL) and extracted with diethyl ether/hexane  (1:1) (3 x 2 mL).  
The combined organic extracts were washed with saturated aqueous KHSO4  ( 1 mL ) 
and then with saturated aqueous NaCl (3 x 1 mL). The combined organics were dried 
over Na2SO4, and concentrated by rotary evaporator.  The crude oil was chromatographed 
(ethyl acetate in hexane 10⇒50% on SiO2) to yield 150 mg (64%) of 152 as a white 
powder.   
Major: 1H NMR (500 MHz, CDCl3) δ 6.90 (d, J = 6.5 Hz, 1H), 6.03 (dd, J = 11.0, 17.5 
Hz, 1H), 4.99 (d, J = 17.5 Hz, 1H), 4.99 (d, J = 11.0 Hz, 1H), 2.95 (s, 1H), 2.93 (d, J = 
6.5 Hz, 1H), 1.66–1.39 (m, 4H), 1.32–1.29 (m, 1H), 1.26 (s, 3H), 1.07 (s, 3H), 0.99 (s, 
3H), 0.91 (s, 9H), 0.29 (s, 3H), 0.27 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 170.6, 169.1, 
149.2, 139.7, 110.5, 98.7, 84.6, 60.4, 56.7, 48.2, 40.1, 38.7, 36.9, 29.8, 25.5, 24.5, 20.7, 
18.1, 17.5, –4.8, –4.8. 
Minor: 1H NMR (500 MHz, CDCl3) δ 6.90 (d, J = 6.5 Hz, 1H), 6.40 (dd, J = 11.0, 17.5 
Hz, 1H), 5.05 (dd, J = 1.0, 11.0 Hz, 1H), 5.03–4.98 (m, 1H), 2.91 (d, J = 6.5 Hz, 1H), 
2.86 (s, 1H), 1.85 (dt, J = 3.5, 13.5 Hz, 1H), 1.66–1.39 (m, 3H), 1.36 (s, 3H), 1.34–1.29 
(m, 1H), 1.05 (s, 3H), 0.98 (s, 3H), 0.90 (s, 9H), 0.30 (s, 3H), 0.28 (s, 3H); 13C NMR 
(125 MHz, CDCl3) δ 170.6, 169.3, 141.3, 139.9, 112.9, 98.3, 84.7, 61.8, 56.8, 48.4, 39.6, 
39.4, 37.2, 29.6, 25.6, 25.4, 24.4, 20.8, 17.5, –4.9, –4.9. 
FTIR (Neat Film NaCl) 2959, 2929, 2857, 1760, 1716, 1708, 1471, 1284, 1250, 1173, 
1022, 967, 840, 827, 789, 736 cm-1; HRMS (Multimode-ESI/APCI) m/z calc’d for 
C23H36O4ISi [M+H]+: 531.1422, found 531.1432. 
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75a Transtaganolide C
(aka Basiliolide A2)
O
MeO
O
O
O
H
75b Transtaganolide D
(aka Basiliolide A1)  
 
Transtaganolides (75). In a nitrogen filled glovebox, to a solution of 152 (16 mg, 0.030 
mmol, 1.0 equiv) and Pd(PPh3)4 (35 mg, 0.030 mmol, 1 equiv) in dimethylformamide 
(0.30 mL, 0.10 M) was added tributyl(2-methoxyethynyl)stananne (151) (32 mg, 0.090 
mmol, 3.0 equiv).  The reaction was stirred at 31 ˚C for 16 h.  The reaction mixture was 
then treated with water (30 µL) and stirred at room temperature for 1 hour.  The mixture 
was diluted with ethyl acetate (1 mL) and washed with water (4 x 0.5 mL) and 
concentrated by rotary evaporation.  The crude oil was purified by normal phase HPLC to 
yield 2.1 mg (21%) of transtaganolide C (75a) and 1.1 mg (10%) of transtaganolide D 
(75b) as white powders. Crystals were grown by slow evaporation from acetonitrile. 
Procedure 2. In a nitrogen filled glovebox, to a solution of 152 (16 mg, 0.030 mmol, 1.0 
equiv) and Pd(t-Bu3P)2 (15 mg, 0.030 mmol, 1.0 equiv) in dimethylformamide (0.30 mL, 
0.10 M) was added tributyl(2-methoxyethynyl)stannane (10) (32 mg, 0.090 mmol, 3.0 
equiv).  The reaction was stirred at 31 ºC for 10 hours. The reaction mixture was then 
treated with water (30 µL) and stirred at room temperature for 1 hour.  The mixture was 
diluted with ethyl acetate (1 mL) and washed with water (4 x 0.5 mL) and concentrated 
by rotary evaporation.  The crude oil was purified by normal phase HPLC to yield 2.0 mg 
(19%) of transtaganolide C (75a) and 1.0 mg (10%) of transtaganolide D (75b) as white 
powders.  
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Transtaganolide C (75a). 
1H NMR (500 MHz, CDCl3) δ6.07 (dd, J = 1.5, 6.5 Hz, 1H), 5.80 (dd, J = 11.0, 17.5 Hz, 
1H), 5.07 (d, J = 17.5 Hz, 1H), 5.03 (d, J = 11.0 Hz, 1H), 5.00 (d, J = 1.5 Hz, 1H), 3.71 
(s, 3H), 3.23 (s, 1H), 3.06 (d, J = 6.5 Hz, 1H), 1.71–1.63 (m, 3H), 1.60 (s, 3H), 1.44 (m, 
1H), 1.30 (m, 1H), 1.08 (s, 3H), 0.97 (s, 3H); 13C NMR (125 MHz, CDCl3) 
δ 171.8, 162.3, 156.7, 146.5, 138.0, 123.6, 112.8, 87.3, 79.3, 56.3, 53.8, 50.6, 48.1, 38.4, 
38.3, 33.3, 29.9, 24.8, 19.9, 19.2; FTIR (Neat Film NaCl) 2965, 2928, 2872, 1791, 1761, 
1668, 1619, 1456, 1334, 1267, 1233, 1178, 1115, 970, 954, 828 cm-1; HRMS 
(Multimode-ESI/APCI) m/z calc’d for C20H24O5 [M+H]+: 345.1697, found 345.1703; 
MP: 135–160 ºC (at these temperatures decarboxylation is thought to occur, as the 
crystalline sample and the resulting liquid were vigorously bubbling throughout the 
measurement; thus it is unclear whether thermal decomposition precluded state change). 
Transtaganolide D (75b).  
1H NMR (500 MHz, CDCl3) δ 7.00 (dd, J = 11.0, 17.5 Hz, 1H), 6.09 (dd, J = 1.0, 6.5 Hz, 
1H), 5.15 (dd, J = 1.0, 11.0 Hz, 1H), 5.05 (dd, J = 1.0, 17.5 Hz, 1H), 5.02 (d, J = 1.0 Hz, 
1H), 3.73 (s, 3H), 3.13 (s, 1H), 3.06 (d, J = 6.5 Hz, 1H), 1.91 (dt, J = 3.5, 13.5 Hz, 1H), 
1.64 (dquint, J = 3.0, 13.5 Hz, 1H), 1.58 (m, 1H), 1.39 (dt, J = 3.5, 13.5 Hz, 1H), 1.33 
(dd, J = 4.5, 13.5 Hz, 1H), 1.22 (s, 3H), 1.04 (s, 3H), 0.97 (s, 3H); 13C NMR (125 MHz, 
CDCl3) δ 171.7, 162.6, 156.7, 142.9, 137.7, 123.9, 112.1, 87.3, 79.4, 56.3, 54.0, 53.3, 
48.4, 40.5, 38.4, 33.3, 29.9, 28.5, 24.8, 20.5; FTIR (Neat Film NaCl) 2964, 2929, 2872, 
1764, 1760, 1738, 1667, 1620, 1467, 1334, 1267, 1235, 1195, 1177, 1106, 1009, 954, 827 
cm-1; HRMS (Multimode-ESI/APCI) m/z calc’d for C20H24O5 [M+H]+: 345.1697, found 
345.1698; MP: 135–160 ºC (at these temperatures decarboxylation is thought to occur, as 
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the crystalline sample and the resulting liquid were vigorously bubbling throughout the 
measurement; thus it is unclear whether thermal decomposition precluded state change). 
 
 
O
I
O
O O
CO2Me  
 
Ester 140c.  To a solution of 12 (140 mg, 0.70 mmol, 1.0 equiv) and 13 (210 mg, 0.70 
mmol, 1.0 equiv) in acetonitrile (7.0 mL) was added N,N'-dicyclohexylcarbodiimide (190 
mg, 0.91 mmol, 1.3 equiv) at 0 ˚C.  The reaction was warmed to 25 ºC and stirred for 
seven additional hours.  The reaction mixture was then filtered through a pad of Celite, 
and then concentrated by rotary evaporation.  The crude reaction mixture was then 
chromatographed (ethyl acetate in hexane 0⇒30% on SiO2 ) to give 300 mg (94%) of 7b 
as a pale yellow oil.  1H NMR (500 MHz, CDCl3) δ 7.45 (d, J = 10.0 Hz, 1H), 6.70 (tq, J 
= 1.5, 7.5 Hz, 1H), 6.06 (d, J = 10.0 Hz, 1H), 5.35 (tq, J = 1.5, 7.0 Hz, 1H), 4.67 (d, J = 
7.0 Hz, 2H), 3.77 (s, 2H), 3.72 (s, 3H), 2.30 (q, J = 7.5 Hz, 2H), 2.16 (t, J = 7.5 Hz, 2H), 
1.83 (q, J = 1.5 Hz, 3H), 1.72 (q, J = 1.5 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 168.5, 
166.6, 160.3, 157.9, 151.2, 142.0, 141.3, 128.0, 118.3, 116.1, 70.6, 62.5, 51.7, 42.6, 38.0, 
26.8, 16.5, 12.4; FTIR (Neat Film NaCl) 2988, 2950, 1738, 1714, 1438, 1366, 1268, 
1232, 1126, 1082, 1023, 955, 745 cm-1; HRMS (Multimode-ESI/APCI) m/z calc’d for 
C18H25NO6I [M+NH4]+:478.0721, found 478.0725. 
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Iodoacid 138c.  To a solution of 140c (96 mg, 0.21 mmol, 1.0 equiv) in toluene (1.1 mL) 
in a sealed tube were successively added triethylamine (6.0 µL, 0.042 mmol, 0.20 equiv) 
and N,O-bis(trimethylsilyl)acetamide (100 µL, 0.42 mmol, 2.0 equiv).  The reaction 
mixture was heated to 110 ˚C and stirred for 20 minutes, then cooled to 25 ˚C.  The 
reaction mixture was diluted with toluene (250 mL) and heated to 100 ˚C for 48 hours.  
The reaction was then cooled to 25 ˚C, the solvent removed by rotary evaporation, and 
the crude residue chromatographed (hexane/ethyl acetate/acetic acid, 1:1:0.01 on SiO2) to 
give 64 mg (67%) of 138c as a colorless foam. 
Major: 1H NMR (500 MHz, CDCl3) δ 6.93 (d, J = 6.5 Hz, 1H), 6.02 (dd, J = 10.5, 17.5 
Hz, 1H), 5.07–5.03 (m, 2H), 3.72 (s, 3H), 3.56–3.53 (m, 1H), 3.03 (s, 1H), 2.40–2.33 (m, 
1H), 1.77–1.56 (m, 4H), 1.32 (s, 3H), 1.30 (s, 3H); 13C NMR (125 MHz, CDCl3) δ  147.9, 
139.7, 111.6, 99.2, 84.2, 59.2, 53.0, 52.6, 47.8, 44.5, 40.0, 38.1, 20.8, 18.4. 
Minor: 1H NMR (500 MHz, CDCl3) δ 6.93 (d, J = 6.5 Hz, 1H), 6.33 (dd, J = 11.0, 17.5 
Hz, 1H), 5.10 (d, J = 11.0 Hz, 1H), 5.07–5.03 (m, 1H), 3.72 (s, 3H), 3.56–3.53 (m, 1H), 
2.97 (s, 1H), 2.40–2.33 (m, 1H), 1.98–1.95 (m, 1H), 1.77–1.56 (m, 3H), 1.38 (s, 3H), 
1.30 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 169.1, 169.0, 140.4, 140.0, 113.5, 98.8, 
84.3, 60.6, 52.7, 48.0, 39.45, 38.5, 29.8, 20.8, 20.8, 20.8. 
FTIR (Neat Film NaCl) 3080, 2951, 1756, 1739, 1734, 1700, 1559, 1506, 1457, 1211, 
911, 756 cm-1; HRMS (Multimode-ESI/APCI) m/z calc’d for C18H22O6I [M+H]+: 
461.0456, found 461.0460. 
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tert-Butyldimethylsilyl ester 154.  To a solution of 138c (89 mg, 0.11 mmol, 1.0 equiv) 
in dimethylformamide (0.52 mL) were added tert-butyldimethylsilylchloride (150 mg, 
0.97 mmol, 5.0 equiv) and imidazole (130 mg, 1.9 mmol, 10 equiv).  The reaction 
mixture was warmed to 40 ˚C and stirred for 3 hours.  The crude mixture was then diluted 
with saturated aqueous NaCl (1 mL) and extracted with diethyl ether/hexane (1:1) (3 x 2 
mL).  The combined organic extracts were washed with saturated aqueous NaCl (3 x 1 
mL), dried over Na2SO4, and concentrated by rotary evaporation to yield 76 mg (68%) of 
154 as a pale yellow powder.   
Procedure 2. To a solution of 138c (61 mg, 0.13 mmol, 1 equiv) in acetonitrile (0.13 mL, 
1.0 M) was added N-methyl-N-(tert-butyldimethylsilyl)trifluoroacetamide (320 mg, 1.3 
mmol, 10 equiv) at 25 ˚C and stirred for 15 minutes. The reaction mixture was diluted 
with saturated aqueous NaCl (1 mL) and extracted with diethyl ether/hexane  (1:1) (3 x 2 
mL).  The combined organic extracts were washed with saturated aqueous KHSO4  (1 
mL) and then with saturated aqueous NaCl (3 x 1 mL). The combined organics were 
dried over Na2SO4, and concentrated by rotary evaporator.  The crude oil was 
chromatographed (ethyl acetate in hexane 10⇒50% on SiO2) to yield 51 mg (66%) of 
154 as a white powder. 
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Major: 1H NMR (500 MHz, CDCl3) δ 6.92 (d, J = 6.5 Hz, 1H), 6.04 (dd, J = 10.5, 17.5 
Hz, 1H), 5.01 (d, J = 10.5 Hz, 1H), 5.01 (d, J = 17.5 Hz, 1H), 3.72 (s, 3H), 3.53 (d, J = 
6.5 Hz, 1H), 2.98 (s, 1H), 2.38–2.31 (m, 1H), 1.76–1.54 (m, 4H), 1.31 (s, 3H), 1.27 (s, 
3H), 0.90 (s, 9H), 0.29 (s, 3H), 0.26 (s, 3H); 13C NMR (125 MHz, CDCl3) 
 Minor: 1H NMR (500 MHz, CDCl3) δ 6.92 (d, J = 6.5 Hz, 1H), 6.37 (dd, J = 11.0, 17.5 
Hz, 1H), 5.06 (d, J = 11.0 Hz, 1H), 5.03–4.99 (m, 1H), 3.72 (s, 3H), 3.51 (d, J = 6.5 Hz, 
1H), 2.90 (s, 1H), 2.38–2.31 (m, 1H), 1.92–1.88 (m, 1H), 1.76–1.54 (m, 3H), 1.38 (s, 
3H), 1.29 (s, 3H), 0.89 (s, 9H), 0.29 (s, 3H), 0.28 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 
174.9, 169.1, 169.1, 141.0, 139.7, 113.0, 99.5, 84.3, 61.8, 52.9, 52.9, 48.3, 39.6, 39.0, 
29.7, 25.3, 20.9, 20.8, 17.5, –4.90, –4.90. 
FTIR (Neat Film NaCl) 2951, 2928, 2856, 1767, 1733, 1717, 1447, 1274, 1251, 1215, 
1191, 968, 843, 828, 792, 736 cm-1; HRMS (Multimode-ESI/APCI) m/z calc’d for 
C24H36O6ISi [M+H]+: 575.1320, found 575.1317. 
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76b epi-8-Basiliolide B  
 
Basiliolides (76a, 76b). In a nitrogen filled glovebox, to a solution of 154 (15 mg, 0.030 
mmol, 1.0 equiv) and Pd(PPh3)4 (35 mg, 0.030 mmol, 1.0 equiv) in dimethylformamide 
(0.30 mL, 0.10 M) was added tributyl(2-methoxyethynyl)stananne (151) (53 mg, 0.050 
mmol, 5.0 equiv).  The reaction was stirred at 30 ˚C for 16 hours, then treated with water 
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(30 µL) and stirred at 25 ˚C for an additional 1 hour.  The mixture was then diluted with 
ethyl acetate (1 mL) and washed with water (4 x 0.5 mL) and concentrated by rotary 
evaporation.  The crude oil was purified by normal phase HPLC to yield 0.6 mg (6%) of 
basiliolide B (76a) and 1.2 mg (12%) of epi-8-basiliolide B (76b) as white powders. 
Procedure 2. In a nitrogen filled glovebox, to a solution of 154 (16 mg, 0.030 mmol, 1.0 
equiv) and Pd(t-Bu3P)2 (15 mg, 0.030 mmol, 1.0 equiv) in dimethylformamide (0.30 mL, 
0.10 M) was added tributyl(2-methoxyethynyl)stananne (43 mg, 0.12 mmol, 4.0 equiv).  
The reaction was stirred at 30 ºC for 10 hours, and then an addition aliquot (22 mg, 0.060 
mmol, 2.0 equiv) of stannane 151 was added and stirred for an additional two hours.  The 
reaction was treated with water (30 µL) and stirred at 25 ˚C for an additional 1 hour.  The 
crude reaction mixture was diluted with ethyl acetate (1 mL) and washed with water (4 x 
0.5 mL) and concentrated by rotary evaporation. .  The crude oil was purified by normal 
phase HPLC to yield 0.6 mg (5%) of basiliolide B (76a) and 1.6 mg (14%) of epi-8-
basiliolide B (76b) as white powders. 
 
Basiliolide B (76a).   
1H NMR (500 MHz, CDCl3) δ 7.00 (dd, J = 11.5, 18 Hz, 1H), 6.08 (d, J = 5.5 Hz, 1H), 
5.17 (d, J = 11.5 Hz, 1H), 5.06 (d, J = 18 Hz, 1H), 4.96 (s, 1H), 3.72 (s, 3H), 3.71 (s, 3H), 
3.67 (d, J = 5.5 Hz, 1H), 3.17 (s, 1H), 2.29 (dd, J = 5.0, 12.5 Hz, 1H), 1.96 (dt, J = 3.0 
Hz, 13.5 Hz, 1H), 1.74–1.65 (m, 2H), 1.54–1.48 (m, 1H), 1.30 (s, 3H), 1.24 (s, 3H); 13C 
NMR (125 MHz, CDCl3) δ 175.2, 170.1, 162.3, 156.7, 142.7, 139.2, 123.4, 112.3, 87.0, 
79.2, 56.4, 53.3, 52.9, 50.0, 44.8, 44.7, 40.2, 38.5, 28.6, 21.0, 20.8; FTIR (Neat Film 
NaCl) 2951, 2875, 1791, 1761, 1771, 1767, 1733, 1668, 1663, 1456, 1334, 1262, 1230, 
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1213, 1180, 1107, 1011, 960, 908, 833, 736 cm-1; HRMS (Multimode-ESI/APCI) m/z 
calc’d for C21H24O7 [M+H]+: 389.1595, found 389.1599. 
epi-8-Basiliolide B (76b).   
1H NMR (500 MHz, CDCl3) δ 6.06 (d, J = 6.0 Hz, 1H), 5.80 (dd, J = 10.5, 17.5 Hz, 1H), 
5.09 (d, J = 10.5 Hz, 1H), 5.05 (d, J = 17.5 Hz, 1H), 4.94 (s, 1H), 3.71 (s, 3H), 3.70 (s, 
3H), 3.66 (d, J = 6.0 Hz, 1H), 3.26 (s, 1H), 2.25 (dd, J = 7.0, 12.0 Hz, 1H), 1.79–1.67 (m, 
4H), 1.61 (s, 3H), 1.34 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 175.1, 170.1, 162.0, 
146.2, 139.5, 123.2, 113.0, 87.0, 79.0, 56.3, 52.9, 50.5, 49.9, 44.7, 44.6, 38.5, 38.2, 21.0, 
20.3, 19.3; FTIR (Neat Film NaCl) 2980, 2951, 2929, 1770, 1767, 1761, 1732, 1668, 
1619, 1442, 1335, 1261, 1219, 1182, 1106, 971, 960, 918, 834, 732 cm-1; HRMS 
(Multimode-ESI/APCI) m/z calc’d for C21H24O7 [M+H]+: 389.1595, found 389.1604.  
 
O
Bu3Sn  
 
Tributyl(2-methoxyethynyl)stannane (151).  To a solution of freshly distilled 
diethylamine (9.6 mL, 92 mmol, 3.9 equiv) in tetrahydrofuran (300 mL) at 0 ˚C was 
added n-butyllithium (2.5 M in hexanes, 32 mL, 80 mmol, 3.4 equiv).  After stirring for 
10 min, 1,1-dimethoxy-2-chloro-acetaldehyde (4.0 mL, 26 mmol, 1.1 equiv) was added 
dropwise to the reaction mixture.  The reaction was stirred for 2 hours at 0 ˚C.  
Tributyltin chloride (6.2 mL, 24 mmol, 1.0 equiv) was then added to the reaction mixture.  
The reaction was warmed to 23 ºC over 1 hour and stirred for 8 hours.  The volatiles were 
removed in vacuo and the reaction mixture was re-suspended in hexane (30 mL) and 
filtered through a glass frit under an argon atmosphere.  The solution was then re-
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concentrated by rotary evaporation and distilled by Kugelrohr to yield 6.4 g (78%) of 10 
as a colorless oil.  1H NMR (500 MHz, CDCl3) δ 3.87 (s, 3H), 1.54 (m, 6H), 1.33 (sextet, 
J = 7.5 Hz, 6H), 0.94 (m, 6H), 0.90 (t, J = 7.5 Hz, 9H); 13C NMR (125 MHz, CDCl3) δ 
114.7, 65.8, 31.5, 28.9, 27.0, 13.7, 11.2; FTIR (Neat Film NaCl) 2955, 2927, 2871, 2161, 
1457, 1208, 1126, 910, 865 cm-1; Elemental analysis found: C, 52.40%; H, 8.54%.  
Calc’d for C15H30OSn: C, 52.20%; H, 8.76%. 
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3.9  Notes and References.
                                                
Note:         Portions of this chapter have been published, see: Nelson, H. M.; Murakami,                     
K.; Virgil, S. C.; Stoltz, B. M. Angew. Chem. Int. Ed. 2011, 50, 3688–3691. 
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Scheme A4.1. Development of the ICR/IMPDA cascade reaction 
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Scheme A4.2. Synthesis of methoxyacetylene reagent 
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Scheme A4.3. Total synthesis of transtaganolides C and D and X-ray crystal structure 
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Scheme A4.4. Synthesis of basiliolide B and epi-8-basiliolide B  
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APPENDIX 5 
Spectra Relevant to: The Total Syntheses of (±)-Transtaganolide C, (±)-
Transtaganolide D, (±)-Basiliolide B, and (±)-epi-8-Basiliolide B 
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Figure A5.1.2  Infrared spectrum (thin film/NaCl) of compound 138b 
Figure A5.1.2  13C NMR (125 MHz, CDCl3) of compound 138b 
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Figure A5.2.2  13C NMR (125 MHz, CDCl3) of compound 152 
 
Figure A5.2.2  Infrared spectrum (thin film/NaCl) of compound 152 
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Figure A5.3.2  Infrared spectrum (thin film/NaCl) of compound 75a 
 
Figure A5.3.2  13C NMR (125 MHz, CDCl3) of compound 75a 
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Figure A5.4.2  13C NMR (125 MHz, CDCl3) of compound 75b 
 
Figure A5.4.2  Infrared spectrum (thin film/NaCl) of compound 75b 
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Figure A5.5.2  Infrared spectrum (thin film/NaCl) of compound 140c 
 
Figure A5.5.2  13C NMR (125 MHz, CDCl3) of compound 140c 
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Figure A5.6.2  13C NMR (125 MHz, CDCl3) of compound 138c 
 
Figure A5.6.2  Infrared spectrum (thin film/NaCl) of compound 138c 
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Figure A5.7.2  Infrared spectrum (thin film/NaCl) of compound 154 
 
Figure A5.7.2  13C NMR (125 MHz, CDCl3) of compound 154 
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Figure A5.8.2  13C NMR (125 MHz, CDCl3) of compound 76a 
 
Figure A5.8.2  Infrared spectrum (thin film/NaCl) of compound 76a 
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Figure A5.9.2  Infrared spectrum (thin film/NaCl) of compound 76b 
 
Figure A5.9.2  13C NMR (125 MHz, CDCl3) of compound 76b 
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Figure A5.10.2  13C NMR (125 MHz, CDCl3) of compound 151 
 
Figure A5.10.2  Infrared spectrum (thin film/NaCl) of compound 151 
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Figure A6.1. Ortep diagram of 75a. The crystallographic data have been deposited in the Cambridge 
Database (CCDC) and has been placed on hold pending further instructions from me.  The 
deposition number is 796908.  Ideally the CCDC would like the publication to contain a 
footnote of the type: "Crystallographic data have been deposited at the CCDC, 12 Union 
Road, Cambridge CB2 1EZ, UK and copies can be obtained on request, free of charge, by 
quoting the publication citation and the deposition number 796908." 
 
Table A6.1  Crystal data and structure refinement for 75a (CCDC 796908) 
Empirical formula  C20H24O5 
Formula weight  344.39 
Crystallization Solvent  Acetonitrile 
Crystal Habit  Plate 
Crystal size 0.24 x 0.19 x 0.08 mm3 
Crystal color  Colorless  
 Data Collection  
Type of diffractometer  Bruker KAPPA APEX II 
Wavelength  0.71073 Å MoKα  
Data Collection Temperature  100(2) K 
θ range for 9950 reflections used 
in lattice determination  2.46 to 31.12° 
Unit cell dimensions a = 11.3376(4) Å α= 90° 
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 b = 15.6613(5) Å β= 90° 
 c = 19.2798(7) Å γ  = 90° 
Volume 3423.4(2) Å3 
Z 8 
Crystal system  Orthorhombic 
Space group  P bca 
Density (calculated) 1.336 Mg/m3 
F(000) 1472 
Data collection program Bruker APEX2 v2009.7-0 
θ range for data collection 2.11 to 33.14° 
Completeness to θ = 33.14° 97.9 %  
Index ranges -17 ≤ h ≤ 17, -24 ≤ k ≤ 24, -28 ≤ l ≤ 28 
Data collection scan type  ω scans; 8 settings 
Data reduction program  Bruker SAINT-Plus v7.66A 
Reflections collected 70734 
Independent reflections 6384 [Rint= 0.0712] 
Absorption coefficient 0.095 mm-1 
Absorption correction None 
Max. and min. transmission 0.9924 and 0.977 
 
 Structure solution and Refinement  
Structure solution program  SHELXS-97 (Sheldrick, 2008) 
Primary solution method  Direct methods 
Secondary solution method  Difference Fourier map 
Hydrogen placement  Difference Fourier map 
Structure refinement program  SHELXL-97 (Sheldrick, 2008) 
Refinement method Full matrix least-squares on F2 
Data / restraints / parameters 6384 / 0 / 322 
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Treatment of hydrogen atoms  Unrestrained 
Goodness-of-fit on F2 1.673 
Final R indices [I>2σ(I),  4393 reflections] R1 = 0.0432, wR2 = 0.0519 
R indices (all data) R1 = 0.0703, wR2 = 0.0533 
Type of weighting scheme used Sigma 
Weighting scheme used w=1/σ2(Fo2) 
Max shift/error  0.001 
Average shift/error  0.000 
Largest diff. peak and hole 0.368 and -0.374 e.Å-3 
 Special Refinement Details  
Crystals were mounted on a glass fiber using Paratone oil then placed on the diffractometer under 
a nitrogen stream at 100K. 
Refinement of F2 against ALL reflections.  The weighted R-factor (wR) and goodness of fit (S) are 
based on F2, conventional R-factors (R) are based on F, with F set to zero for negative F2. The threshold 
expression of F2 > 2σ( F2) is used only for calculating R-factors(gt) etc. and is not relevant to the choice of 
reflections for refinement.  R-factors based on F2 are statistically about twice as large as those based on F, 
and R-factors based on ALL data will be even larger. 
All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full 
covariance matrix.  The cell esds are taken into account individually in the estimation of esds in distances, 
angles and torsion angles; correlations between esds in cell parameters are only used when they are defined 
by crystal symmetry.  An approximate (isotropic) treatment of cell esds is used for estimating esds 
involving l.s. planes. 
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Table A6.2.  Atomic coordinates ( x 104) and equivalent isotropic displacement 
parameters (Å2x 103) for 75a (CCDC 796908).  U(eq) is defined as the trace of the 
orthogonalized Uij tensor.  
________________________________________________________________________________ 
 x y z Ueq 
________________________________________________________________________________ 
O(1) -665(1) 1162(1) 5055(1) 19(1) 
O(2) -56(1) 1806(1) 6020(1) 13(1) 
O(3) -1466(1) 2178(1) 7396(1) 19(1) 
O(4) -223(1) 1263(1) 7857(1) 18(1) 
O(5) 1084(1) 850(1) 8621(1) 20(1) 
C(1) 126(1) 1285(1) 5465(1) 15(1) 
C(2) 1354(1) 928(1) 5448(1) 15(1) 
C(3) 1520(1) 472(1) 6129(1) 16(1) 
C(4) 1335(1) 957(1) 6685(1) 14(1) 
C(5) 973(1) 1863(1) 6489(1) 12(1) 
C(6) 2001(1) 2267(1) 6072(1) 14(1) 
C(7) 2226(1) 1707(1) 5410(1) 16(1) 
C(8) 3497(1) 1372(1) 5414(1) 21(1) 
C(9) 2014(1) 2184(1) 4728(1) 20(1) 
C(10) 1808(1) 3218(1) 5947(1) 18(1) 
C(11) 1571(1) 3682(1) 6629(1) 17(1) 
C(12) 439(1) 3369(1) 6992(1) 14(1) 
C(13) 598(1) 2402(1) 7117(1) 12(1) 
C(14) -453(1) 1977(1) 7450(1) 15(1) 
C(15) 908(1) 942(1) 7932(1) 16(1) 
C(16) 1599(1) 731(1) 7407(1) 16(1) 
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C(17) -637(1) 3614(1) 6545(1) 18(1) 
C(18) 328(1) 3843(1) 7675(1) 18(1) 
C(19) 333(1) 3540(1) 8312(1) 23(1) 
C(20) 2259(1) 605(1) 8824(1) 26(1) 
________________________________________________________________________________
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Table  A6.3.   Bond lengths [Å] and angles [°] for 75a 
_______________________________________________________________________________
O(1)-C(1)  1.2115(10) 
O(2)-C(1)  1.3627(10) 
O(2)-C(5)  1.4782(10) 
O(3)-C(14)  1.1951(11) 
O(4)-C(15)  1.3858(11) 
O(4)-C(14)  1.3896(11) 
O(5)-C(15)  1.3499(10) 
O(5)-C(20)  1.4414(13) 
C(1)-C(2)  1.5005(13) 
C(2)-C(3)  1.5072(14) 
C(2)-C(7)  1.5710(13) 
C(2)-H(2)  0.997(9) 
C(3)-C(4)  1.3298(13) 
C(3)-H(3)  0.955(10) 
C(4)-C(16)  1.4684(13) 
C(4)-C(5)  1.5244(13) 
C(5)-C(13)  1.5361(13) 
C(5)-C(6)  1.5512(13) 
C(6)-C(10)  1.5255(14) 
C(6)-C(7)  1.5685(13) 
C(6)-H(6)  0.968(9) 
C(7)-C(8)  1.5328(13) 
C(7)-C(9)  1.5313(14) 
C(8)-H(8A)  1.013(10) 
C(8)-H(8B)  0.995(10) 
C(8)-H(8C)  0.985(10) 
C(9)-H(9A)  0.979(11) 
C(9)-H(9B)  1.006(10) 
C(9)-H(9C)  0.994(10) 
C(10)-C(11)  1.5253(14) 
C(10)-H(10A)  1.031(9) 
C(10)-H(10B)  0.987(10) 
C(11)-C(12)  1.5422(13) 
C(11)-H(11A)  0.999(10) 
C(11)-H(11B)  0.973(9) 
C(12)-C(18)  1.5159(13) 
C(12)-C(17)  1.5431(13) 
C(12)-C(13)  1.5436(13) 
C(13)-C(14)  1.5082(13) 
C(13)-H(13)  0.964(9) 
C(15)-C(16)  1.3220(13) 
C(16)-H(16)  0.924(9) 
C(17)-H(17A)  0.977(9) 
C(17)-H(17B)  0.979(9) 
C(17)-H(17C)  1.025(10) 
C(18)-C(19)  1.3158(14) 
C(18)-H(18)  0.954(10) 
C(19)-H(19A)  1.017(11) 
C(19)-H(19B)  0.975(10) 
C(20)-H(20A)  1.000(11) 
C(20)-H(20B)  1.041(9) 
C(20)-H(20C)  0.973(11) 
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C(1)-O(2)-C(5) 113.39(7) 
C(15)-O(4)-C(14) 121.69(7) 
C(15)-O(5)-C(20) 115.58(8) 
O(1)-C(1)-O(2) 119.71(9) 
O(1)-C(1)-C(2) 127.90(9) 
O(2)-C(1)-C(2) 112.39(8) 
C(1)-C(2)-C(3) 105.85(8) 
C(1)-C(2)-C(7) 107.22(8) 
C(3)-C(2)-C(7) 109.24(8) 
C(1)-C(2)-H(2) 109.0(5) 
C(3)-C(2)-H(2) 112.7(5) 
C(7)-C(2)-H(2) 112.4(5) 
C(4)-C(3)-C(2) 114.29(10) 
C(4)-C(3)-H(3) 125.7(5) 
C(2)-C(3)-H(3) 120.0(5) 
C(3)-C(4)-C(16) 126.43(9) 
C(3)-C(4)-C(5) 112.03(9) 
C(16)-C(4)-C(5) 120.96(8) 
O(2)-C(5)-C(4) 107.93(7) 
O(2)-C(5)-C(13) 107.24(7) 
C(4)-C(5)-C(13) 113.04(8) 
O(2)-C(5)-C(6) 107.49(7) 
C(4)-C(5)-C(6) 107.74(8) 
C(13)-C(5)-C(6) 113.15(8) 
C(10)-C(6)-C(5) 111.80(8) 
C(10)-C(6)-C(7) 116.19(8) 
C(5)-C(6)-C(7) 108.44(8) 
 C(10)-C(6)-H(6) 107.0(6) 
 C(5)-C(6)-H(6) 104.9(5) 
C(7)-C(6)-H(6) 107.8(5) 
C(8)-C(7)-C(9) 108.55(8) 
C(8)-C(7)-C(6) 109.91(8) 
C(9)-C(7)-C(6) 113.58(9) 
C(8)-C(7)-C(2) 109.02(9) 
C(9)-C(7)-C(2) 108.60(8) 
C(6)-C(7)-C(2) 107.10(8) 
C(7)-C(8)-H(8A) 110.6(6) 
C(7)-C(8)-H(8B) 111.9(6) 
H(8A)-C(8)-H(8B) 108.6(8) 
C(7)-C(8)-H(8C) 109.3(6) 
H(8A)-C(8)-H(8C) 108.1(8) 
H(8B)-C(8)-H(8C) 108.2(8) 
C(7)-C(9)-H(9A) 111.7(5) 
C(7)-C(9)-H(9B) 113.1(5) 
H(9A)-C(9)-H(9B) 108.7(8) 
C(7)-C(9)-H(9C) 110.0(6) 
H(9A)-C(9)-H(9C) 106.6(8) 
H(9B)-C(9)-H(9C) 106.5(7) 
C(11)-C(10)-C(6) 110.82(8) 
C(11)-C(10)-H(10A) 110.2(5) 
C(6)-C(10)-H(10A) 110.6(5) 
C(11)-C(10)-H(10B) 110.2(6) 
C(6)-C(10)-H(10B) 109.4(6) 
H(10A)-C(10)-H(10B) 105.5(7) 
C(10)-C(11)-C(12) 112.75(9) 
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C(10)-C(11)-H(11A) 110.8(5) 
C(12)-C(11)-H(11A) 107.9(5) 
C(10)-C(11)-H(11B) 111.0(5) 
C(12)-C(11)-H(11B) 109.5(5) 
H(11A)-C(11)-H(11B) 104.4(8) 
C(18)-C(12)-C(17) 107.35(8) 
C(18)-C(12)-C(11) 107.96(8) 
C(17)-C(12)-C(11) 108.94(8) 
C(18)-C(12)-C(13) 110.78(8) 
C(17)-C(12)-C(13) 114.99(8) 
C(11)-C(12)-C(13) 106.63(8) 
C(14)-C(13)-C(5) 108.18(8) 
C(14)-C(13)-C(12) 114.05(8) 
C(5)-C(13)-C(12) 116.66(8) 
C(14)-C(13)-H(13) 107.4(5) 
C(5)-C(13)-H(13) 104.0(5) 
C(12)-C(13)-H(13) 105.6(6) 
O(3)-C(14)-O(4) 116.20(9) 
O(3)-C(14)-C(13) 127.22(9) 
O(4)-C(14)-C(13) 116.57(8) 
C(16)-C(15)-O(5) 129.76(10) 
C(16)-C(15)-O(4) 123.95(9) 
O(5)-C(15)-O(4) 106.16(8) 
C(15)-C(16)-C(4) 123.05(10) 
C(15)-C(16)-H(16) 118.4(6) 
C(4)-C(16)-H(16) 118.2(6) 
C(12)-C(17)-H(17A) 112.3(5) 
C(12)-C(17)-H(17B) 112.8(6) 
H(17A)-C(17)-H(17B) 107.6(8) 
C(12)-C(17)-H(17C) 107.9(6) 
H(17A)-C(17)-H(17C) 109.8(8) 
H(17B)-C(17)-H(17C) 106.2(7) 
C(19)-C(18)-C(12) 129.26(11) 
C(19)-C(18)-H(18) 118.9(5) 
C(12)-C(18)-H(18) 111.9(5) 
C(18)-C(19)-H(19A) 122.3(5) 
C(18)-C(19)-H(19B) 121.3(6) 
H(19A)-C(19)-H(19B) 116.4(8) 
O(5)-C(20)-H(20A) 111.9(6) 
O(5)-C(20)-H(20B) 105.9(5) 
H(20A)-C(20)-H(20B) 109.8(8) 
O(5)-C(20)-H(20C) 111.0(6) 
H(20A)-C(20)-H(20C) 109.4(9) 
H(20B)-C(20)-H(20C) 108.8(8)
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Table  A6.4.   Anisotropic displacement parameters (Å2x 104) for 75a.  The 
anisotropic displacement factor exponent takes the form: -2π2[ h2a*2U11 + ... + 2 h k 
a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
O(1) 155(4)  237(4) 178(4)  -35(3) -36(3)  -13(3) 
O(2) 109(3)  152(4) 138(3)  -23(3) -18(3)  2(3) 
O(3) 133(4)  227(4) 216(4)  -8(3) 18(3)  0(3) 
O(4) 148(4)  191(4) 209(4)  62(3) 18(3)  -6(3) 
O(5) 237(4)  214(4) 149(4)  33(3) -27(3)  -10(3) 
C(1) 162(5)  133(5) 149(5)  8(4) 22(4)  -20(4) 
C(2) 142(5)  172(5) 139(5)  -43(4) 4(4)  6(4) 
C(3) 129(5)  143(5) 219(6)  -2(5) -9(4)  20(4) 
C(4) 109(5)  135(5) 178(5)  11(4) -4(4)  -12(4) 
C(5) 89(4)  143(5) 126(5)  -13(4) -27(4)  -6(4) 
C(6) 105(5)  168(5) 137(5)  -6(4) -7(4)  -13(4) 
C(7) 121(5)  202(6) 142(5)  -15(4) 6(4)  4(4) 
C(8) 137(5)  301(7) 198(6)  -29(6) 14(5)  19(5) 
C(9) 186(6)  256(6) 149(6)  -1(5) 8(5)  -13(5) 
C(10) 184(6)  171(6) 170(6)  17(4) 29(5)  -35(5) 
C(11) 194(6)  138(5) 183(6)  7(5) -3(5)  -25(5) 
C(12) 144(5)  125(5) 145(5)  -5(4) -11(4)  5(4) 
C(13) 103(5)  144(5) 120(5)  1(4) -11(4)  -5(4) 
C(14) 169(5)  145(5) 124(5)  -32(4) -7(4)  -17(4) 
C(15) 163(5)  129(5) 185(6)  33(4) -35(4)  -32(4) 
C(16) 147(5)  137(5) 191(6)  16(4) -19(5)  0(4) 
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C(17) 185(6)  176(6) 177(6)  11(5) -17(5)  27(5) 
C(18) 179(5)  147(6) 207(6)  -34(5) -20(4)  26(4) 
C(19) 283(7)  227(6) 185(6)  -55(5) -29(5)  36(5) 
C(20) 251(7)  275(7) 246(7)  60(6) -81(5)  -46(6) 
______________________________________________________________________________
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Table  A6.5.   Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 103) for 
75a  
________________________________________________________________________________ 
 x  y  z  Uiso 
________________________________________________________________________________ 
H(2) 1432(8) 540(6) 5040(4) 13(3) 
H(3) 1765(8) -111(6) 6135(4) 15(3) 
H(6) 2683(8) 2213(6) 6371(4) 12(3) 
H(8A) 3640(8) 988(7) 5000(5) 28(3) 
H(8B) 3678(8) 1047(7) 5844(5) 27(3) 
H(8C) 4047(9) 1858(7) 5384(5) 24(3) 
H(9A) 2565(9) 2659(7) 4669(5) 22(3) 
H(9B) 1186(9) 2407(6) 4683(4) 21(3) 
H(9C) 2142(8) 1793(7) 4329(5) 26(3) 
H(10A) 1119(8) 3314(6) 5607(4) 15(3) 
H(10B) 2509(8) 3462(6) 5717(4) 21(3) 
H(11A) 1493(8) 4310(7) 6551(4) 16(3) 
H(11B) 2238(8) 3628(6) 6943(4) 13(3) 
H(13) 1250(8) 2351(6) 7435(4) 11(3) 
H(16) 2316(8) 476(6) 7503(4) 16(3) 
H(17A) -1382(8) 3537(6) 6793(4) 17(3) 
H(17B) -685(8) 3284(6) 6114(5) 21(3) 
H(17C) -544(9) 4240(7) 6401(4) 24(3) 
H(18) 242(8) 4443(7) 7608(4) 21(3) 
H(19A) 445(9) 2908(7) 8415(5) 31(3) 
H(19B) 237(9) 3915(7) 8712(5) 30(3) 
H(20A) 2450(8) 9(7) 8677(5) 24(3) 
H(20B) 2279(8) 647(6) 9363(5) 28(3) 
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H(20C) 2843(9) 996(7) 8634(5) 35(3) 
________________________________________________________________________________ 
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Chapter 4 
The Enantioselective Total Syntheses of Transtaganolides A–D and the 
Biosynthetic Implications 
 
 
4.1 Introduction 
Recently our group disclosed a general strategy for the total syntheses of several 
transtaganolide natural products (75 and 76, Scheme 4.1).1  In its simplest embodiment, 
racemic transtaganolides C (75a) and D (75b) were prepared in 5 steps from commercial 
starting materials.  Integral to our approach was an Ireland–Claisen 
rearrangement/intramolecular pyrone Diels–Alder cyclization cascade (ICR/IMPDA) 
furnishing the stereochemically complex, tricyclic core (138) in a single step from a 
monocyclic achiral precursor (140) (Scheme 4.2).2  Furthermore, a novel Pd-mediated 
[5+2] annulation reaction of a reactive alkoxyacetylene (151) allowed for late-stage 
formation of the fragile cyclic ketene-acetal (C-ring), the structural trademark of these 
unique metabolites. 
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Scheme 4.1. The transtaganolides and basiliolides 
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Scheme 4.2. General strategy for total synthesis 
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 While concise and modular, our approach fell short of achieving two key goals: 
the preparation of enantioenriched products and the synthesis of transtaganolides A (85a) 
and B (85b), the most complex members of the natural product family.  Transtaganolides 
A (85a) and B (85b) are unique within their class due to their lack of an 
oxabicyclo[2.2.2]octene structural motif (Scheme 4.1, 85 vs.75 and 76).  Replacing it is a 
fused 5-membered lactone (E ring, 85), which is bridged by an ether linkage (D ring) that 
contorts the pentacyclic core into a compact, caged structure (Scheme 4.1 and 4.3).  
Herein, strategies to overcome these synthetic challenges are presented, culminating in 
the enantioselective total syntheses of (–)-transtaganolide A (85a) and (+)-
transtaganolide B (85b), which to date have eluded total synthesis. Furthermore, (–)-
transtaganolide C (75a) and (+)-transtaganolide D (75b), which were the subject of our 
previous racemic synthesis, have been prepared enantioslectively.  The absolute 
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configurations of these compounds are also disclosed and discussed within the context of 
existing biosynthetic hypotheses.2 
4.2 Strategy for the Enantioselective Syntheses of Transtaganolides A–D 
After several unsuccessful attempts to utilize reported methods for asymmetric 
ester-enolate-Claisen rearrangements on our unique system,3 we turned to the early work 
of Ireland and co-workers.4  They demonstrated the efficient employment of α-acyloxy 
allylic silanes (e.g., 157 in Scheme 4.3) as chiral, primary alcohol equivalents in Ireland-
Claisen rearrangements.  We envisioned that the use of such a chiral directing group in 
our key ICR/IMPDA cyclization cascade could serve as an entry point into the 
enantioselective synthesis of all members of the natural product family, including 
transtaganolides A and B. 
 
Scheme 4.3. Retrosynthetic analysis with inclusion of chiral directing group 
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Retrosynthetically, transtaganolides A and B (85) could derive from optically 
active tetracycle 155 by application of our previously disclosed [5+2] annulation 
technology (Scheme 4.3).1 We envisioned that the tetracyclic core (155) could in turn 
arise from a translactonization/acetalization reaction of hydrated aldehyde 156.  Similar 
to our previously disclosed strategy, tricycle 156 could be derived from an ICR/IMPDA 
cascade of enantioenriched monocyclic precursor 157b with the requisite aldehyde 
oxidation state.  Notably, enantioenriched transtaganolides C and D (75) could be 
prepared from tricycle 138b, which could also derive from a chiral pyrone ester such as 
157a by our ICR/IMPDA cascade reaction. 
4.3 Enantioselective Total Syntheses of Transtaganolides C and D 
 Our studies began with the application of this retrosynthetic hypothesis to 
transtaganolides C (75a) and D (75b) (Scheme 4.4).  Hoppe’s enantioenriched geraniol 
derivative 159 was prepared by treatment of carbamate 158 with n-BuLi, freshly distilled 
(–)-sparteine, and trimethylsilyl chloride.5 Subsequent reduction of the intermediate 
carbamate furnished enantioenriched geraniol equivalent 159 in good yield and 89.5% ee.  
Coupling of alcohol 159 to pyrone acid 142b provided the desired cascade substrate 157a 
in good yield.  Gratifyingly, exposure of pyrone ester 157a to our ICR/IMPDA cascade 
conditions afforded vinyl silanes 160a and 160b in 78% yield as a 4:1 mixture of 
diastereomers with 89.5% ee and 80.5% ee, respectively. We were pleased to find that 
subsequent exposure of vinyl silanes 160 to aqueous HBF4 yielded tricycles 138a and 
138b. Protection of free acids 138 as silyl esters 161a and 161b followed by treatment 
with stannane 151 and Pd(PPh3)4 yielded (–)-transtaganolide C (75a) and (+)-
transtaganolide D (75b). 
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Scheme 4.4. Enantioselective total synthesis of transtaganolides C and D 
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4.4 Enantioselective Total Syntheses of Transtaganolides A and B 
Having established the feasibility of the chiral geraniol approach to setting critical 
stereochemistry, we sought to prepare enantioenriched transtaganolides A (85a) and B 
(85b).  The most apparent path to this goal relies on the utilization of a chiral Z-enal such 
as 157b in our ICR/IMPDA cyclization cascade to produce aldehydes 163a and 163b, 
predisposed by proximity to undergo the desired skeletal rearrangement (Scheme 4.5).  
However, we found that Z-enal 157b was difficult to prepare and configurationally 
unstable under myriad reaction conditions.6 
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Scheme 4.5.  Initial attempts at preparing the tricyclic cores of transtaganolides A and B 
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Prompted by these experimental cues, efforts refocused on preparing a protected 
aldehyde equivalent.  Enantioenriched geraniol derivative 159 was protected as the 
acetate ester under standard conditions (Scheme 4.6).7  Selective oxidation with m-
CPBA, followed by oxidation of the intermediate epoxide with periodic acid cleanly 
provided aldehyde 164.8  Utilization of the Still–Gennari modification of the Horner–
Wadsworth–Emmons reaction followed by deprotection of the acetate group allowed for 
formation of Z-methylenoate 166 in good yield and excellent diastereoselectivity.9  
Coupling of 166 to iodoacid 142b yielded ICR/IMPDA cascade substrate, pyrone ester 
167.  Prolonged heating of ester 167 with N,O-bis(trimethylsilyl)acetamide (BSA) in the 
presence of a catalytic amount of triethylamine afforded tricycles 168a and 168b in 
synthetically useful yield. 
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Scheme 4.6.  Syntheses of enantioenriched tricyclic cores of transtaganolides A and B 
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To our delight, brief exposure of acids 168a and 168b to an excess of DIBAL-H 
at low temperature, followed by carefully quenching with acetic acid at low temperatures 
resulted in clean and chemoselective reduction to the corresponding aldehydes 163a and 
163b (Scheme 4.7).  The crude aldehydes 163, when exposed to aqueous HBF4, 
underwent the desired translactonization/acetalization process and protodesilylation in 
one pot to yield caged tetracycles 155a and 155b.  Transient protection of the free acids 
(155) as the TBS-esters (169), followed by application of our [5+2] annulation 
technology allowed for the enantioselective syntheses of (+)-transtaganolide B (85b) and 
(–)-transtaganolide A (85a) in good yield and good optical purity.  
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Scheme 4.7.  Enantioselective total syntheses of transtaganolides A and B 
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4.5  Biosynthetic Implication of Enantioselective Total Synthesis 
Recently, Larsson and co-workers have proposed that the co-isolated prenylated 
pyrone 89 is the direct biosynthetic precursor of transtaganolides C and D (75) (Scheme 
4.8).2b,10  They hypothesized that an unprecedented enzymatic ester-enolate-Claisen 
rearrangement is responsible for the production of “optically pure” transtaganolides.2b 
Under this scenario, and assuming that the C9 proton is relatively acidic due to the 
withdrawing nature of the pyrone, we would expect that an enzymatic and presumably 
enantioselective11 rearrangement would produce C9 diastereomers 170, optically pure at 
C8.  The demonstrated propensity of these systems to undergo diastereoselective Diels–
Alder rearrangements under allylic strain control,12 would lead to pseudo-enantiomeric 
transtaganolides C and D (75, Scheme 4.8).  Having prepared enantioenriched 
transtaganolides A–D via an analogous, synthetic enantioselective Ireland–Claisen 
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rearrangement, we believed that determination of the absolute stereochemistries of the 
synthetic transtaganolides could provide insight into this biosynthetic hypothesis. 
 
Scheme 4.8.  Larsson’s biosynthetic proposal 
OO
O
O
8
4
89
O
MeO
O
O
O
O
MeO
OH
8
4
enzyme ?
pseudo-enantiomers
set 
by enzyme
170
99
O
O
MeO
H
O
O
8
4
O
O
MeO
H
O
O
8
4
+
75a 75b
9 9
 
 Hoppe has previously established the absolute stereochemistry of geraniol 
derivatives such as 159 prepared by (–)-sparteine mediated deprotonation as the (R)-
enantiomer (Scheme 4.6).5   As acyclic Ireland-Claisen rearrangements prefer chair 
transition states,13 we postulated that the Ireland–Claisen rearrangement of esters 157 or 
167 could proceed through two ketene-acetal geometry dependent pathways (Scheme 4.9, 
Z-171 and E-171).  Furthermore, the ensuing Diels–Alder cyclization is known to 
proceed through allylic (A1,3) strain minimized geometries Z-172 and E-172.12  These 
proposed reaction pathways result in the formation of diastereomeric intermediates 
160a/168a and 160b/168b.  Acid 160a (R2=Me) was converted to the corresponding 
methyl ester (173) by treatment with diazomethane, and anomalous dispersion analysis of 
a single crystal confirmed the hypothesized stereochemistry of 160a (Scheme 4.10).14  As 
160a was advanced to (+)-transtaganolide C, we unambiguously assign its absolute 
structure as 75a (Scheme 4.4).  Furthermore, by analogy we assigned (–) transtaganolide 
D as 75b (Scheme 4.4), (–)-transtaganolide A as 85a and (+)-transtaganolide B as 85b 
(Scheme 4.7). 
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Scheme 4.9. Stereochemical analysis of chiral silane directed ICR/IMPDA 
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Scheme 4.10. Determination of the absolute stereochemistry of intermediate 173 
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        The optical rotations obtained from synthetic and natural transtaganolides A–D 
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are depicted in Table 4.1.15  Interestingly, the moderately enantioenriched synthetic 
transtaganolides uniformly rotate plane polarized light to a greater extent than their 
naturally occurring counterparts, introducing the possibility that the naturally occurring 
transtaganolides are scalemates.  
  Furthermore, while the naturally occurring C8 diastereomeric pairs (e.g., 
transtaganolides C and D) rotate plane-polarized light in the same direction, the samples 
derived from a synthetic, enantioselective ICR rotate light oppositely.  This data does not 
support the action of an enzymatic Ireland–Claisen rearrangement, as an enzyme-
controlled, and likely asymmetric, Ireland–Claisen rearrangement should have analogous 
rotations to the synthetic transtaganolides (Scheme 4.8). As demonstrated by our 
synthetic efforts, the Ireland–Claisen/Diels–Alder cascade of prenylated pyrones similar 
to 89 is a facile process. As such, the metabolites may therefore be biosynthetically 
derived from 89, however without action of an “Ireland–Claisenase” enzyme; any 
observed optical enrichment may derive from post-biosynthetic resolution or partial 
resolution (e.g. by the action of esterases and etc.) 
 
Table 4.1. Comparison of the optical rotations of synthetic and natural transtaganolides A–D 
synthetic
natural
transtaganolide A transtaganolide B transtaganolide C transtaganolide D
– 105.4 + 207.9 + 49.0 – 41.2
– 44.8 – 25.8 – 10.0 – 14.2
 
 
Comparison of the natural compounds to the synthetic counterparts by chiral 
phase chromatography is needed before a conclusion can be drawn.  Unfortunately, 
efforts to obtain samples of the natural products from the isolation chemists has been 
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unsuccessful.  However at this juncture, the data strongly suggests that prenylated pyrone 
89 is not an “Ireland-Claisenase” substrate in the biosynthesis of transtaganolides C and 
D.  As previously proposed, pyrone 89 can still be viewed as a decomposition product of 
epoxide 107 or oxepine 108, which can be derived from co-isolated coumarin 103 
(Scheme 4.11).10,15a   
 
Scheme 4.11. Possible biosynthetic origin of  89 
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4.5  Conclusion 
In conclusion, enantioenriched transtaganolides A–D have been prepared by the 
use of a chiral geraniol equivalent in an Ireland–Claisen/Diels–Alder cascade that 
proceeds with excellent stereofidelity.  Remarkably, all of the titled natural products were 
prepared in 10 steps or less from known compounds.  Single crystal X-ray diffraction 
studies of a synthetic intermediate have unambiguously determined the absolute 
stereochemistry of (+)-transtaganolide C (75a).  By inference, the absolute 
stereochemistries of (–)-transtaganolide D (75b), (–)-transtaganolide A (85a), and (+)-
transtaganolide B (85b) have been proposed.  Finally, analysis of optical rotation data  
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does not support the role of a putative “Ireland–Claisenase“  in the biosynthesis of the 
transtaganolides. 
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4.7 Experimental 
4.7.1 Materials and Methods 
Unless otherwise stated, reactions were performed in flame-dried glassware under an 
argon or nitrogen atmosphere using dry deoxygenated solvents.  Solvents were dried by 
passage through an activated alumina column under argon.  Chemicals were purchased 
from Sigma-Aldrich Chemical Company and used as received.  Pd(PPh3)4 was prepared 
using known methods.  Thin layer chromatography (TLC), both preparatory and 
analytical, were performed using E. Merck silica gel 60 F254 pre-coated plates (0.25 
mm) and visualized by UV fluorescence quenching, p-anisaldehyde, I2, or KMnO4 
staining.  ICN Silica gel (particle size 0.032–0.063 mm) was used for flash 
chromatography.  1H NMR, and 13C NMR spectra were recorded on a Varian Mercury 
300 (at 300 MHz) or on a Varian Unity Inova 500 (at 500 MHz).  1H NMR spectra are 
reported relative to CDCl3 (7.26 ppm).  Data for 1H NMR spectra are reported as follows: 
chemical shift, multiplicity, coupling constant (Hz), integration.  Multiplicities are 
reported as follows:    s = singlet, d = doublet, t = triplet, q = quartet, sept. = septet, m = 
multiplet, bs = broad singlet.  13C NMR spectra are reported relative to CDCl3 (77.0 
ppm).  FTIR spectra were recorded on a Perkin Elmer SpectrumBX spectrometer and are 
reported in frequency of absorption (cm-1).  HRMS were acquired using an Agilent 6200 
Series TOF with an Agilent G1978A Multimode source in electrospray ionization (ESI), 
atmospheric pressure chemical ionization (APCI) or multimode-ESI/APCI.  
Crystallographic data were obtained from the Caltech X-ray Diffraction Facility. 
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4.7.2 Experimental Procedures 
 
 
HO
SiMe3
 
 
Silane 159.  To a 23 °C solution of known diisopropyl geraniol carbamate (158) (519 mg, 
1.84 mmol) in toluene (9.2 mL, 0.2M) was added freshly distilled (–)-sparteine (635 µL, 
1.5 equiv) and TMSCl (352 µL, 1.5 equiv).  The solution was then cooled to 78 °C and a 
solution of 2.5M n-BuLi in hexanes (1.11 mL, 1.5 equiv) was added dropwise.  The 
reaction was allowed to stir at –78 °C for 3 hours.  The reaction was then quenched at –
78 °C by slow addition of MeOH (250 µL) and allowed to warm to 23 °C.  The reaction 
was washed with saturated NH4Cl (2x 10 mL).  Aqueous layers were combined and back 
extracted with Et2O (3x 20 mL).  The combined organics were than washed with 
saturated brine (20 mL), dried over MgSO4, and concentrated by rotary evaporation.  This 
crude oil could be taken on without further purification.  Purification, if desired, was 
done via column chromatography (ethyl acetate in hexanes 2⇒10% on SiO2) to yield 602 
mg (92% yield) of silylated diisopropyl geraniol carbamate, as a colorless oil. 
 Silylated diisopropyl geraniol carbamate (2.36 g, 6.68 mmol) was dissolved in 
THF (67 mL, .1M with respect to substrate) and hexanes (40mL, 1M with respect to 
DIBAL-H) and cooled to 0 °C.  To this 0 °C solution we then slowly added neat DIBAL-
H (7.1 mL, 6 equiv) dropwise.  After the addition, the reaction was warmed to 23 °C and 
stirred for 6 hours.  The reaction was then cooled to 0 °C and slowly quenched with 
saturated Rochelle’s salt (35 mL) with vigorous stirring to help stop coagulation of the 
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aluminum salts that precipitate from reaction mixture.  After addition of Rochelle’s salt, 
the reaction was allowed to warm to 23 °C and celite (10 g) was added to further prevent 
coagulation.  The suspension was vigorously stirred for another 5 minutes and then 
filtered through a small pad of celite.  The organic layer was then collected, washed with 
saturated brine (35 mL), dried over MgSO4, and concentrated by rotary evaporation.  
Once again the crude oil could be taken on without further purification.  Purification, if 
desired, was accomplished by column chromatography (ethyl acetate in hexanes 2⇒20% 
on SiO2) to yield 1.38 g (91% yield) of colorless oil 159.  [α]
! 
D
20  = +69.71 (c 1.00 in 
CHCl3). All spectral data match the literature.16 
 
 
O
O
I
O
O SiMe3
 
 
Pyrone ester 157a.  To a solution 0 °C of enantioenriched geraniol derivative 159 (202 
mg, 0.89 mmol) in MeCN (9 mL, 0.1 M) was added sequentially pyrone acid 142b (300 
mg, 1.2 equiv) and DCC (221 mg, 1.2 equiv).  After 20 min at 0 °C, while still cold, the 
reaction was filtered through a plug of celite using MeCN to remove the excess urea 
byproduct.  The filtrate was collected and concentrated by rotary evaporation.  The crude 
oil was purified by column chromatography (ethyl acetate in hexanes 2⇒10% on SiO2) 
to yield 384 mg (88% yield) of ICR/DA precursor 157a as a colorless oil. 
1H NMR (500 MHz, CDCl3) δ 7.46 (d, J = 9.7 Hz, 1H), 6.06 (d, J = 9.7 Hz, 1H), 5.42 (d, 
J = 10.4 Hz, 1H), 5.14 (dq, J = 10.4, 1.2 Hz, 1H), 5.04 (tm, J = 6.2, 1H), 3.76 (s, 2H), 
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2.16 – 2.00 (m, 4H), 1.66 (d, J = 1.4 Hz, 6H), 1.59 (d, J = 1.2 Hz, 3H), 0.01 (s, 9H); 13C 
NMR (125 MHz, CDCl3) δ 166.6, 160.6, 158.6, 151.4, 138.0, 131.8, 124.1, 120.9, 116.1, 
70.5, 69.7, 43.1, 40.0, 26.6, 25.9, 17.9, 17.0, –3.7. 
FTIR (Neat Film NaCl) 2959, 2923, 2854, 1741, 1607, 1546, 1445, 1404, 1382, 1336, 
1293, 1273, 1249, 1206, 1170, 1134, 1062, 1016, 960, 908, 842, 819, 750 cm-1; HRMS 
(Multimode-ESI/APCI) m/z calc’d for C20H29IO4Si [M–H]–: 487.0807, found 487.0821;  
 
 
HO O
O
O
H
I
HO O
O
O
H
I
SiMe3 SiMe3
 
 
Vinyl silanes 160a and 160b.  To a 23 °C solution of pyrone ester 157a (384 mg, 0.79 
mmol) in toluene (4 mL, 0.2M) in a 500 mL sealed tube was added N,O-
bis(trimetylsilyl)acetamide (BSA) (384 µL, 2 equiv) and NEt3 (11 µL, 0.1 equiv).  This 
reaction mixture was heated to    110 °C and stirred for 20 minutes.  The solution was 
then cooled to 23 °C and diluted with toluene (450 mL), leaving ample headspace in the 
sealed tube to allow for solvent expansion which was observed upon heating.  The 
reaction mixture was then re-heated to 100 °C and stirred for 4 days, until completion, 
which was determined after monitoring by NMR.  The reaction mixture was then cooled 
to 23 °C and 0.02% HCl(aq) (20 mL) was added and the reaction mixture was stirred 
vigorously for 1 minute.  The organic phase was then separated and washed with 0.02% 
HCl(aq) (3 x 25 mL) making sure aqueous phase is acidic.  The aqueous phases were then 
combined and back extracted with ethyl acetate (3 x 30 mL).  All organic phases were 
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combined, dried with Na2SO4, and concentrated by rotary evaporation.  The crude oil was 
purified by column chromatography (ethyl acetate in hexanes with 0.1% AcOH 5⇒30% 
on SiO2) to yield 294 mg (77% yield) of a 3:1 diastereomeric mixture of Claisen-Diels-
Alder products 160a and 160b as white solids. 
Major: 1H NMR (300 MHz, CDCl3) δ 6.94 (d, J = 6.8 Hz, 1H), 6.12 (d, J = 18.9 Hz, 
1H), 5.64 (d, J = 18.9 Hz, 1H), 3.01 (s, 1H), 2.97 (d, J = 6.9 Hz, 1H), 1.72–1.21 (m, 5H), 
1.28 (s, 3H), 1.08 (s, 3H), 1.00 (s, 3H), 0.07 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 
173.6, 170.8, 155.4, 140.2, 125.3, 98.0, 84.7, 59.3, 56.7, 48.1, 41.3, 38.2, 36.9, 29.9, 24.6, 
20.8, 18.5, –1.0. 
Minor: 1H NMR (300 MHz, CDCl3) δ 6.94 (d, J = 6.8 Hz, 1H), 6.44 (d, J = 19.2 Hz, 
1H), 5.68 (d, J = 19.2 Hz, 1H), 2.95 (d, J = 6.8 Hz, 1H), 2.95 (s, 1H) 1.96 (dt, J = 13.5, 
3.1 Hz, 2H), 1.72–1.21 (m, 3H), 1.31 (s, 3H), 1.04 (s, 3H), 0.99 (s, 3H), 0.06 (s, 9H); 13C 
NMR (125 MHz, CDCl3) δ 173.4, 169.9, 148.0, 140.5, 127.8, 97.5, 84.8, 61.2, 56.8, 47.9, 
40.5, 38.1, 37.0, 29.7, 24.6, 20.7, 18.5, –1.1. 
FTIR (Neat Film NaCl) 3075, 3014, 2955, 2671, 2545, 1755, 1713, 1612, 1464, 1455, 
1415, 1397, 1386, 1373, 1338, 1286, 1246, 1218, 1174, 1133, 1103, 1048, 1016, 990, 
967, 932, 903, 867, 838, 796, 757 cm-1; HRMS (Multimode-ESI/APCI) m/z calc’d for 
C20H29IO4Si [M+H]+: 489.0953, found 489.0952; [α]
! 
D
20  = +13.28 (c 2.00 in CHCl3). 
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Iodoacids 138a and 138b.  To a 23 °C solution of vinyl silane 160 (36.5 mg, 0.075 
mmol) in MeCN (1.5 mL, 0.05M) was added HBF4(aq) (48% w/w, 75 µL, 8 equiv).  The 
reaction was stirred for 4.5 hours and then diluted with ethyl acetate (15 mL).  The 
organic layer was then washed with 0.02% HCl(aq) (3 x 5 mL).  The aqueous phases were 
combined and back extracted with ethyl acetate (3 x 5 mL).  The combined organic 
phases were dried with Na2SO4 and concentrated by rotary evaporation.  Purification by 
column chromatography (ethyl acetate in hexanes with 0.1% AcOH 5⇒30% on SiO2) 
yielded 27.5 mg (89% yield) of a 3.5:1 diastereomeric mixture of the desilylated tricycles 
138a and 138b as a white solid.  [α]
! 
D
20  = +42.73 (c 1.00 in CHCl3).  The  spectral data 
obtained matches that of the reported for the racemic compounds. 
 
 
TBSO O
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TBS-ester 161.  To a 23 °C solution of iodoacid 160 (46 mg, 0.11 mmol,) in DMF (300 
µL, 0.35M) were added sequentially imidazole (76 mg, 10 equiv) and TBSCl (84 mg, 5 
equiv).  The reaction was warmed to 40 °C and then stirred for 12 hours.  The solution 
was then diluted with saturated brine solution (1 mL) and extracted with Et2O/hexane 
(1:1) (3 x 2 mL).  The combined organic extracts were washed with saturated aqueous 
KHSO4 (1 mL) and then with saturated brine (3 x 1 mL).  The combined organics were 
dried over Na2SO4, and concentrated by rotary evaporation.  The crude oil was purified 
by column chromatography (ethyl acetate in hexane 10⇒50% on SiO2) to yield 39 mg 
Chapter 4 — The Enantioselective Total Syntheses of Transtaganolides A–D and the Biosynthetic 
Implications 
 
 170 
(66% yield) of a 4:1 mixture of protected diastereomers 161a and 161b as white powders.  
[α]
! 
D
20  = +41.42 (c 1.00 in CHCl3). The  spectral data obtained matches that of the reported 
for the racemic compounds. 
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Transtaganolides C and D (75a and 75b).  In a nitrogen filled glovebox, to a solution 
of TBS-esters  161a and 161b (13 mg, 0.026 mmol) and Pd(PPh3)4 (33 mg, 1.1 equiv) in 
DMF (260 µL, 0.1 M) was added tributyl(2-methoxyethynyl)stananne (151) (34 mg, 4 
equiv). The reaction was stirred at 31 °C for 14 h.  The reaction mixture was then filtered 
through glass wool and eluted with Et2O (1.0 mL) (this removes a large excess of the 
undisolved Pd(PPh3)4) and is removed from the glovebox.  The Et2O was removed by 
rotary evaporation, and the reaction was diluted with MeCN (15 mL).  To this solution 
was added pH 7 phosphate buffer (200 µL) and reaction was stirred vigorously at 23 °C 
for 2 hrs.  Upon completion, the reaction was then concentrated by rotary evaporation, as 
to remove the copious amounts of MeCN, and then diluted with ethyl acetate (4 mL).  
This was then washed with water (3 x 1 mL) and the combined aqueous washes were 
back extracted with ethyl acetate (2 x 1 mL).  All organics were pooled, dried with 
Na2SO4, and concentrated by rotary evaporation. The crude oil was purified by normal 
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phase HPLC to yield 1.7 mg (25% yield) of transtaganolide C (75a) and 0.9 mg (11% 
yield) of transtaganolide D (75b) as white powders. 
Transtaganolides C: [α]
! 
D
20  = +49.03 (c 0.09 in CHCl3). 
Transtaganolides D: [α]
! 
D
20  = –41.14 (c 0.09 in CHCl3). 
The  spectral data obtained matches that of the reported for the racemic compounds. 
 
 
AcO
SiMe3
 
 
Acetate SI-1.  To a 0 °C solution of 159 (256 mg, 1.13 mmol) in pyridine (11 mL, 0.1M) 
was added acetic anhydride (534 µL, 5 equiv).  The reaction was allowed to warm to 23 
°C and was stirred for 6 hours until completion as monitored by TLC.  Following 
completion of the reaction, the solution was diluted with ethyl acetate (30 mL) and 
quenched with saturated NaHCO3 (10 mL).  The organic layer was then washed with 
saturated aqueous CuSO4 (4x 10 mL) until the dark blue color no longer persisted in the 
aqueous phase.  This was followed by another saturated NaHCO3 wash (10 mL), a 
saturated brine wash (10 mL), and then drying over MgSO4.  Concentration by rotary 
evaporation gave a crude, colorless oil which could be taken on without further 
purification.  Purification, if desired, was done by column chromatography (ethyl acetate 
in hexanes 2⇒10% on SiO2) to yield 260 mg (86% yield) of acetate SI-1, as a colorless 
oil. 
1H NMR (300 MHz, CDCl3) δ 5.42 (d, J = 10.4 Hz, 1H), 5.16 (dm J = 10.5 Hz, 1H), 
5.10–5.00 (m, 1H), 2.18–1.94 (m, 7H), 1.66 (s, 6H), 1.59 (s, 3H), 0.02 (s, 9H); 13C NMR 
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(125 MHz, CDCl3) δ 171.1, 137.0, 131.7, 124.2, 121.7, 67.6, 40.0, 26.6, 25.9, 21.4, 17.9, 
17.0, -3.7. 
FTIR (Neat Film NaCl) 2962, 2927, 2856, 1737, 1443, 1368, 1290, 1248, 1237, 1158, 
1109, 1014, 957, 842, 750 cm-1; [α]
! 
D
20  = +49.50 (c 1.00 in CHCl3). 
 
 
AcO
SiMe3
O  
 
Epoxide SI-2.  To a –78 °C solution of  acetate SI-1 (260 mg, 0.97 mmol) in CH2Cl2 (10 
mL, 0.1M) was added m-CPBA (max 77% by weight) (240 mg, 1.1 equiv).  The reaction 
was then removed from the –78 °C bath and placed in a 0 °C.  The reaction was then 
carefully monitored by TLC.  After 30 minutes the reaction had reached completion.  If 
the reaction does not reach completion and appears to have stalled, the reaction must first 
be cooled back to –78 °C prior to the addition of more m-CPBA.  After addition, the 
reaction should be once again warmed up to 0 °C and carefully monitored by TLC.  If the 
reaction once again stalls the above protocol is repeated until complete consumption of 
allyl acetate SI-1 is observed.  The cooling and heating and careful monitoring of the 
reaction is necessary to prevent over oxidation, an observable byproduct of the reaction.  
Once the reaction had reached completion, it was quenched with 10% aqueous Na2SO3 (5 
mL) at 0 °C.  The organic layer is then separated from the aqueous and washed again 
with 10% Na2SO3 (5 mL).  The combined aqueous layers were then combined and back 
extracted with CH2Cl2 (3x 10 mL).  The combined organic layers were washed with 
saturated NaHCO3 (15 mL), saturated brine (15 mL), and then dried over MgSO4.  
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Concentration by rotary evaporation gave a crude oil, which was purified by column 
chromatography (ethyl acetate in hexanes 2⇒10% on SiO2) to yield 215 mg (78% yield) 
of SI-2 as a colorless oil and a 1:1 mixture of diastereomers.   
1H NMR (500 MHz, CDCl3) δ 5.40 (d, J = 10.3 Hz, 1H), 5.21 (dm, J = 10.4, 1H), 2.69 
(td, J = 6.5, 5.3 Hz, 1H), 2.24 – 2.05 (m, 2H), 2.02 (s, 3H), 1.71 – 2.05 (m, 3H), 1.68 – 
1.56 (m, 2H), 1.30 – 1.24 (m, 6H), 0.02 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 171.04, 
171.02, 136.32, 136.20, 122.26, 122.09, 67.40, 64.08, 58.49, 58.48, 36.64, 36.56, 27.74, 
27.50, 25.03, 25.00, 21.32, 18.86, 18.83, 17.12, 16.94, -3.64. 
FTIR (Neat Film NaCl) 2960, 2928, 1736, 1732, 1446, 1377, 1369, 1323, 1291, 1248, 
1238, 1123, 1046, 1015, 958, 842, 795, 751, 718 cm-1; HRMS (ESI) m/z calc’d for 
C15H28O3Si [M+Na]+: 307.1700, found 307.1706; [α]
! 
D
20  = +34.03 (c 1.00 in CHCl3). 
 
 
AcO
SiMe3
O
H  
 
Aldehyde 164.  To a solution of epoxide SI-2 (244 mg, 0.86 mmol) in THF (8.6 mL, 
0.1M) and water (4.8 mL, 0.18M) at 0 °C was added periodic acid (391 mg, 2 equiv).  
The reaction stirred for 7 hours then diluted with Et2O (25 mL) and quenched with 
saturated NaHCO3 (10 mL).  The aqueous layer was separated from the organic layer and 
back extracted with Et2O (2 x 10 mL).  The combined organics were washed with 
saturated brine (3x 15 mL), dried over MgSO4, and concentrated by rotary evaporation.  
Chapter 4 — The Enantioselective Total Syntheses of Transtaganolides A–D and the Biosynthetic 
Implications 
 
 174 
Purification by column chromatography (ethyl acetate in hexanes 5⇒25% on SiO2) 
yielded 161 mg (77% yield) of aldehyde 164 as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ 9.74 (t, J = 1.7 Hz, 1H), 5.37 (d, J = 10.3 Hz, 1H), 5.18 
(dm, J = 10.3, 1H), 2.58 – 2.47 (m, 2H), 2.41 – 2.28 (m, 2H), 2.01 (s, 3H), 0.00 (s, 9H); 
13C NMR (75 MHz, CDCl3) δ 202.1, 171.0, 134.9, 122.7, 67.3, 42.2, 32.0, 21.3, 17.1, -
3.7.  
FTIR (Neat Film NaCl) 3432, 2958, 2902, 2823, 2720, 2479, 2113, 1732, 1415, 1368, 
1291, 1248, 1142, 1115, 1046, 1016, 958, 842, 769, 752, 718 cm-1; HRMS (ESI) m/z 
calc’d for C12H22O3Si [M+Na]+: 265.1230, found 265.1232; [α]
! 
D
20  = +41.93 (c 1.00 in 
CHCl3). 
 
 
AcO
SiMe3
O OMe
 
 
(Z)-Enone SI-3.  To a –78 °C solution of KHMDS (35 mg, 1.2 equiv) in THF (2 mL) 
was added a solution of Stille-Genari reagent 165 (53.5 mg, 0.16 mmol, 1.1 equiv) and 
18-crown-6 (193.5 mg, 5 equiv) in THF (600 µL).  After stirring the reaction mixture for 
10 minutes at –78 °C, a solution of aldehyde 164 (35.5 mg, 0.146 mmol, 1 equiv) in THF 
(600 µL) was added.  The total volume of THF is set to 3.2 mL, which is a 0.05M 
solution with respect to Stille-Genari reagent 165.  The reaction was stirred at –78 °C for 
20 minutes and then quenched with a saturated NH4Cl solution (1 mL) at –78 °C.  After 
allowing the reaction mixture to warm to 23 °C the reaction mixture was diluted with 
Et2O (10 mL) and washed with saturated NH4Cl (1 x 3 mL).  Aqueous layers were 
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combined and back extracted with Et2O (2 x 3 mL).  The combined organic layers were 
washed with saturated brine (10 mL), dried over MgSO4, and concentrated by rotary 
evaporation.  Purification was accomplished by column chromatography (ethyl acetate in 
hexanes 2⇒10% on SiO2) to yield 42.5 mg (93% yield) of exclusively the Z-isomer of 
enone SI-3 as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ 5.88 (tm, J = 7.2 Hz, 1H), 5.39 (d, J = 10.3 Hz, 1H), 5.17 
(dm, J = 10.5 Hz, 1H), 3.72 (s, 3H), 2.58 (q, J = 7.5 Hz, 2H), 2.11 (t, J = 7.3 Hz, 2H), 
2.02 (s, 3H), 1.88 – 1.85  (m, 3H), 1.67 – 1.66 (m, 3H), 0.01 (s, 9H); 13C NMR (75 MHz, 
CDCl3) δ 168.4, 143.0, 136.3, 127.2, 122.3, 67.4, 51.3, 39.4, 27.9, 21.3, 20.8, 16.9, -3.7. 
FTIR (Neat Film NaCl) 2954, 2928, 2855, 1722, 1649, 1453, 1434, 1368, 1289, 1248, 
1238, 1199, 1131, 1104, 1085, 1015, 958, 842, 769, 751 cm-1; HRMS (ESI) m/z calc’d 
for C16H28O4Si [M+Na]+: 335.1649, found 335.1648; [α]
! 
D
20  = +49.43 (c 1.00 in CHCl3). 
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SiMe3
O OMe
 
 
Alcohol 166.  To a 23 °C solution of (Z)-enone SI-3 (143 mg, 0.458 mmol) in MeOH    
(10 mL, 0.05M) was added K2CO3 (32 mg, 0.5 equiv). The resulting suspension was then 
stirred for 2.5 days until complete deprotection was observed.  Following completion, the 
reaction was diluted with Et2O (100 mL) and washed with water (2 x 75 mL).  The 
combined aqueous washes with then back extracted with Et2O (3 x 75 mL).  All organic 
phases were combined, washed with saturated brine (100 mL), dried over MgSO4, and 
concentrated by rotary evaporation.  Purification was accomplished by column 
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chromatography (ethyl acetate in hexanes 5⇒10% on SiO2) to yield 96 mg (78%) of  the 
Z-isomer of alcohol 166 as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ 5.89 (tm, J = 7.3 Hz, 1H), 5.27 (dm, J = 10.1 Hz, 1H), 
4.16 (d, J = 10.1 Hz, 1H), 3.71 (s, 3H), 2.63 – 2.52 (m, 2H), 2.11 (t, J = 7.3 Hz, 2H), 1.88 
– 1.84 (m, 3H), 1.58 (d, J = 1.2 Hz, 3H), 0.01 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 
168.5, 142.9, 134.3, 127.2, 126.9, 64.5, 51.4, 39.5, 28.0, 20.8, 16.7, -4.0. 
FTIR (Neat Film NaCl) 3424, 2953, 2928, 2854, 1719, 1648, 1454, 1437, 1382, 1366, 
1331, 1246, 1198, 1129, 1083, 1032, 978, 856, 841, 791, 749 cm-1; HRMS (ESI) m/z 
calc’d for C14H26O3Si [M+Na]+: 293.1543, found 293.1538; [α]
! 
D
20  = +56.83 (c 1.00 in 
CHCl3). 
 
 
O
O
I
O
O SiMe3 OMeO
 
 
Pyrone ester 167.  To a 0 °C solution of alcohol 166 (297 mg, 1.10 mmol) in MeCN 
(11mL, 0.1M) was added sequentially pyrone acid 142b (339 mg, 1.1 equiv) and DCC 
(250 mg, 1.1 equiv).  After 20 min at 0 °C, while still cold, the reaction was filtered 
through a plug of celite using MeCN to remove the excess urea byproduct.  The filtrate 
was collected and concentrated by rotary evaporation.  The crude oil was purified by 
column chromatography (ethyl acetate in hexanes 2⇒10% on SiO2) to yield 534 mg 
(91% yield) of pyrone ester 167 as a yellow oil. 
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1H NMR (300 MHz, CDCl3) δ 7.46 (d, J = 9.7 Hz, 1H), 6.06 (d, J = 9.8 Hz, 1H), 5.88 
(tm, J = 7.2 Hz, 1H), 5.41 (d, J = 10.4 Hz, 1H), 5.16 (dm, J = 10.4 Hz, 1H), 3.76 (s, 2H), 
3.73 (s, 3H), 2.59 (tdm, J = 7.3, 7.2 Hz, 2H), 2.13 (t, J = 7.3 Hz, 2H), 1.87 (d, J = 1.4 Hz, 
3H), 1.67 (d, J = 1.3 Hz, 3H), 0.01 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 166.6, 160.5, 
158.5, 151.4, 142.9, 137.3, 127.2, 121.5, 116.1, 70.5, 69.6, 51.4, 43.1, 39.4, 27.9, 20.9, 
16.9, -3.7. 
FTIR (Neat Film NaCl) 2953, 2923, 2854, 1742, 1648, 1607, 1546, 1451, 1434, 1405, 
1382, 1365, 1336, 1249, 1202, 1172, 1131, 1085, 1062, 1016, 960, 842, 764, 751, 729 
cm-1; HRMS (Multimode-ESI/APCI) m/z calc’d for C21H29IO6Si [M–H]–: 531.0705, 
found 531.0712; [α]
! 
D
20  = +17.79 (c 1.00 in CHCl3). 
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Vinyl silanes 168.  To a 23 °C solution of pyrone ester 167 (298 mg, 0.560 mmol) in 
toluene (2.8 mL, 0.2M) in a 500 mL sealed tube was added BSA (274 µL, 2 equiv) and 
NEt3      (8 µL, 0.1 equiv).  The reaction mixture was heated to 110 °C and stirred for 20 
minutes.  The mixture was then cooled to 23 °C and diluted with toluene (450 mL), 
leaving ample headspace in the sealed tube to allow for solvent expansion which was 
observed upon heating.  The reaction mixture was then re-heated to 100 °C and stirred for 
19 days, until completion, which was determined after monitoring by NMR.  The reaction 
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mixture was then cooled back to 23 °C and 0.02% HCl(aq) (20 mL) was added and the 
reaction mixture was stirred vigorously for 1 minute.  The organic phase was then 
separated and washed with 0.02% HCl(aq) (3 x 25 mL). The aqueous phases were then 
combined and back extracted with ethyl acetate (3 x 30 mL).  All organic phases were 
combined, dried with Na2SO4, and concentrated by rotary evaporation.  The crude oil was 
purified by column chromatography (ethyl acetate in hexanes with 0.1% acetic acid 
5⇒30% on SiO2) to yield 186 mg (62% yield) of a 3:1 mixture of ICR/DA diastereomers 
168a and 168b as a yellow solid.  It is important to note that compound 168, and all 
subsequent compounds in the total synthesis have very poor solubility in most common 
organic solvents excluding ethyl acetate.  Therefore all transfers of products  should be 
accomplished using ethyl acetate and vessels should be repeatedly washed. 
Major: 1H NMR (500 MHz, CDCl3) δ 6.96 (d, J = 7.0 Hz, 1H), 6.09 (d, J = 18.8 Hz, 
1H), 5.64 (d, J = 18.8 Hz, 1H), 3.74 (s, 3H), 3.36 (d, J = 7.0 Hz, 1H), 2.96 (s, 1H), 1.98 – 
1.36 (m, 5H), 1.27 (s, 6H), 0.06 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 173.5, 172.1, 
168.9, 154.9, 139.8, 125.8, 99.8, 83.8, 59.2, 52.7, 51.5, 49.5, 49.2, 41.4, 37.9, 24.6, 20.8, 
18.7, -1.0. 
Minor: 1H NMR (500 MHz, CDCl3) δ 6.95 (d, J = 6.9 Hz, 1H), 6.41 (d, J = 19.1 Hz, 
1H), 5.64 (d, J = 19.1 Hz, 1H), 3.70 (s, 3H), 3.34 (d, J = 7.1 Hz, 1H), 2.91 (s, 1H), 1.98 – 
1.36 (m, 5H), 1.30 (s, 3H), 1.25 (s, 3H), 0.06 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 
173.3, 171.9, 168.0, 147.5, 140.1, 128.1, 99.2, 83.9, 61.2, 52.5, 51.5, 49.6, 49.0, 40.6, 
37.6, 29.6, 24.6, 20.7, -1.1. 
FTIR (Neat Film NaCl) 3077, 2952, 1773, 1736, 1611, 1492, 1459, 1453, 1382, 1309, 
1276, 1247, 1184, 1161, 1122, 1047, 1019, 989, 970, 935, 870, 838, 783, 754 cm-1; 
Chapter 4 — The Enantioselective Total Syntheses of Transtaganolides A–D and the Biosynthetic 
Implications 
 
 179 
HRMS (Multimode-ESI/APCI) m/z calc’d for C21H29IO6Si [M+H]+: 533.0851, found 
533.0847; [α]
! 
D
20  = +10.47 (c 1.00 in CHCl3). 
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Tetracycle 155.  It is important to note that the selective single hydride reduction of 
methyl ester 168 was only made possible using a glass cannula as it allows for the precise 
temperature control necessary to exact the transformation on such a complex substrate 
bearing many electrophilic carbonyl functionalities (Figure SI-1).  A solution of vinyl 
silane 168 (31 mg, 0.06 mmol) in toluene (600 µL, 0.1M) was stirred in the receiving 
chamber of the glass cannula at –78 °C (the entire glass cannula is placed in a –78 °C 
bath submerging both chambers and the cannula itself).  A freshly made 1M solution of 
DIBAL-H (300 µL, 5 equiv) in toluene was added to the addition chamber of the glass 
cannula, further diluted with toluene (500 µL), and stirred at –78 °C.  Once both solutions 
and the entire glass cannula were sufficiently cooled, the –78 °C solution of DIBAL-H 
was slowly added to vinyl silane 168 dropwise.  The reaction was stirred for another 10 
minutes and then slowly quenched by a –78 °C solution of AcOH (200 µL) in toluene 
(1.5 mL) via the addition chamber of the glass cannula.  Once complete, the reaction 
vessel was removed from the –78 °C bath, allowed to warm to 23 °C, and then diluted 
with ethyl acetate (10 mL).  The reaction was washed with a 1% solution of AcOH in 
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water (3 x 2 mL) and the aqueous phases were combined and back extracted with ethyl 
acetate (2 x 2 mL).  All organic phases were pooled, dried over Na2SO4, and concentrated 
by rotary evaporation to give the desired aldehyde 163 as an orange-brown solid.  
Aldehyde 163 was used immediately in the following tandem cyclization, TMS cleavage 
protocol without further purification. 
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Figure 4.1.  Reaction schematic for the single hydride reduction of vinyl silanes 168 using a glass 
cannula 
To a 23 °C solution of the crude  aldehyde products 163 in MeCN (150 µL, 0.4M 
assuming quantitative yield from the reduction) was added aqueous HBF4 (48% w/w, 100 
µL, 13 equiv).  The reaction was stirred at 23 °C for 8 hours and then diluted with ethyl 
acetate (5 mL).  This was washed with pH 2–3 water (0.02% HCl solution) (3 x 1 mL), 
and the aqueous phases were back extracted with ethyl acetate (2 x 1 mL).  All organics 
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were pooled, dried over Na2SO4, and concentrated by rotary evaporation. Purification 
was accomplished by column chromatography (ethyl acetate in hexanes with 0.1% acetic 
acid 5⇒30% on SiO2) to yield 15 mg (57% yield over 2 steps) of a 2.5:1 mixture of the 
reduced, cyclized, and desilylated diastereomers 155 as a yellow solid. 
Major: 1H NMR (500 MHz, CDCl3) δ 6.69 (d, J = 5.8 Hz, 1H), 6.03 (dd, J = 17.3, 10.8 
Hz, 1H), 5.75 (s, 1H), 5.10 (d, J = 10.9 Hz, 1H), 5.04 (d, J = 17.4 Hz, 1H), 3.08 (d, J = 
5.9 Hz, 1H), 2.92 (s, 1H), 2.21 – 2.14 (m, 1H), 1.97 – 1.38 (m, 4H), 1.36 (s, 3H), 1.19 (s, 
3H); 13C NMR (125 MHz, CDCl3) δ 173.1, 169.5, 147.1, 136.1, 112.3, 108.9, 107.3, 
87.1, 61.5, 54.7, 49.1, 48.8, 39.7, 36.2, 20.1, 18.8, 15.9. 
Minor: 1H NMR (500 MHz, CDCl3) δ 6.69 (d, J = 5.8 Hz, 1H), 6.07 (dd, J = 17.5, 11.0 
Hz, 1H), 5.67 (s, 1H), 5.12 (d, J = 11.1 Hz, 1H), 5.08 (d, J = 17.5 Hz, 1H), 3.07 (d, J = 
5.9 Hz, 1H), 2.88 (s, 1H), 2.21 – 2.14 (m, 1H), 1.97 – 1.38 (m, 4H), 1.36 (s, 3H), 1.33 (s, 
3H); 13C NMR (125 MHz, CDCl3) δ 173.2, 169.7, 139.5, 136.3, 114.6, 108.8, 107.0, 
87.1, 63.1, 54.7, 49.3, 48.8, 39.4, 36.3, 29.6, 20.0, 15.8. 
FTIR (Neat Film NaCl) 3300, 3077, 3007, 2958, 2933, 2873, 1785, 1748, 1708, 1456, 
1375, 1286, 1239, 1217, 1199, 1182, 1157, 1115, 1083, 1046, 1034, 992, 964, 957, 910, 
895, 873, 829, 814, 796, 752 cm-1; HRMS (Multimode-ESI/APCI) m/z calc’d for 
C17H19IO5 [M+H]+: 431.0350 found 431.0359; [α]
! 
D
20  = +18.71 (c 0.94 in CHCl3). 
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TBS-esters 169. To a 23 °C solution of acetal 163 (15 mg, 0.034 mmol) in DMF (600 
µL, 0.055M) were added sequentially imidazole (14 mg, 6 equiv) and TBSCl (21 mg, 4 
equiv).  The reaction was stirred at 23 °C for 2 hours.  The reaction mixture was then 
diluted with saturated brine (2 mL) and extracted with ethyl acetate/hexane (1:1) (4 x 3 
mL).  The combined organic extracts were washed with saturated aqueous NaHCO3 (3 
mL) and then with saturated brine (2 x 3 mL).  The combined organics were dried over 
Na2SO4, and concentrated by rotary evaporation.  The crude oil was purified by column 
chromatography (ethyl acetate in hexane 10⇒50% on SiO2) to yield 12.5 mg (67% yield) 
of a 4:1 mixture of diastereomers 169a and 169b as a white solid. 
Major: 1H NMR (500 MHz, CDCl3) δ 6.61 (d, J = 6.0 Hz, 1H), 6.00 (dd, J = 17.5, 10.6 
Hz, 1H), 5.68 (s, 1H), 4.99 (d, J = 10.8 Hz, 1H), 4.98 (d, J = 17.3 Hz, 1H), 2.98 (dd, J = 
6.0, 0.8 Hz, 1H), 2.80 (s, 1H), 2.08 – 2.00 (m, 1H), 1.90 – 1.35 (m, 4H), 1.29 (s, 3H), 
1.18 (s, 3H), 0.92 (s, 9H), 0.31 (s, 3H), 0.25 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 
174.4, 169.7, 149.2, 135.4, 110.9, 110.0, 109.8, 87.0, 61.1, 55.1, 49.5, 48.7, 40.0, 37.4, 
25.7, 20.6, 18.2, 17.7, 16.0, -4.7. 
Minor: 1H NMR (500 MHz, CDCl3) δ 6.61 (d, J = 6.1 Hz, 1H), 6.26 (dd, J = 17.6, 11.0 
Hz, 1H), 5.58 (s, 1H), 5.03 (dd, J = 11.1, 1.1 Hz, 1H), 4.97 (dd, J = 17.7, 1.2 Hz, 1H), 
2.96 (dd, J = 6.1, 0.9 Hz, 1H), 2.72 (s, 1H), 2.08 – 2.00 (m, 1H), 1.90 – 1.35 (m, 4H), 
1.32 (s, 3H), 1.26 (s, 3H), 0.93 (s, 9H), 0.31 (s, 3H), 0.25 (s, 3H); 13C NMR (125 MHz, 
CDCl3) δ 174.5, 169.9, 141.4, 135.6, 112.8, 109.9, 109.4, 87.0, 62.6, 55.1, 49.6, 48.9, 
39.6, 37.7, 30.4, 25.6, 20.6, 17.6, 15.9, -4.8. 
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FTIR (Neat Film NaCl) 3083, 2930, 2857, 1784, 1716, 1638, 1601, 1471, 1463, 1413, 
1390, 1362, 1338, 1317, 1282, 1250, 1235, 1222, 1196, 1183, 1160, 1144, 1115, 1084, 
1049, 1036, 1000, 960, 942, 908, 895, 895, 884, 868, 843, 828, 816, 787, 752 cm-1; 
HRMS (Multimode-ESI/APCI) m/z calc’d for C23H33IO5Si [M+H]+: 545.1215, found 
545.1218; [α]
! 
D
20  = +49.09 (c 1.00 in CHCl3). 
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Transtaganolides B and A (85b and 85a).  In a nitrogen filled glovebox, to a solution of 
TBS-ester 169 (9 mg, 0.0165 mmol) and Pd(PPh3)4 (21 mg, 1.1 equiv) in DMF (165 µL, 
0.1M) was added tributyl(2-methoxyethynyl)stananne (151) (22 mg, 4 equiv). The 
heterogeneous reaction mixture was vigorously stirred at 31 °C for 7.5 h. The reaction 
mixture was then filtered through a glass wool with MeCN (1.5 mL) (this removes a large 
excess of the undisolved Pd(PPh3)4 and is removed from the glovebox.  Outside of the 
glovebox, pH 7 phosphate buffer (75 µL) was added to the MeCN solution, which was 
then vigorously stirred for 36 hr.  The reaction was then concentrated by rotary 
evaporation, as to remove some of the copious amounts of MeCN, and then diluted with 
ethyl acetate (2 mL).  This was washed with water (3 x 750 µL) and the combined 
aqueous washes were back extracted with ethyl acetate (2 x 750 µL).  All organics were 
pooled, dried with Na2SO4, and concentrated by rotary evaporation. The crude oil was 
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purified by normal phase HPLC to yield 0.6 mg (12% yield) of transtaganolide A (85a) 
and 1.5 mg (24% yield) of transtaganolide B (85b) as white powders. 
Transtaganolide B: 1H NMR (500 MHz, CDCl3) δ 5.80 (dd, J = 17.4, 10.8 Hz, 1H), 
5.65 (s, 1H), 5.58 (dd, J = 6.0, 0.9 Hz, 1H), 5.05 (d, J = 17.5 Hz, 1H), 5.02 (d, J = 10.8 
Hz, 1H), 4.96 (s, 1H), 3.68 (s, 3H), 3.12 (d, J = 6.0 Hz, 1H), 3.08 (s, 1H), 1.94 (dd, J = 
12.3, 6.3 Hz, 1H), 1.72 (ddt, J = 13.1, 6.3, 3.3 Hz, 1H), 1.63 (dt, J = 13.3, 3.3 Hz, 1H), 
1.55 (s, 3H), 1.55–1.35 (m, 2H), 1.33 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 175.6, 
163.8, 154.5, 146.7, 144.2, 119.4, 112.7, 109.8, 87.7, 84.4, 56.5, 51.6, 49.8, 49.5, 48.8, 
38.1, 37.0, 20.1, 19.4, 15.9. 
HRMS (Multimode-ESI/APCI) m/z calc’d for C20H22O6 [M–H]–: 357.1344, found 
357.1356; [α]
! 
D
20  = +207.93 (c 0.15 in CHCl3). 
Transtaganolide A: 1H NMR (500 MHz, CDCl3) δ 6.90 (dd, J = 17.9, 11.1 Hz, 1H), 
5.62 (s, 1H), 5.60 (dd, J = 5.9, 1.0 Hz, 1H), 5.12 (ddd, J = 11.1, 1.1, 0.6 Hz, 1H), 5.03 
(dd, J = 17.9, 1.1 Hz, 1H), 4.98 (s, 1H), 3.70 (s, 3H), 3.11 (dt, J = 5.9, 0.8 Hz, 1H), 2.98 
(s, 1H), 1.95 (dd, J = 12.3, 6.3 Hz, 1H), 1.83 (ddd, J = 12.9, 3.7, 2.6 Hz, 1H), 1.60–1.30 
(m, 3H), 1.30 (s, 3H), 1.22 (s, 3H);; HRMS (Multimode-ESI/APCI) m/z calc’d for 
C20H22O6 [M–H]–: 357.1344, found 357.1356; [α]
! 
D
20  = –98.76 (c 0.06 in CHCl3). 
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Scheme A7.1. Enantioselective total synthesis of transtaganolides C and D 
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Scheme A7.3.  Enantioselective total syntheses of transtaganolides A and B 
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Figure A8.1.3  13C NMR (125 MHz, CDCl3) of compound 157 
Figure A8.1.2 Infrared spectrum (thin film/NaCl) of compound 157 
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Figure A8.2.3  13C NMR (125 MHz, CDCl3) of compound 160 
 
Figure A8.2.2 Infrared spectrum (thin film/NaCl) of compound 160 
 
Appendix 8 — Spectra Relevant to Chapter 4 
 
 195 
Ac
O
Si
M
e 3
Fi
gu
re
 A
8.
3.
1 
1 H
 N
M
R
 (5
00
 M
H
z,
 C
D
C
l 3)
 o
f c
om
po
un
d 
SI
-1
 
 
Appendix 8 — Spectra Relevant to Chapter 4 
 
 196 
 
Figure A8.3.2 Infrared spectrum (thin film/NaCl) of compound SI-1 
 
Figure A8.3.3  13C NMR (125 MHz, CDCl3) of compound SI-1 
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Figure A8.4.2 Infrared spectrum (thin film/NaCl) of compound SI-2 
 
Figure A8.4.3  13C NMR (125 MHz, CDCl3) of compound SI-2 
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Figure A8.5.3  13C NMR (125 MHz, CDCl3) of compound 164 
 
Figure A8.5.2 Infrared spectrum (thin film/NaCl) of compound 164 
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Figure A8.6.3  13C NMR (125 MHz, CDCl3) of compound SI-3 
 
Figure A8.6.2 Infrared spectrum (thin film/NaCl) of compound SI-3 
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Figure A8.7.2 Infrared spectrum (thin film/NaCl) of compound 166 
 
Figure A8.7.3  13C NMR (125 MHz, CDCl3) of compound 166 
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Figure A8.8.3  13C NMR (125 MHz, CDCl3) of compound 167 
 
Figure A8.8.2 Infrared spectrum (thin film/NaCl) of compound 167 
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Figure A8.9.2 Infrared spectrum (thin film/NaCl) of compound 168 
 
Figure A8.9.3  13C NMR (125 MHz, CDCl3) of compound 168 
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Figure A8.10.3  13C NMR (125 MHz, CDCl3) of compound 155 
 
Figure A8.10.2 Infrared spectrum (thin film/NaCl) of compound 155 
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Figure A8.11.3  13C NMR (125 MHz, CDCl3) of compound 169 
 
Figure A8.11.2 Infrared spectrum (thin film/NaCl) of compound 169 
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Figure A8.12.3  13C NMR (125 MHz, CDCl3) of compound 85b 
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Figure A9.1. Ortep diagram of 173. The crystallographic data have been deposited in the Cambridge 
Database (CCDC) and has been placed on hold pending further instructions. 
 
Table A9.1  Crystal data and structure analysis details for 173. 
Empirical formula  C21 H31 I O4 Si 
Formula weight  502.45 
Crystallization solvent  Hexanes/Pentane  
Crystal shape  block 
Crystal color  colourless  
Crystal size 0.28 x 0.3 x 0.38 mm 
 
 Data Collection  
Preliminary photograph(s)  rotation  
Type of diffractometer  Bruker APEX-II CCD 
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Wavelength  0.71073 ≈ MoK 
Data collection temperature  100 K 
Theta range for 9418 reflections used 
in lattice determination  2.69 to 49.27∞ 
Unit cell dimensions a = 7.8106(6) ≈ α= 90∞ 
 b = 9.9557(9) ≈ β= 90∞ 
 c = 29.925(3) ≈ γ = 90∞ 
Volume 2326.9(3) ≈3 
Z 4 
Crystal system  orthorhombic 
Space group  P 21 21 21   (# 19) 
Density (calculated) 1.434 g/cm3 
F(000) 1024 
Theta range for data collection 2.2 to 51.0∞ 
Completeness to theta = 25.00∞ 99.9%  
Index ranges -16 ≤ h ≤ 8, -21 ≤ k ≤ 21, -61 ≤ l ≤ 65 
Data collection scan type  and scans 
Reflections collected 91039 
Independent reflections 24693 [Rint= 0.0329] 
Reflections > 2σ(I) 22910  
Average σ(I)/(net I) 0.0301 
Absorption coefficient 1.45 mm-1 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.8799 and 0.8128  
 Structure Solution and Refinement  
Primary solution method  dual 
Secondary solution method  difmap 
Hydrogen placement  geom 
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Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 24693 / 0 / 368 
Treatment of hydrogen atoms  refall 
Goodness-of-fit on F2 1.71 
Final R indices [I>2σ(I), 22910 reflections] R1 = 0.0322, wR2 = 0.0520 
R indices (all data) R1 = 0.0364, wR2 = 0.0525 
Type of weighting scheme used calc 
Weighting scheme used calc w=1/[^2^(Fo^2^)] 
Max shift/error  0.002 
Average shift/error  0.000 
Absolute structure parameter -0.001(5) 
Largest diff. peak and hole 2.58 and -2.43 e∑≈-3 
 
 Programs Used  
Cell refinement   SAINT V8.18C (Bruker-AXS, 2007) 
Data collection   APEX2 2012.2-0 (Bruker-AXS, 2007) 
Data reduction   SAINT V8.18C (Bruker-AXS, 2007) 
Structure solution   SHELXS-97 (Sheldrick, 1990) 
Structure refinement   SHELXL-97 (Sheldrick, 1997) 
Graphics  DIAMOND 3 (Crystal Impact, 1999) 
Table A9.2.  Atomic coordinates  ( x 104) and equivalent  isotropic 
displacement parameters (≈2x 103) for 173.  U(eq) is defined as one 
third of the trace of the orthogonalized Uij tensor.  
________________________________________________________________________________  
 x y z Ueq 
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________________________________________________________________________________   
I(1) 3229(1) 3273(1) 1007(1) 15(1) 
Si(1) 8286(1) 9598(1) 296(1) 18(1) 
O(1) 5867(1) 5072(1) 2118(1) 11(1) 
O(2) 5592(1) 4487(1) 2829(1) 19(1) 
O(3) 3205(1) 6242(1) 1658(1) 17(1) 
O(4) 4368(1) 7639(1) 1154(1) 18(1) 
C(1) 6046(1) 4527(1) 1664(1) 10(1) 
C(2) 6004(1) 5727(1) 1341(1) 10(1) 
C(3) 7647(1) 6616(1) 1326(1) 12(1) 
C(4) 9209(1) 5673(1) 1298(1) 17(1) 
C(5) 9286(1) 4665(1) 1680(1) 15(1) 
C(6) 7759(1) 3724(1) 1662(1) 12(1) 
C(7) 7701(1) 2636(1) 2044(1) 13(1) 
C(8) 5895(1) 2726(1) 2272(1) 13(1) 
C(9) 4551(1) 2554(1) 1916(1) 14(1) 
C(10) 4638(1) 3483(1) 1598(1) 12(1) 
C(11) 5751(1) 4138(1) 2445(1) 12(1) 
C(12) 4363(1) 6542(1) 1412(1) 11(1) 
C(13) 2917(1) 8524(1) 1196(1) 21(1) 
C(14) 7682(1) 7423(1) 893(1) 14(1) 
C(15) 8219(1) 8682(1) 840(1) 17(1) 
C(16) 7633(2) 8455(1) -168(1) 29(1) 
C(17) 6799(3) 11047(2) 328(1) 51(1) 
C(18) 10497(2) 10244(2) 195(1) 31(1) 
C(19) 7776(1) 7534(1) 1736(1) 15(1) 
C(20) 9053(1) 2839(1) 2411(1) 20(1) 
C(21) 7953(1) 1234(1) 1846(1) 20(1) 
________________________________________________________________________________  
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Table A9.3.   Bond lengths [≈] and angles [∞] for  173. 
___________________________________________________________________________________  
I(1)-C(10)  2.0931(7) 
Si(1)-C(15)  1.8650(8) 
Si(1)-C(16)  1.8677(12) 
Si(1)-C(17)  1.8543(14) 
Si(1)-C(18)  1.8672(13) 
O(1)-C(1)  1.4684(9) 
O(1)-C(11)  1.3539(10) 
O(2)-C(11)  1.2063(11) 
O(3)-C(12)  1.2049(10) 
O(4)-C(12)  1.3363(10) 
O(4)-C(13)  1.4404(11) 
C(1)-C(2)  1.5377(11) 
C(1)-C(6)  1.5580(11) 
C(1)-C(10)  1.5261(11) 
C(2)-H(2)  1.015(14) 
C(2)-C(3)  1.5596(10) 
C(2)-C(12)  1.5307(10) 
C(3)-C(4)  1.5419(12) 
C(3)-C(14)  1.5258(11) 
C(3)-C(19)  1.5320(12) 
C(4)-H(4A)  1.008(15) 
C(4)-H(4B)  0.875(17) 
C(4)-C(5)  1.5223(12) 
C(5)-H(5A)  1.052(15) 
C(5)-H(5B)  0.959(14) 
C(5)-C(6)  1.5178(12) 
C(6)-H(6)  1.030(13) 
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C(6)-C(7)  1.5739(12) 
C(7)-C(8)  1.5698(11) 
C(7)-C(20)  1.5367(12) 
C(7)-C(21)  1.5297(13) 
C(8)-H(8)  1.004(16) 
C(8)-C(9)  1.5052(12) 
C(8)-C(11)  1.5022(12) 
C(9)-H(9)  0.930(16) 
C(9)-C(10)  1.3303(11) 
C(13)-H(13A)  0.951(16) 
C(13)-H(13B)  0.993(14) 
C(13)-H(13C)  0.904(18) 
C(14)-H(14)  0.928(14) 
C(14)-C(15)  1.3312(13) 
C(15)-H(15)  0.997(18) 
C(16)-H(16A)  0.915(17) 
C(16)-H(16B)  1.04(2) 
C(16)-H(16C)  1.020(18) 
C(17)-H(17A)  0.80(3) 
C(17)-H(17B)  1.01(2) 
C(17)-H(17C)  0.99(2) 
C(18)-H(18A)  1.020(18) 
C(18)-H(18B)  0.93(2) 
C(18)-H(18C)  0.88(2) 
C(19)-H(19A)  0.904(15) 
C(19)-H(19B)  0.952(15) 
C(19)-H(19C)  0.886(16) 
C(20)-H(20A)  0.920(16) 
C(20)-H(20B)  0.950(17) 
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C(20)-H(20C)  0.924(16) 
C(21)-H(21A)  1.003(14) 
C(21)-H(21B)  0.889(18) 
C(21)-H(21C)  0.987(16) 
 
C(15)-Si(1)-C(16) 110.06(5) 
C(15)-Si(1)-C(18) 109.60(5) 
C(17)-Si(1)-C(15) 108.59(6) 
C(17)-Si(1)-C(16) 109.91(9) 
C(17)-Si(1)-C(18) 108.64(10) 
C(18)-Si(1)-C(16) 110.01(6) 
C(11)-O(1)-C(1) 114.95(6) 
C(12)-O(4)-C(13) 116.59(7) 
O(1)-C(1)-C(2) 106.94(6) 
O(1)-C(1)-C(6) 105.89(6) 
O(1)-C(1)-C(10) 107.66(6) 
C(2)-C(1)-C(6) 114.54(6) 
C(10)-C(1)-C(2) 115.60(6) 
C(10)-C(1)-C(6) 105.64(6) 
C(1)-C(2)-H(2) 105.4(8) 
C(1)-C(2)-C(3) 116.17(6) 
C(3)-C(2)-H(2) 107.3(8) 
C(12)-C(2)-C(1) 110.08(6) 
C(12)-C(2)-H(2) 103.7(8) 
C(12)-C(2)-C(3) 113.09(6) 
C(4)-C(3)-C(2) 107.88(7) 
C(14)-C(3)-C(2) 109.73(6) 
C(14)-C(3)-C(4) 105.03(6) 
C(14)-C(3)-C(19) 111.41(7) 
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C(19)-C(3)-C(2) 111.72(6) 
C(19)-C(3)-C(4) 110.80(7) 
C(3)-C(4)-H(4A) 109.0(8) 
C(3)-C(4)-H(4B) 108.2(11) 
H(4A)-C(4)-H(4B) 110.6(13) 
C(5)-C(4)-C(3) 113.04(7) 
C(5)-C(4)-H(4A) 109.2(8) 
C(5)-C(4)-H(4B) 106.8(10) 
C(4)-C(5)-H(5A) 110.4(8) 
C(4)-C(5)-H(5B) 106.8(8) 
H(5A)-C(5)-H(5B) 109.1(12) 
C(6)-C(5)-C(4) 110.45(7) 
C(6)-C(5)-H(5A) 111.9(8) 
C(6)-C(5)-H(5B) 108.1(8) 
C(1)-C(6)-H(6) 106.3(7) 
C(1)-C(6)-C(7) 109.03(6) 
C(5)-C(6)-C(1) 111.02(7) 
C(5)-C(6)-H(6) 108.4(7) 
C(5)-C(6)-C(7) 114.99(7) 
C(7)-C(6)-H(6) 106.6(7) 
C(8)-C(7)-C(6) 107.59(6) 
C(20)-C(7)-C(6) 114.06(7) 
C(20)-C(7)-C(8) 107.40(7) 
C(21)-C(7)-C(6) 110.09(7) 
C(21)-C(7)-C(8) 109.68(7) 
C(21)-C(7)-C(20) 107.94(7) 
C(7)-C(8)-H(8) 110.6(9) 
C(9)-C(8)-C(7) 108.20(6) 
C(9)-C(8)-H(8) 114.9(9) 
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C(11)-C(8)-C(7) 105.71(7) 
C(11)-C(8)-H(8) 109.7(9) 
C(11)-C(8)-C(9) 107.34(7) 
C(8)-C(9)-H(9) 119.6(9) 
C(10)-C(9)-C(8) 113.10(7) 
C(10)-C(9)-H(9) 127.0(9) 
C(1)-C(10)-I(1) 123.83(5) 
C(9)-C(10)-I(1) 120.64(6) 
C(9)-C(10)-C(1) 114.63(7) 
O(1)-C(11)-C(8) 112.82(6) 
O(2)-C(11)-O(1) 119.90(8) 
O(2)-C(11)-C(8) 127.25(8) 
O(3)-C(12)-O(4) 123.87(7) 
O(3)-C(12)-C(2) 125.54(7) 
O(4)-C(12)-C(2) 110.58(6) 
O(4)-C(13)-H(13A) 107.9(10) 
O(4)-C(13)-H(13B) 110.3(8) 
O(4)-C(13)-H(13C) 110.2(12) 
H(13A)-C(13)-H(13B) 109.1(12) 
H(13A)-C(13)-H(13C) 114.6(15) 
H(13B)-C(13)-H(13C) 104.8(14) 
C(3)-C(14)-H(14) 113.4(9) 
C(15)-C(14)-C(3) 127.14(8) 
C(15)-C(14)-H(14) 119.3(9) 
Si(1)-C(15)-H(15) 116.0(10) 
C(14)-C(15)-Si(1) 125.05(7) 
C(14)-C(15)-H(15) 118.5(10) 
Si(1)-C(16)-H(16A) 108.5(10) 
Si(1)-C(16)-H(16B) 110.7(10) 
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Si(1)-C(16)-H(16C) 113.9(11) 
H(16A)-C(16)-H(16B) 106.6(15) 
H(16A)-C(16)-H(16C) 112.0(15) 
H(16B)-C(16)-H(16C) 104.8(15) 
Si(1)-C(17)-H(17A) 105(2) 
Si(1)-C(17)-H(17B) 110.7(13) 
Si(1)-C(17)-H(17C) 103.4(14) 
H(17A)-C(17)-H(17B) 103(2) 
H(17A)-C(17)-H(17C) 126(2) 
H(17B)-C(17)-H(17C) 108.5(18) 
Si(1)-C(18)-H(18A) 111.1(11) 
Si(1)-C(18)-H(18B) 109.9(13) 
Si(1)-C(18)-H(18C) 104.1(16) 
H(18A)-C(18)-H(18B) 109.8(16) 
H(18A)-C(18)-H(18C) 108.5(18) 
H(18B)-C(18)-H(18C) 113(2) 
C(3)-C(19)-H(19A) 112.9(10) 
C(3)-C(19)-H(19B) 112.8(9) 
C(3)-C(19)-H(19C) 110.1(9) 
H(19A)-C(19)-H(19B) 104.8(13) 
H(19A)-C(19)-H(19C) 105.1(13) 
H(19B)-C(19)-H(19C) 110.7(13) 
C(7)-C(20)-H(20A) 107.2(10) 
C(7)-C(20)-H(20B) 110.3(10) 
C(7)-C(20)-H(20C) 110.6(9) 
H(20A)-C(20)-H(20B) 107.5(13) 
H(20A)-C(20)-H(20C) 111.0(14) 
H(20B)-C(20)-H(20C) 110.3(14) 
C(7)-C(21)-H(21A) 107.9(8) 
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C(7)-C(21)-H(21B) 114.7(12) 
C(7)-C(21)-H(21C) 113.7(9) 
H(21A)-C(21)-H(21B) 110.7(12) 
H(21A)-C(21)-H(21C) 109.6(12) 
H(21B)-C(21)-H(21C) 100.0(14) 
  ___________________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
  
Table A9.4.   Anisotropic displacement parameters  (≈2x 104 ) for 
hmn03.  The anisotropic displacement factor exponent takes the 
form: -2π 2 [ h2 a*2U 11  + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
I(1) 153(1)  162(1) 141(1)  -20(1) -36(1)  -19(1) 
Si(1) 248(1)  130(1) 151(1)  45(1) 40(1)  16(1) 
O(1) 155(2)  82(2) 85(2)  0(2) 5(2)  6(2) 
O(2) 318(4)  150(3) 106(2)  8(2) 23(2)  13(2) 
O(3) 139(2)  179(3) 181(2)  39(2) 29(2)  33(2) 
O(4) 154(2)  162(3) 233(3)  93(2) 1(2)  34(2) 
C(1) 116(2)  85(3) 86(2)  1(2) -1(2)  3(2) 
C(2) 110(2)  91(3) 94(2)  6(2) -6(2)  -1(2) 
C(3) 120(2)  109(3) 117(3)  16(2) -6(2)  -15(2) 
C(4) 117(3)  181(4) 200(4)  68(3) 24(2)  9(2) 
C(5) 106(3)  166(4) 192(3)  48(3) -7(2)  8(2) 
C(6) 119(2)  112(3) 115(3)  6(2) 5(2)  24(2) 
C(7) 148(3)  98(3) 148(3)  17(2) -11(2)  20(2) 
C(8) 167(3)  90(3) 131(3)  22(2) -1(2)  2(2) 
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C(9) 149(3)  98(3) 160(3)  5(2) 2(2)  -15(2) 
C(10) 115(2)  103(3) 128(3)  -4(2) -16(2)  -9(2) 
C(11) 161(3)  103(3) 108(3)  14(2) 5(2)  7(2) 
C(12) 118(2)  99(3) 118(3)  7(2) -19(2)  9(2) 
C(13) 192(4)  165(4) 271(4)  34(3) -35(3)  58(3) 
C(14) 151(3)  149(3) 115(3)  23(2) 9(2)  -11(2) 
C(15) 237(3)  132(3) 147(3)  26(2) 28(3)  -6(3) 
C(16) 380(6)  294(6) 191(4)  60(4) -41(3)  -109(4) 
C(17) 732(12)  401(8) 403(8)  181(7) 221(8)  366(9) 
C(18) 363(6)  296(6) 274(5)  104(5) -16(4)  -138(5) 
C(19) 190(3)  143(3) 124(3)  8(3) -24(2)  -49(3) 
C(20) 189(3)  211(4) 188(4)  57(3) -58(3)  5(3) 
C(21) 238(4)  119(3) 256(4)  -9(3) 21(3)  51(3) 
______________________________________________________________________________ 
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 Table A9.5.   Hydrogen coordinates ( x 103) and isotropic  
displacement parameters (≈2x 103) for hmn03. 
________________________________________________________________________________  
 x  y  z  Uiso 
________________________________________________________________________________  
  
H(2) 585(2) 532(1) 103(1) 16(3) 
H(4A) 917(2) 517(1) 100(1) 18(3) 
H(4B) 1014(2) 616(2) 132(1) 23(4) 
H(5A) 937(2) 517(2) 199(1) 20(3) 
H(5B) 1030(2) 414(1) 164(1) 11(3) 
H(6) 779(2) 321(1) 136(1) 10(3) 
H(8) 581(2) 208(2) 253(1) 24(4) 
H(9) 384(2) 181(2) 192(1) 22(3) 
H(13A) 197(2) 811(2) 105(1) 28(4) 
H(13B) 316(2) 940(1) 105(1) 16(3) 
H(13C) 273(2) 872(2) 149(1) 38(5) 
H(14) 735(2) 693(2) 64(1) 17(3) 
H(15) 848(2) 923(2) 111(1) 37(5) 
H(16A) 657(2) 812(2) -11(1) 30(4) 
H(16B) 845(2) 763(2) -19(1) 40(5) 
H(16C) 768(2) 889(2) -48(1) 42(5) 
H(17A) 587(4) 1072(3) 33(1) 80(10) 
H(17B) 680(3) 1156(2) 4(1) 65(6) 
H(17C) 731(3) 1162(2) 56(1) 59(6) 
H(18A) 1056(2) 1077(2) -10(1) 37(5) 
H(18B) 1127(3) 953(2) 19(1) 48(6) 
H(18C) 1068(3) 1080(2) 42(1) 58(6) 
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H(19A) 875(2) 802(2) 174(1) 22(4) 
H(19B) 777(2) 705(2) 201(1) 23(4) 
H(19C) 694(2) 814(2) 173(1) 21(3) 
H(20A) 885(2) 220(2) 263(1) 23(4) 
H(20B) 892(2) 370(2) 255(1) 25(4) 
H(20C) 1014(2) 275(2) 229(1) 24(4) 
H(21A) 910(2) 121(2) 170(1) 14(3) 
H(21B) 714(2) 98(2) 166(1) 31(4) 
H(21C) 788(2) 50(2) 207(1) 25(4) 
________________________________________________________________________________ 
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